BINDING MOLECULES FOR BCMA AND CD3

Abstract

The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster 3 of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.

Claims

1. (canceled)

2. An antibody comprising: a first portion comprising a binding domain that binds to human CD3; and a second portion comprising an amino acid sequence of SEQ ID NO: 732 with not more than 6 amino acid substitutions.

3. The antibody of claim 2, wherein the antibody is human or humanized.

4. The antibody of claim 2, further comprising an IgG framework.

5. The antibody of claim 2, further comprising an Fc constant domain.

6. The antibody of claim 2, wherein the first portion binds to human CD3 with a KD of about 10.sup.−6 M or stronger.

7. A method of processing a cell culture supernatant comprising: equilibrating an immobilized metal affinity chromatography column loaded with ZnCl.sub.2 with a buffer consisting of 20 mM sodium phosphate buffer pH 7.2 and 0.1 M NaCl (Buffer A); applying 10 ml of 0.2 m filtered cell culture supernatant from cells expressing a soluble BCMA protein comprising a modified histidine tag having the sequence SGHHGGHHGGHH to the immobilized metal affinity chromatography column at a flow rate of 3 ml/min; washing the immobilized metal affinity chromatography column with Buffer A to remove unbound sample; eluting bound protein using a two-step gradient of a buffer consisting of 20 mM sodium phosphate buffer pH 7.2, 0.1 M NaCl, and 0.5 M imidazole (Buffer B) according to the following procedure: a) 10% buffer B in 6 column volumes, b) 100% buffer B in 6 column volumes; and pooling eluted protein fractions from step b).

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0361] FIG. 1:

[0362] Sequence alignment of the extracellular domain (ECD) of human BCMA (amino acid residues 1-54 of the full-length protein) and murine BCMA (amino acid residues 1-49 of the full-length protein). Highlighted are the regions (domains or amino acid residues) which were exchanged in the chimeric constructs, as designated for the epitope clustering. Cysteines are depicted by black boxes. Disulfide bonds are indicated.

[0363] FIGS. 2A-B:

[0364] Epitope mapping of the BCMA constructs. Human and murine BCMA (FIG. 2A) as well as seven chimeric human-murine BCMA constructs (FIG. 2B) expressed on the surface of CHO cells as shown by flow cytometry. The expression of human BCMA on CHO was detected with a monoclonal anti-human BCMA antibody. Murine BCMA expression was detected with a monoclonal anti-murine BCMA-antibody. Bound monoclonal antibody was detected with an anti-rat IgG-Fc-gamma-specific antibody conjugated to phycoerythrin.

[0365] FIG. 3:

[0366] Examples of binding molecules specific for epitope cluster E3, as detected by epitope mapping of the chimeric BCMA constructs (see example 3).

[0367] FIGS. 4A-D:

[0368] Determination of binding constants of bispecific binding molecules (anti BCMA x anti CD3) on human and macaque BCMA using the Biacore system. Antigen was immobilized in low to intermediate density (100 RU) on CM5 chip. Dilutions of binders were floated over the chip surface and binding determined using BiaEval Software. Respective off-rates and the binding constant (KD) of the respective binders are depicted below every graph. FIG. 4A depicts the measured binding constant of BCMA-101 x CD3 on human BCMA. FIG. 4B depicts the measured binding constant of BCMA-101 x CD3 on macaque BCMA. FIG. 4C depicts the measured binding constant of BCMA-102 x CD3 on human BCMA. FIG. 4D depicts the measured binding constant of BCMA-102 x CD3 on macaque BCMA.

[0369] FIGS. 5A-B:

[0370] Cytotoxic activity of BCMA bispecific antibodies as measured in an 18-hour .sup.51chromium release assay. Effector cells: stimulated enriched human CD8 T cells. Target cells: Human BCMA transfected CHO cells (FIG. 5A) and macaque BCMA transfected CHO cells (FIG. 5B). Effector to target cell (E:T) ratio: 10:1.

[0371] FIGS. 6A-H:

[0372] Determination of binding constants of BCMA/CD3 bispecific antibodies of epitope cluster E3 on human and macaque BCMA and on human and macaque CD3 using the Biacore system. Antigen was immobilized in low to intermediate density (100-200 RU) on CM5 chip. Dilutions of bispecific antibodies were floated over the chip surface and binding determined using BiaEval Software. Respective on- and off-rates and the resulting binding constant (KD) of the respective bispecific antibodies are depicted below every graph. FIG. 6A depicts a measured binding constant of BCMA-34 x CD3 on human BCMA. FIG. 6B depicts a measured binding constant of BCMA-34 x CD3 on macaque BCMA. FIG. 6C depicts a measured binding constant of BCMA-34 x CD3 on human CD3. FIG. 6D depicts a measured binding constant of BCMA-34 x CD3 on macaque CD3. FIG. 6E depicts a measured binding constant of BCMA-98 x CD3 on human BCMA. FIG. 6F depicts a measured binding constant of BCMA-98 x CD3 on macaque BCMA. FIG. 6G depicts a measured binding constant of BCMA-98 x CD3 on human CD3. FIG. 6H depicts a measured binding constant of BCMA-98 x CD3 on macaque CD3.

[0373] FIGS. 7A-F:

[0374] FACS analysis of BCMA/CD3 bispecific antibodies of epitope cluster E3 on indicated cell lines: human BCMA transfected CHO cells (FIG. 7A), human CD3 positive human T cell line HBP-ALL (FIG. 7B), macaque BCMA transfected CHO cells (FIG. 7C), macaque T cell line 4119 LnPx (FIG. 7D), BCMA-positive human multiple myeloma cell line NCI-H929 (FIG. 7E), and untransfected CHO cells (FIG. 7F). Negative controls [for FIGS. 7A-F]: detection antibodies without prior BCMA/CD3 bispecific antibody.

[0375] FIGS. 8A-D:

[0376] Scatchard analysis of BCMA/CD3 bispecific antibodies on BCMA-expressing cells. Cells were incubated with increasing concentrations of monomeric antibody until saturation. Antibodies were detected by flow cytometry. Values of triplicate measurements were plotted as hyperbolic curves and as sigmoid curves to demonstrate a valid concentration range used. Maximal binding was determined using Scatchard evaluation, and the respective KD values were calculated. FIG. 8A depicts a Scatchard analysis of BCMA-20 x CD3 on CHO cells expressing human BCMA as a hyperbolic curve. FIG. 8B depicts a Scatchard analysis of BCMA-20 x CD3 on CHO cells expressing human BCMA as a sigmoid curve. FIG. 8C depicts a Scatchard analysis of BCMA-20 x CD3 on CHO cells expressing macaque BCMA as a hyperbolic curve. FIG. 8D depicts a Scatchard analysis of BCMA-20 x CD3 on CHO cells expressing macaque BCMA as a sigmoid curve.

[0377] FIGS. 9A-B:

[0378] Cytotoxic activity of BCMA/CD3 bispecific antibodies of epitope cluster E3, as measured in an 18-hour 51-chromium release assay against CHO cells transfected with human BCMA. Effector cells: stimulated enriched human CD8 T cells. Effector to target cell (E:T) ratio: 10:1. FIG. 9A depicts a measured 51-chromium release assay of BCMA-97 x CD3, BCMA-98 x CD3, BCMA-99 x CD3, and BCMA-100 x CD3 on CHO cells expressing human BCMA. FIG. 9B depicts a measured 51-chromium release assay of BCMA-82 x CD3, BCMA-83 x CD3, and BCMA-84 x CD3 on CHO cells expressing human BCMA.

[0379] FIG. 10:

[0380] Cytotoxic activity of BCMA/CD3 bispecific antibodies of epitope cluster E3 as measured in a 48-hour FACS-based cytotoxicity assay. Effector cells: unstimulated human PBMC. Target cells: CHO cells transfected with human BCMA. Effector to target cell (E:T)-ratio: 10:1.

[0381] FIGS. 11A-H:

[0382] FACS analysis of BCMA/CD3 bispecific antibodies of epitope cluster E3 on BAFF-R and TACI transfected CHO cells. Cell lines: 1) human BAFF-R transfected CHO cells, 2) human TACI transfected CHO cells 3) multiple myeloma cell line L363; negative controls: detection antibodies without prior BCMA/CD3 bispecific antibody. Positive controls: BAFF-R detection: goat anti hu BAFF-R (R&D AF1162; 1:20) detected by anti-goat antibody-PE (Jackson 705-116-147; 1:50) TACI-detection: rabbit anti TACI antibody (abcam AB 79023; 1:100) detected by goat anti rabbit-antibody PE (Sigma P9757; 1:20). FIG. 11A depicts FACS analysis of CHO cells expressing human BAFF-R treated with BCMA-98. FIG. 11B depicts FACS analysis of CHO cells expressing human TACI treated with BCMA-98. FIG. 11C depicts FACS analysis of L393 cells treated with BCMA-98. FIG. 11D depicts FACS analysis of CHO cells expressing human BAFF-R treated with BCMA-34. FIG. 11E depicts FACS analysis of CHO cells expressing human TACI treated with BCMA-34. FIG. 11F depicts FACS analysis of L393 cells treated with BCMA-34. FIG. 11G depicts a positive control FACS analysis of CHO cells expressing human BAFF-R with an anti-BAFF-R antibody. FIG. 11H depicts a positive control FACS analysis of CHO cells expressing human TACI with an anti-TACI antibody.

[0383] FIG. 12:

[0384] Cytotoxic activity of BCMA/CD3 bispecific antibodies as measured in an 18-hour 51-chromium release assay. Effector cells: stimulated enriched human CD8 T cells. Target cells: BCMA-positive human multiple myeloma cell line L363 (i.e. natural expresser). Effector to target cell (E:T) ratio: 10:1.

[0385] FIG. 13:

[0386] Cytotoxic activity of BCMA/CD3 bispecific antibodies as measured in a 48-hour FACS-based cytotoxicity assay. Effector cells: unstimulated human PBMC. Target cells: human multiple myeloma cell line L363 (natural BCMA expresser). Effector to target cell (E:T)-ratio: 10:1.

[0387] FIG. 14:

[0388] Cytotoxic activity of BCMA/CD3 bispecific antibodies as measured in a 48-hour FACS-based cytotoxicity assay. Effector cells: unstimulated human PBMC. Target cells: BCMA-positive human multiple myeloma cell line NCI-H929. Effector to target cell (E:T)-ratio: 10:1.

[0389] FIG. 15:

[0390] Cytotoxic activity of BCMA/CD3 bispecific antibodies as measured in a 48-hour FACS-based cytotoxicity assay. Effector cells: macaque T cell line 4119LnPx. Target cells: CHO cells transfected with macaque BCMA. Effector to target cell (E:T) ratio: 10:1.

[0391] FIG. 16:

[0392] Anti-tumor activity of BCMA/CD3 bispecific antibodies of epitope cluster E3 in an advanced-stage NCI-H929 xenograft model (see Example 16).

[0393] FIGS. 17A-F:

[0394] FACS-based cytotoxicity assay using human multiple myeloma cell lines NCI-H929, L-363 and OPM-2 as target cells and human PBMC as effector cells (48 h; E:T=10:1). The figure depicts the cytokine levels [pg/ml] which were determined for Il-2, IL-6, IL-10, TNF and IFN-gamma at increasing concentrations of the BCMA/CD3 bispecific antibodies of epitope cluster E3 (see Example 22). FIG. 17A depicts a measured cytotoxicity assay of NCI-H929 cells treated with BCMA-98 x CD3. FIG. 17B depicts a measured cytotoxicity assay of NCI-H929 cells treated with BCMA-34 x CD3. FIG. 17C depicts a measured cytotoxicity assay of OPM-2 cells treated with BCMA-98 x CD3. FIG. 17D depicts a measured cytotoxicity assay of OPM-2 cells treated with BCMA-34 x CD3. FIG. 17E depicts a measured cytotoxicity assay of L-363 cells treated with BCMA-98 x CD3. FIG. 17F depicts a measured cytotoxicity assay of L-363 cells treated with BCMA-34 x CD3.

EXAMPLES

[0395] The following examples illustrate the invention. These examples should not be construed as to limit the scope of this invention. The examples are included for purposes of illustration, and the present invention is limited only by the claims.

Example 1

[0396] Generation of CHO Cells Expressing Chimeric BCMA

[0397] For the construction of the chimeric epitope mapping molecules, the amino acid sequence of the respective epitope domains or the single amino acid residue of human BCMA was changed to the murine sequence. The following molecules were constructed: [0398] Human BCMA ECD/E1 murine (SEQ ID NO: 1009)

[0399] Chimeric extracellular BCMA domain: Human extracellular BCMA domain wherein epitope cluster 1 (amino acid residues 1-7 of SEQ ID NO: 1002 or 1007) is replaced by the respective murine cluster (amino acid residues 1-4 of SEQ ID NO: 1004 or 1008) [0400] deletion of amino acid residues 1-3 and G6Q mutation in SEQ ID NO: 1002 or 1007 [0401] Human BCMA ECD/E2 murine (SEQ ID NO: 1010)

[0402] Chimeric extracellular BCMA domain: Human extracellular BCMA domain wherein epitope cluster 2 (amino acid residues 8-21 of SEQ ID NO: 1002 or 1007) is replaced by the respective murine cluster (amino acid residues 5-18 of SEQ ID NO: 1004 or 1008) [0403] S9F, Q10H, and N11S mutations in SEQ ID NO: 1002 or 1007 [0404] Human BCMA ECD/E3 murine (SEQ ID NO: 1011)

[0405] Chimeric extracellular BCMA domain: Human extracellular BCMA domain wherein epitope cluster 3 (amino acid residues 24-41 of SEQ ID NO: 1002 or 1007) is replaced by the respective murine cluster (amino acid residues 21-36 of SEQ ID NO: 1004 or 1008) [0406] deletion of amino acid residues 31 and 32 and Q25H, S30N, L35A, and R39P mutation in SEQ ID NO: 1002 or 1007 [0407] Human BCMA ECD/E4 murine (SEQ ID NO: 1012)

[0408] Chimeric extracellular BCMA domain: Human extracellular BCMA domain wherein epitope cluster 4 (amino acid residues 42-54 of SEQ ID NO: 1002 or 1007) is replaced by the respective murine cluster (amino acid residues 37-49 of SEQ ID NO: 1004 or 1008) [0409] N42D, A43P, N47S, N53Y and A54T mutations in SEQ ID NO: 1002 or 1007 [0410] Human BCMA ECD/E5 murine (SEQ ID NO: 1013)

[0411] Chimeric extracellular BCMA domain: Human extracellular BCMA domain wherein the amino acid residue at position 22 of SEQ ID NO: 1002 or 1007 (isoleucine) is replaced by its respective murine amino acid residue of SEQ ID NO: 1004 or 1008 (lysine, position 19) [0412] I22K mutation in SEQ ID NO: 1002 or 1007 [0413] Human BCMA ECD/E6 murine (SEQ ID NO: 1014)

[0414] Chimeric extracellular BCMA domain: Human extracellular BCMA domain wherein the amino acid residue at position 25 of SEQ ID NO: 1002 or 1007 (glutamine) is replaced by its respective murine amino acid residue of SEQ ID NO: 1004 or 1008 (histidine, position 22) [0415] Q25H mutation in SEQ ID NO: 1002 or 1007 [0416] Human BCMA ECD/E7 murine (SEQ ID NO: 1015)

[0417] Chimeric extracellular BCMA domain: Human extracellular BCMA domain wherein the amino acid residue at position 39 of SEQ ID NO: 1002 or 1007 (arginine) is replaced by its respective murine amino acid residue of SEQ ID NO: 1004 or 1008 (proline, position 34) [0418] R39P mutation in SEQ ID NO: 1002 or 1007

[0419] A) The cDNA constructs were cloned into the mammalian expression vector pEF-DHFR and stably transfected into CHO cells. The expression of human BCMA on CHO cells was verified in a FACS assay using a monoclonal anti-human BCMA antibody. Murine BCMA expression was demonstrated with a monoclonal anti-mouse BCMA-antibody. The used concentration of the BCMA antibodies was 10 μg/ml in PBS/2% FCS. Bound monoclonal antibodies were detected with an anti-rat-IgG-Fcy-PE (1:100 in PBS/2% FCS; Jackson-Immuno-Research #112-116-071). As negative control, cells were incubated with PBS/2% FCS instead of the first antibody. The samples were measured by flow cytometry on a FACSCanto II instrument (Becton Dickinson) and analyzed by FlowJo software (Version 7.6). The surface expression of human-murine BCMA chimeras, transfected CHO cells were analyzed and confirmed in a flow cytometry assay with different anti-BCMA antibodies (FIGS. 2A-B).

[0420] B) For the generation of CHO cells expressing human, macaque, mouse and human/mouse chimeric transmembrane BCMA, the coding sequences of human, macaque, mouse BCMA and the human-mouse BCMA chimeras (BCMA sequences as published in GenBank, accession numbers NM_001192 [human]; NM_011608 [mouse] and XM_001106892 [macaque]) were obtained by gene synthesis according to standard protocols. The gene synthesis fragments were designed as to contain first a Kozak site for eukaryotic expression of the constructs and the coding sequence of a 19 amino acid immunoglobulin leader peptide, followed in frame by the coding sequence of the BCMA proteins respectively in case of the chimeras with the respective epitope domains of the human sequence exchanged for the murine sequence.

[0421] Except for the human BCMA ECD/E4 murine and human BCMA constructs the coding sequence of the extracellular domain of the BCMA proteins was followed in frame by the coding sequence of an artificial Ser1-Gly4-Ser1-linker followed by the intracellular domain of human EpCAM (amino acids 226-314; sequence as published in GenBank accession number NM_002354).

[0422] All coding sequences were followed by a stop codon. The gene synthesis fragments were also designed as to introduce suitable restriction sites. The gene synthesis fragments were cloned into a plasmid designated pEF-DHFR (pEF-DHFR is described in Raum et al. Cancer Immunol Immunother 50 (2001) 141-150). All aforementioned procedures were carried out according to standard protocols (Sambrook, Molecular Cloning; A Laboratory Manual, 3rd edition, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, N.Y. (2001)). For each antigen a clone with sequence-verified nucleotide sequence was transfected into DHFR deficient CHO cells for eukaryotic expression of the constructs. Eukaryotic protein expression in DHFR deficient CHO cells was performed as described by Kaufman R. J. (1990) Methods Enzymol. 185, 537-566. Gene amplification of the constructs was induced by increasing concentrations of methotrexate (MTX) to a final concentration of up to 20 nM MTX.

Example 2

[0423] 2.1 Transient Expression in HEK 293 Cells

[0424] Clones of the expression plasmids with sequence-verified nucleotide sequences were used for transfection and protein expression in the FreeStyle 293 Expression System (Invitrogen GmbH, Karlsruhe, Germany) according to the manufacturer's protocol. Supernatants containing the expressed proteins were obtained, cells were removed by centrifugation and the supernatants were stored at −20 C.

[0425] 2.2 Stable Expression in CHO Cells

[0426] Clones of the expression plasmids with sequence-verified nucleotide sequences were transfected into DHFR deficient CHO cells for eukaryotic expression of the constructs. Eukaryotic protein expression in DHFR deficient CHO cells was performed as described by Kaufman R. J. (1990) Methods Enzymol. 185, 537-566. Gene amplification of the constructs was induced by increasing concentrations of methotrexate (MTX) to a final concentration of 20 nM MTX. After two passages of stationary culture the cells were grown in roller bottles with nucleoside-free HyQ PF CHO liquid soy medium (with 4.0 mM L-Glutamine with 0.1% Pluronic F-68; HyClone) for 7 days before harvest. The cells were removed by centrifugation and the supernatant containing the expressed protein was stored at −20 C.

[0427] 2.3 Protein Purification

[0428] Purification of soluble BCMA proteins was performed as follows: Akta® Explorer System (GE Healthcare) and Unicorn® Software were used for chromatography. Immobilized metal affinity chromatography (“IMAC”) was performed using a Fractogel EMD Chelate® (Merck) which was loaded with ZnCl2 according to the protocol provided by the manufacturer. The column was equilibrated with buffer A (20 mM sodium phosphate buffer pH 7.2, 0.1 M NaCl) and the filtrated (0.2 μm) cell culture supernatant was applied to the column (10 ml) at a flow rate of 3 ml/min. The column was washed with buffer A to remove unbound sample. Bound protein was eluted using a two-step gradient of buffer B (20 mM sodium phosphate buffer pH 7.2, 0.1 M NaCl, 0.5 M imidazole) according to the following procedure:

[0429] Step 1: 10% buffer B in 6 column volumes

[0430] Step 2: 100% buffer B in 6 column volumes

[0431] Eluted protein fractions from step 2 were pooled for further purification. All chemicals were of research grade and purchased from Sigma (Deisenhofen) or Merck (Darmstadt).

[0432] Gel filtration chromatography was performed on a HiLoad 16/60 Superdex 200 prep grade column (GE/Amersham) equilibrated with Equi-buffer (10 mM citrate, 25 mM lysine-HCl, pH 7.2 for proteins expressed in HEK cells and PBS pH 7.4 for proteins expressed in CHO cells). Eluted protein samples (flow rate 1 ml/min) were subjected to standard SDS-PAGE and Western Blot for detection. Protein concentrations were determined using OD280 nm.

[0433] Proteins obtained via transient expression in HEK 293 cells were used for immunizations. Proteins obtained via stable expression in CHO cells were used for selection of binders and for measurement of binding.

Example 3

[0434] Epitope Clustering of Murine scFv-Fragments

[0435] Cells transfected with human or murine BCMA, or with chimeric BCMA molecules were stained with crude, undiluted periplasmic extract containing scFv binding to human/macaque BCMA. Bound scFv were detected with 1 μg/ml of an anti-FLAG antibody (Sigma F1804) and a R-PE-labeled anti-mouse Fc gamma-specific antibody (1:100; Dianova #115-116-071). All antibodies were diluted in PBS with 2% FCS. As negative control, cells were incubated with PBS/2% FCS instead of the periplasmic extract. The samples were measured by flow cytometry on a FACSCanto II instrument (Becton Dickinson) and analyzed by FlowJo software (Version 7.6); see FIG. 3.

Example 4

[0436] Procurement of Different Recombinant Forms of Soluble Human and Macaque BCMA

[0437] A) The coding sequences of human and rhesus BCMA (as published in GenBank, accession numbers NM_001192 [human], XM_001106892 [rhesus]) coding sequences of human albumin, human Fcγ1 and murine albumin were used for the construction of artificial cDNA sequences encoding soluble fusion proteins of human and macaque BCMA respectively and human albumin, human IgG1 Fc and murine albumin respectively as well as soluble proteins comprising only the extracellular domains of BCMA. To generate the constructs for expression of the soluble human and macaque BCMA proteins, cDNA fragments were obtained by PCR mutagenesis of the full-length BCMA cDNAs described above and molecular cloning according to standard protocols.

[0438] For the fusions with human albumin, the modified cDNA fragments were designed as to contain first a Kozak site for eukaryotic expression of the constructs followed by the coding sequence of the human and rhesus (or Macaca mulatta) BCMA proteins respectively, comprising amino acids 1 to 54 and 1 to 53 corresponding to the extracellular domain of human and rhesus BCMA, respectively, followed in frame by the coding sequence of an artificial Ser1-Gly4-Ser1-linker, followed in frame by the coding sequence of human serum albumin, followed in frame by the coding sequence of a Flag tag, followed in frame by the coding sequence of a modified histidine tag (SGHHGGHHGGHH) and a stop codon.

[0439] For the fusions with murine IgG1, the modified cDNA fragments were designed as to contain first a Kozak site for eukaryotic expression of the constructs followed by the coding sequence of the human and macaque BCMA proteins respectively, comprising amino acids 1 to 54 and 1 to 53 corresponding to the extracellular domain of human and rhesus BCMA, respectively, followed in frame by the coding sequence of an artificial Ser1-Gly4-Ser1-linker, followed in frame by the coding sequence of the hinge and Fc gamma portion of human IgG1, followed in frame by the coding sequence of a hexahistidine tag and a stop codon.

[0440] For the fusions with murine albumin, the modified cDNA fragments were designed as to contain first a Kozak site for eukaryotic expression of the constructs followed by the coding sequence of the human and macaque BCMA proteins respectively, comprising amino acids 1 to 54 and 1 to 53 corresponding to the extracellular domain of human and rhesus BCMA, respectively, followed in frame by the coding sequence of an artificial Ser1-Gly4-Ser1-linker, followed in frame by the coding sequence of murine serum albumin, followed in frame by the coding sequence of a Flag tag, followed in frame by the coding sequence of a modified histidine tag (SGHHGGHHGGHH) and a stop codon.

[0441] For the soluble extracellular domain constructs, the modified cDNA fragments were designed as to contain first a Kozak site for eukaryotic expression of the constructs followed by the coding sequence of the human and macaque BCMA proteins respectively, comprising amino acids 1 to 54 and 1 to 53 corresponding to the extracellular domain of human and rhesus BCMA, respectively, followed in frame by the coding sequence of an artificial Ser1-Gly1-linker, followed in frame by the coding sequence of a Flag tag, followed in frame by the coding sequence of a modified histidine tag (SGHHGGHHGGHH) and a stop codon.

[0442] The cDNA fragments were also designed to introduce restriction sites at the beginning and at the end of the fragments. The introduced restriction sites, EcoRI at the 5′ end and SalI at the 3′ end, were utilized in the following cloning procedures. The cDNA fragments were cloned via EcoRI and SalI into a plasmid designated pEF-DHFR (pEF-DHFR is described in Raum et al. Cancer Immunol Immunother 50 (2001) 141-150). The aforementioned procedures were all carried out according to standard protocols (Sambrook, Molecular Cloning; A Laboratory Manual, 3rd edition, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, N.Y. (2001)).

[0443] B) The coding sequences of human and macaque BCMA as described above and coding sequences of human albumin, human Fcγ1, murine Fcγ1, murine Fcγ2a, murine albumin, rat albumin, rat Fcγ1 and rat Fcγ2b were used for the construction of artificial cDNA sequences encoding soluble fusion proteins of human and macaque BCMA respectively and human albumin, human IgG1 Fc, murine IgG1 Fc, murine IgG2a Fc, murine albumin, rat IgG1 Fc, rat IgG2b and rat albumin respectively as well as soluble proteins comprising only the extracellular domains of BCMA. To generate the constructs for expression of the soluble human and macaque BCMA proteins cDNA fragments were obtained by PCR mutagenesis of the full-length BCMA cDNAs described above and molecular cloning according to standard protocols.

[0444] For the fusions with albumins the modified cDNA fragments were designed as to contain first a Kozak site for eukaryotic expression of the constructs and the coding sequence of a 19 amino acid immunoglobulin leader peptide, followed in frame by the coding sequence of the extracellular domain of the respective BCMA protein followed in frame by the coding sequence of an artificial Ser1-Gly4-Ser1-linker, followed in frame by the coding sequence of the respective serum albumin, followed in frame by the coding sequence of a Flag tag, followed in frame by the coding sequence of a modified histidine tag (SGHHGGHHGGHH) and a stop codon.

[0445] For the fusions with IgG Fcs the modified cDNA fragments were designed as to contain first a Kozak site for eukaryotic expression of the constructs and the coding sequence of a 19 amino acid immunoglobulin leader peptide, followed in frame by the coding sequence of the extracellular domain of the respective BCMA protein followed in frame by the coding sequence of an artificial Ser1-Gly4-Ser1-linker, except for human IgG1 Fc where an artificial Ser1-Gly1-linker was used, followed in frame by the coding sequence of the hinge and Fc gamma portion of the respective IgG, followed in frame by the coding sequence of a Flag tag, followed in frame by the coding sequence of a modified histidine tag (SGHHGGHHGGHH) and a stop codon.

[0446] For the soluble extracellular domain constructs the modified cDNA fragments were designed as to contain first a Kozak site for eukaryotic expression of the constructs and the coding sequence of a 19 amino acid immunoglobulin leader peptide, followed in frame by the coding sequence of the extracellular domain of the respective BCMA protein followed in frame by the coding sequence of an artificial Ser1-Gly1-linker, followed in frame by the coding sequence of a Flag tag, followed in frame by the coding sequence of a modified histidine tag (SGHHGGHHGGHH) and a stop codon.

[0447] For cloning of the constructs suitable restriction sites were introduced. The cDNA fragments were all cloned into a plasmid designated pEF-DHFR (pEF-DHFR is described in Raum et al. 2001). The aforementioned procedures were all carried out according to standard protocols (Sambrook, 2001).

[0448] The following constructs were designed to enable directed panning on distinct epitopes. The coding sequence of murine-human BCMA chimeras and murine-macaque BCMA chimeras (mouse, human and macaque BCMA sequences as described above) and coding sequences of murine albumin and murine Fcγ1 were used for the construction of artificial cDNA sequences encoding soluble fusion proteins of murine-human and murine-macaque BCMA chimeras respectively and murine IgG1 Fc and murine albumin, respectively. To generate the constructs for expression of the soluble murine-human and murine-macaque BCMA chimeras cDNA fragments of murine BCMA (amino acid 1-49) with the respective epitope domains mutated to the human and macaque sequence respectively were obtained by gene synthesis according to standard protocols. Cloning of constructs was carried out as described above and according to standard protocols (Sambrook, 2001).

[0449] The following molecules were constructed: [0450] amino acid 1-4 human, murine IgG1 Fc [0451] amino acid 1-4 human, murine albumin [0452] amino acid 1-4 rhesus, murine IgG1 Fc [0453] amino acid 1-4 rhesus, murine albumin [0454] amino acid 5-18 human, murine IgG1 Fc [0455] amino acid 5-18 human, murine albumin [0456] amino acid 5-18 rhesus, murine IgG1 Fc [0457] amino acid 5-18 rhesus, murine albumin [0458] amino acid 37-49 human, murine IgG1 Fc [0459] amino acid 37-49 human, murine albumin [0460] amino acid 37-49 rhesus, murine IgG1 Fc [0461] amino acid 37-49 rhesus, murine albumin

Example 5

[0462] 5.1 Biacore-Based Determination of Bispecific Antibody Affinity to Human and Macaque BCMA and CD3

[0463] Biacore analysis experiments were performed using recombinant BCMA fusion proteins with human serum albumin (ALB) to determine BCMA target binding. For CD3 affinity measurements, recombinant fusion proteins having the N-terminal 27 amino acids of the CD3 epsilon (CD3e) fused to human antibody Fc portion were used. This recombinant protein exists in a human CD3e1-27 version and in a cynomolgous CD3e version, both bearing the epitope of the CD3 binder in the bispecific antibodies.

[0464] In detail, CM5 Sensor Chips (GE Healthcare) were immobilized with approximately 100 to 150 RU of the respective recombinant antigen using acetate buffer pH4.5 according to the manufacturer's manual. The bispecific antibody samples were loaded in five concentrations: 50 nM, 25 nM, 12.5 nM, 6.25 nM and 3.13 nM diluted in HBS-EP running buffer (GE Healthcare). Flow rate was 30 to 35 μl/min for 3 min, then HBS-EP running buffer was applied for 8 min again at a flow rate of 30 to 35 μl/ml. Regeneration of the chip was performed using 10 mM glycine 0.5 M NaCl pH 2.45. Data sets were analyzed using BiaEval Software (see FIGS. 4A-D). In general two independent experiments were performed.

[0465] 5.2 Binding Affinity to Human and Macaque BCMA

[0466] Binding affinities of BCMA/CD3 bispecific antibodies to human and macaque BCMA were determined by Biacore analysis using recombinant BCMA fusion proteins with mouse albumin (ALB).

[0467] In detail, CM5 Sensor Chips (GE Healthcare) were immobilized with approximately 150 to 200 RU of the respective recombinant antigen using acetate buffer pH4.5 according to the manufacturer's manual. The bispecific antibody samples were loaded in five concentrations: 50 nM, 25 nM, 12.5 nM, 6.25 nM and 3.13 nM diluted in HBS-EP running buffer (GE Healthcare). For BCMA affinity determinations the flow rate was 35 μl/min for 3 min, then HBS-EP running buffer was applied for 10, 30 or 60 min again at a flow rate of 35 μl/ml. Regeneration of the chip was performed using a buffer consisting of a 1:1 mixture of 10 mM glycine 0.5 M NaCl pH 1.5 and 6 M guanidine chloride solution. Data sets were analyzed using BiaEval Software (see FIGS. 6A-H). In general two independent experiments were performed.

[0468] Confirmative human and macaque CD3 epsilon binding was performed in single experiments using the same concentrations as applied for BCMA binding; off-rate determination was done for 10 min dissociation time.

[0469] All BCMA/CD3 bispecific antibodies of epitope cluster E3 showed high affinities to human BCMA in the sub-nanomolar range down to 1-digit picomolar range. Binding to macaque BCMA was balanced, also showing affinities in the 1-digit nanomolar down to subnanomolar range. Affinities and affinity gaps of BCMA/CD3 bispecific antibodies are shown in Table 2.

TABLE-US-00002 TABLE 2 Affinities of BCMA/CD3 bispecific antibodies of the epitope cluster E3 to human and macaque BCMA as determined by Biacore analysis, and calculated affinity gaps (ma BCMA:hu BCMA). BCMA/CD3 hu BCMA ma BCMA Affinity gap bispecific antibody [nM] [nM] ma BCMA:hu BCMA BCMA-83 0.031 0.077 2.5 BCMA-98 0.025 0.087 3.5 BCMA-71 0.60 2.2 3.7 BCMA-34 0.051 0.047 1:1.1 BCMA-74 0.088 0.12 1.4 BCMA-20 0.0085 0.016 1.9

[0470] 5.3 Biacore-Based Determination of the Bispecific Antibody Affinity to Human and Macaque BCMA

[0471] The affinities of BCMA/CD3 bispecific antibodies to recombinant soluble BCMA on CM5 chips in Biacore measurements were repeated to reconfirm KDs and especially off-rates using longer dissociation periods (60 min instead of 10 min as used in the previous experiment). All of the tested BCMA/CD3 bispecific antibodies underwent two independent affinity measurements with five different concentrations each.

[0472] The affinities of the BCMA/CD3 bispecific antibodies of the epitope cluster E3 were clearly subnanomolar down to 1-digit picomolar, see examples in Table 3.

TABLE-US-00003 TABLE 3 Affinities (KD) of BCMA/CD3 bispecific antibodies of the epitope cluster E3 from Biacore experiments using extended dissociation times (two independent experiments each). BCMA/CD3 KD [nM] KD [nM] bispecific antibody human BCMA macaque BCMA BCMA-83 0.053 ± 0.017 0.062 ± 0.011 BCMA-98 0.025 ± 0.003 0.060 ± 0.001 BCMA-71 0.242 ± 0.007 0.720 ± 0.028 BCMA-34 0.089 ± 0.019 0.056 ± 0.003 BCMA-74 0.076 ± 0.002 0.134 ± 0.010 BCMA-20 0.0095 ± 0.0050 0.0060 ± 0.0038

Example 6

[0473] Bispecific Binding and Interspecies Cross-Reactivity

[0474] For confirmation of binding to human and macaque BCMA and CD3, bispecific antibodies were tested by flow cytometry using CHO cells transfected with human and macaque BCMA, respectively, the human multiple myeloma cell line NCI-H929 expressing native human BCMA, CD3-expressing human T cell leukemia cell line HPB-ALL (DSMZ, Braunschweig, ACC483) and the CD3-expressing macaque T cell line 4119LnPx (Knappe A, et al., Blood, 2000, 95, 3256-3261). Moreover, untransfected CHO cells were used as negative control.

[0475] For flow cytometry 200,000 cells of the respective cell lines were incubated for 30 min on ice with 50 μl of purified bispecific antibody at a concentration of 5 μg/ml. The cells were washed twice in PBS/2% FCS and binding of the constructs was detected with a murine PentaHis antibody (Qiagen; diluted 1:20 in 50 μl PBS/2% FCS). After washing, bound PentaHis antibodies were detected with an Fc gamma-specific antibody (Dianova) conjugated to phycoerythrin, diluted 1:100 in PBS/2% FCS. Samples were measured by flow cytometry on a FACSCanto II instrument and analyzed by FACSDiva software (both from Becton Dickinson).

[0476] The BCMA/CD3 bispecific antibodies of epitope cluster E3 stained CHO cells transfected with human and macaque BCMA, the human BCMA-expressing multiple myeloma cell line NCI-H929 as well as human and macaque T cells. Moreover, there was no staining of untransfected CHO cells (see FIGS. 7A-F).

Example 7

[0477] Scatchard-Based Determination of Bispecific-Antibody Affinity to Human and Macaque BCMA

[0478] For Scatchard analysis, saturation binding experiments are performed using a monovalent detection system developed at Micromet (anti-His Fab/Alexa 488) to precisely determine monovalent binding of the bispecific antibodies to the respective cell line. 2×10.sup.4 cells of the respective cell line (recombinantly human BCMA-expressing CHO cell line, recombinantly macaque BCMA-expressing CHO cell line) are incubated with each 50 μl of a triplet dilution series (eight dilutions at 1:2) of the respective BCMA bispecific antibody starting at 100 nM followed by 16 h incubation at 4° C. under agitation and one residual washing step. Then, the cells are incubated for further 30 min with 30 μl of an anti-His Fab/Alexa488 solution (Micromet; 30 μg/ml). After one washing step, the cells are resuspended in 150 μl FACS buffer containing 3.5% formaldehyde, incubated for further 15 min, centrifuged, resuspended in FACS buffer and analyzed using a FACS Cantoll machine and FACS Diva software. Data are generated from two independent sets of experiments. Values are plotted as hyperbole binding curves. Respective Scatchard analysis is calculated to extrapolate maximal binding (Bmax). The concentrations of bispecific antibodies at half-maximal binding are determined reflecting the respective KDs. Values of triplicate measurements are plotted as hyperbolic curves. Maximal binding is determined using Scatchard evaluation and the respective KDs are calculated.

[0479] The affinities of BCMA/CD3 bispecific antibodies to CHO cells transfected with human or macaque BCMA were determined by Scatchard analysis as the most reliable method for measuring potential affinity gaps between human and macaque BCMA.

[0480] Cells expressing the BCMA antigen were incubated with increasing concentrations of the respective monomeric BCMA/CD3 bispecific antibody until saturation was reached (16 h). Bound bispecific antibody was detected by flow cytometry. The concentrations of BCMA/CD3 bispecific antibodies at half-maximal binding were determined reflecting the respective KDs.

[0481] Values of triplicate measurements were plotted as hyperbolic curves and as S-shaped curves to demonstrate proper concentration ranges from minimal to optimal binding. Maximal binding (Bmax) was determined (FIGS. 8A-D) using Scatchard evaluation and the respective KDs were calculated. Values depicted in Table 4 were derived from two independent experiments per BCMA/CD3 bispecific antibody.

[0482] Cell based Scatchard analysis confirmed that the BCMA/CD3 bispecific antibodies of the epitope cluster E3 are subnanomolar in affinity to human BCMA and present with a small interspecies BCMA affinity gap of below five.

TABLE-US-00004 TABLE 4 Affinities (KD) of BCMA/CD3 bispecific antibodies of the epitope cluster E3 from cell based Scatchard analysis (two independent experiments each) with the calculated affinity gap KD macaque BCMA/KD human BCMA. x-fold KD difference BCMA/CD3 KD [nM] KD [nM] KD ma vs. bispecific antibody human BCMA macaque BCMA KD hu BCMA BCMA-83 0.40 ± 0.13 1.22 ± 0.25 3.1 BCMA-98 0.74 ± 0.02 1.15 ± 0.64 1.6 BCMA-71 0.78 ± 0.07 3.12 ± 0.26 4.0 BCMA-34 0.77 ± 0.11 0.97 ± 0.33 1.3 BCMA-74 0.67 ± 0.03 0.95 ± 0.06 1.4 BCMA-20 0.78 ± 0.10 0.85 ± 0.01 1.1

Example 8

[0483] Cytotoxic Activity

[0484] 8.1 Chromium Release Assay with Stimulated Human T Cells

[0485] Stimulated T cells enriched for CD8.sup.+ T cells were obtained as described below.

[0486] A petri dish (145 mm diameter, Greiner bio-one GmbH, Kremsmunster) was coated with a commercially available anti-CD3 specific antibody (OKT3, Orthoclone) in a final concentration of 1 μg/ml for 1 hour at 37° C. Unbound protein was removed by one washing step with PBS. 3-5×10.sup.7 human PBMC were added to the precoated petri dish in 120 ml of RPMI 1640 with stabilized glutamine/10% FCS/IL-2 20 U/ml (Proleukin®, Chiron) and stimulated for 2 days. On the third day, the cells were collected and washed once with RPMI 1640. IL-2 was added to a final concentration of 20 U/ml and the cells were cultured again for one day in the same cell culture medium as above.

[0487] CD8.sup.+ cytotoxic T lymphocytes (CTLs) were enriched by depletion of CD4.sup.+ T cells and CD56.sup.+ NK cells using Dynal-Beads according to the manufacturer's protocol.

[0488] Macaque or human BCMA-transfected CHO target cells were washed twice with PBS and labeled with 11.1 MBq .sup.51Cr in a final volume of 100 μl RPMI with 50% FCS for 60 minutes at 37° C. Subsequently, the labeled target cells were washed 3 times with 5 ml RPMI and then used in the cytotoxicity assay. The assay was performed in a 96-well plate in a total volume of 200 μl supplemented RPMI with an E:T ratio of 10:1. A starting concentration of 0.01-1 μg/ml of purified bispecific antibody and threefold dilutions thereof were used. Incubation time for the assay was 18 hours. Cytotoxicity was determined as relative values of released chromium in the supernatant relative to the difference of maximum lysis (addition of Triton-X) and spontaneous lysis (without effector cells). All measurements were carried out in quadruplicates. Measurement of chromium activity in the supernatants was performed in a Wizard 3″ gamma counter (Perkin Elmer Life Sciences GmbH, Köln, Germany). Analysis of the results was carried out with Prism 5 for Windows (version 5.0, GraphPad Software Inc., San Diego, Calif., USA). EC50 values calculated by the analysis program from the sigmoidal dose response curves were used for comparison of cytotoxic activity (see FIGS. 5A-B).

[0489] 8.2 Potency of Redirecting Stimulated Human Effector T Cells Against Human BCMA-Transfected CHO Cells

[0490] The cytotoxic activity of BCMA/CD3 bispecific antibodies was analyzed in a 51-chromium (.sup.51Cr) release cytotoxicity assay using CHO cells transfected with human BCMA as target cells, and stimulated enriched human CD8 T cells as effector cells. The experiment was carried out as described in Example 8.1.

[0491] All BCMA/CD3 bispecific antibodies of epitope cluster E3 showed very potent cytotoxic activity against human BCMA transfected CHO cells with EC50-values in the 1-digit pg/ml range or even below (FIGS. 9A-B and Table 5). So the epitope cluster E3 presents with a very favorable epitope-activity relationship supporting very potent bispecific antibody mediated cytotoxic activity.

TABLE-US-00005 TABLE 5 EC50 values [pg/ml] of BCMA/CD3 bispecific antibodies of the epitope cluster E3 analyzed in a 51-chromium (.sup.51Cr) release cytotoxicity assay using CHO cells transfected with human BCMA as target cells, and stimulated enriched human CD8 T cells as effector cells. BCMA/CD3 bispecific antibody EC50 [pg/ml] R square value BCMA-83 0.38 0.79 BCMA-98 0.27 0.85 BCMA-71 3.2 0.85 BCMA-34 3.4 0.81 BCMA-74 0.73 0.80 BCMA-20 0.83 0.82

[0492] 8.3 FACS-Based Cytotoxicity Assay with Unstimulated Human PBMC

[0493] Isolation of Effector Cells

[0494] Human peripheral blood mononuclear cells (PBMC) were prepared by Ficoll density gradient centrifugation from enriched lymphocyte preparations (buffy coats), a side product of blood banks collecting blood for transfusions. Buffy coats were supplied by a local blood bank and PBMC were prepared on the same day of blood collection. After Ficoll density centrifugation and extensive washes with Dulbecco's PBS (Gibco), remaining erythrocytes were removed from PBMC via incubation with erythrocyte lysis buffer (155 mM NH.sub.4Cl, 10 mM KHCO.sub.3, 100 μM EDTA). Platelets were removed via the supernatant upon centrifugation of PBMC at 100×g. Remaining lymphocytes mainly encompass B and T lymphocytes, NK cells and monocytes. PBMC were kept in culture at 37° C./5% CO.sub.2 in RPMI medium (Gibco) with 10% FCS (Gibco).

[0495] Depletion of CD14.sup.+ and CD56.sup.+ Cells

[0496] For depletion of CD14.sup.+ cells, human CD14 MicroBeads (Milteny Biotec, MACS, #130-050-201) were used, for depletion of NK cells human CD56 MicroBeads (MACS, #130-050-401). PBMC were counted and centrifuged for 10 min at room temperature with 300×g. The supernatant was discarded and the cell pellet resuspended in MACS isolation buffer [80 μL/10.sup.7 cells; PBS (Invitrogen, #20012-043), 0.5% (v/v) FBS (Gibco, #10270-106), 2 mM EDTA (Sigma-Aldrich, #E-6511)]. CD14 MicroBeads and CD56 MicroBeads (20 μL/10.sup.7 cells) were added and incubated for 15 min at 4-8° C. The cells were washed with MACS isolation buffer (1-2 mL/10.sup.7 cells). After centrifugation (see above), supernatant was discarded and cells resuspended in MACS isolation buffer (500 μL/10.sup.8 cells). CD14/CD56 negative cells were then isolated using LS Columns (Miltenyi Biotec, #130-042-401). PBMC w/o CD14+/CD56+ cells were cultured in RPMI complete medium i.e. RPMI1640 (Biochrom AG, #FG1215) supplemented with 10% FBS (Biochrom AG, #S0115), 1× non-essential amino acids (Biochrom AG, #K0293), 10 mM Hepes buffer (Biochrom AG, #L1613), 1 mM sodium pyruvate (Biochrom AG, #L0473) and 100 U/mL penicillin/streptomycin (Biochrom AG, #A2213) at 37° C. in an incubator until needed.

[0497] Target Cell Labeling

[0498] For the analysis of cell lysis in flow cytometry assays, the fluorescent membrane dye DiOC.sub.18 (DiO) (Molecular Probes, #V22886) was used to label human BCMA- or macaque BCMA-transfected CHO cells as target cells and distinguish them from effector cells. Briefly, cells were harvested, washed once with PBS and adjusted to 10.sup.6 cell/mL in PBS containing 2% (v/v) FBS and the membrane dye DiO (5 μL/10.sup.6 cells). After incubation for 3 min at 37° C., cells were washed twice in complete RPMI medium and the cell number adjusted to 1.25×10.sup.5 cells/mL. The vitality of cells was determined using 0.5% (v/v) isotonic EosinG solution (Roth, #45380).

[0499] Flow Cytometry Based Analysis

[0500] This assay was designed to quantify the lysis of macaque or human BCMA-transfected CHO cells in the presence of serial dilutions of BCMA bispecific antibodies.

[0501] Equal volumes of DiO-labeled target cells and effector cells (i.e., PBMC w/o CD14.sup.+ cells) were mixed, resulting in an E:T cell ratio of 10:1. 160 μL of this suspension were transferred to each well of a 96-well plate. 40 μL of serial dilutions of the BCMA bispecific antibodies and a negative control bispecific (an CD3-based bispecific antibody recognizing an irrelevant target antigen) or RPMI complete medium as an additional negative control were added. The bispecific antibody-mediated cytotoxic reaction proceeded for 48 hours in a 7% CO.sub.2 humidified incubator. Then cells were transferred to a new 96-well plate and loss of target cell membrane integrity was monitored by adding propidium iodide (PI) at a final concentration of 1 μg/mL. PI is a membrane impermeable dye that normally is excluded from viable cells, whereas dead cells take it up and become identifiable by fluorescent emission.

[0502] Samples were measured by flow cytometry on a FACSCanto II instrument and analyzed by FACSDiva software (both from Becton Dickinson).

[0503] Target cells were identified as DiO-positive cells. PI-negative target cells were classified as living target cells. Percentage of cytotoxicity was calculated according to the following formula:

[00002]$\mathrm{Cytotoxicity}\left[\%\right]=\frac{n_{\mathrm{dead}\mathrm{targetcell}s}}{n_{\mathrm{targetcells}}}\times 100$$n=\mathrm{number}\mathrm{of}\mathrm{events}$

[0504] Using GraphPad Prism 5 software (Graph Pad Software, San Diego), the percentage of cytotoxicity was plotted against the corresponding bispecific antibody concentrations. Dose response curves were analyzed with the four parametric logistic regression models for evaluation of sigmoid dose response curves with fixed hill slope and EC50 values were calculated.

[0505] 8.4 Unstimulated Human PBMC Against Human BCMA-Transfected Target Cells

[0506] The cytotoxic activity of BCMA/CD3 bispecific antibodies was analyzed in a FACS-based cytotoxicity assay using CHO cells transfected with human BCMA as target cells, and unstimulated human PBMC as effector cells. The assay was carried out as described above (Example 8.3).

[0507] The results of the FACS-based cytotoxicity assays with unstimulated human PBMC as effector cells and human BCMA-transfected CHO cells as targets are shown in FIG. 10 and Table 6.

TABLE-US-00006 TABLE 6 EC50 values [pg/ml] of BCMA/CD3 bispecific antibodies of epitope cluster E3 as measured in a 48-hour FACS-based cytotoxicity assay with unstimulated human PBMC as effector cells and CHO cells transfected with human BCMA as target cells. BCMA/CD3 bispecific antibody EC50 [pg/ml] R square value BCMA-83 212 0.97 BCMA-7 102 0.97 BCMA-5 58.4 0.94 BCMA-98 53.4 0.95 BCMA-71 208 0.94 BCMA-34 149 0.94 BCMA-74 125 0.97 BCMA-20 176 0.98

Example 9

[0508] 9.1 Exclusion of Cross-Reactivity with BAFF-Receptor

[0509] For flow cytometry, 200,000 cells of the respective cell lines were incubated for 30 min on ice with 50 μl of purified bispecific molecules at a concentration of 5 μg/ml. The cells were washed twice in PBS with 2% FCS and binding of the constructs was detected with a murine PentaHis antibody (Qiagen; diluted 1:20 in 50 μl PBS with 2% FCS). After washing, bound PentaHis antibodies were detected with an Fc gamma-specific antibody (Dianova) conjugated to phycoerythrin, diluted 1:100 in PBS with 2% FCS. Samples were measured by flow cytometry on a FACSCanto II instrument and analyzed by FACSDiva software (both from Becton Dickinson). The bispecific binders were shown to not be cross-reactive with BAFF receptor.

[0510] 9.2 Exclusion of BCMA/CD3 Bispecific Antibody Cross-Reactivity with Human BAFF-Receptor (BAFF-R) and TACI

[0511] For exclusion of binding to human BAFF-R and TACI, BCMA/CD3 bispecific antibodies were tested by flow cytometry using CHO cells transfected with human BAFF-R and TACI, respectively. Moreover, L363 multiple myeloma cells were used as positive control for binding to human BCMA. Expression of BAFF-R and TACI antigen on CHO cells was confirmed by two positive control antibodies. Flow cytometry was performed as described in the previous example.

[0512] Flow cytometric analysis confirmed that none of the BCMA/CD3 bispecific antibodies of the epitope cluster E3 cross-reacts with human BAFF-R or human TACI (see FIGS. 11A-H).

Example 10

[0513] Cytotoxic Activity

[0514] The potency of human-like BCMA bispecific antibodies in redirecting effector T cells against BCMA-expressing target cells is analyzed in five additional in vitro cytotoxicity assays:

[0515] 1. The potency of BCMA bispecific antibodies in redirecting stimulated human effector T cells against a BCMA-positive (human) tumor cell line is measured in a 51-chromium release assay.

[0516] 2. The potency of BCMA bispecific antibodies in redirecting the T cells in unstimulated human PBMC against human BCMA-transfected CHO cells is measured in a FACS-based cytotoxicity assay.

[0517] 3. The potency of BCMA bispecific antibodies in redirecting the T cells in unstimulated human PBMC against a BCMA-positive (human) tumor cell line is measured in a FACS-based cytotoxicity assay.

[0518] 4. For confirmation that the cross-reactive BCMA bispecific antibodies are capable of redirecting macaque T cells against macaque BCMA-transfected CHO cells, a FACS-based cytotoxicity assay is performed with a macaque T cell line as effector T cells.

[0519] 5. The potency gap between monomeric and dimeric forms of BCMA bispecific antibodies is determined in a 51-chromium release assay using human BCMA-transfected CHO cells as target cells and stimulated human T cells as effector cells.

Example 11

[0520] Stimulated Human T Cells Against the BCMA-Positive Human Multiple Myeloma Cell Line L363

[0521] The cytotoxic activity of BCMA/CD3 bispecific antibodies was analyzed in a 51-chromium (.sup.51Cr) release cytotoxicity assay using the BCMA-positive human multiple myeloma cell line L363 (DSMZ No. ACC49) as source of target cells, and stimulated enriched human CD8 T cells as effector cells. The assay was carried out as described in Example 8.1.

[0522] In accordance with the results of the 51-chromium release assays with stimulated enriched human CD8 T lymphocytes as effector cells and human BCMA-transfected CHO cells as targets, BCMA/CD3 bispecific antibodies of epitope cluster E3 are very potent in cytotoxic activity (FIG. 12 and Table 7).

[0523] Another group of antibodies was identified during epitope clustering (see Examples 1 and 3), which is capable of binding to epitope clusters 1 and 4 of BCMA (“E1/E4”). Unexpectedly, BCMA/CD3 bispecific antibodies of epitope cluster E1/E4—although potent in cytotoxic activity against CHO cell transfected with human BCMA—proved to be rather weakly cytotoxic against the human multiple myeloma cell line L363 expressing native BCMA at low density on the cell surface (FIG. 12 and Table 7). Without wishing to be bound by theory, the inventors believe that the E1/E4 epitope of human BCMA might be less well accessible on natural BCMA expressers than on BCMA-transfected cells.

TABLE-US-00007 TABLE 7 EC50 values [pg/ml] of BCMA/CD3 bispecific antibodies of epitope clusters E1/E4 (rows 1 and 2) and E3 (rows 3 to 8) analyzed in an 18-hour 51-chromium (.sup.51Cr) release cytotoxicity assay with the BCMA-positive human multiple myeloma cell line L363 as source of target cells, and stimulated enriched human CD8 T cells as effector cells. BCMA/CD3 bispecific antibody EC50 [pg/ml] R square value 1 BCMA-54 685 0.84 2 BCMA-53 1107 0.82 3 BCMA-83 28 0.83 4 BCMA-98 10 0.81 5 BCMA-71 125 0.86 6 BCMA-34 42 0.81 7 BCMA-74 73 0.79 8 BCMA-20 21 0.85

Example 12

[0524] Unstimulated Human PBMC Against the BCMA-Positive Human Multiple Myeloma Cell Line L363

[0525] The cytotoxic activity of BCMA/CD3 bispecific antibodies was furthermore analyzed in a FACS-based cytotoxicity assay using the BCMA-positive human multiple myeloma cell line L363 (DSMZ, ACC49)—showing the weakest surface expression of native BCMA of all tested target T cell lines—as source of target cells and unstimulated human PBMC as effector cells. The assay was carried out as described above (Example 8.3).

[0526] As observed in the 51-chromium release assay with stimulated enriched human CD8 T lymphocytes against the human multiple myeloma cell line L363, the BCMA/CD3 bispecific antibodies of epitope cluster E1/E4—in contrast to their potent cytotoxic activity against CHO cell transfected with human BCMA—proved to be again less potent in redirecting the cytotoxic activity of unstimulated PBMC against the human multiple myeloma cell line L363 expressing native BCMA at low density on the cell surface. This is in line with the theory provided hereinabove, i.e., the E1/E4 epitope of human BCMA may be less well accessible on natural BCMA expressers than on BCMA-transfected cells. BCMA/CD3 bispecific antibodies of the epitope cluster E3 presented with 3-digit pg/ml EC50-values in this assay (see FIG. 13 and Table 8).

TABLE-US-00008 TABLE 8 EC50 values [pg/ml] of BCMA/CD3 bispecific antibodies of epitope clusters E1/E4 (rows 1 and 2) and E3 (rows 3 to 8) as measured in a 48-hour FACS-based cytotoxicity assay with unstimulated human PBMC as effector cells and the human multiple myeloma cell line L363 as source of target cells. BCMA/CD3 bispecific antibody EC50 [pg/ml] R square value 1 BCMA-54 3162 0.99 2 BCMA-53 2284 0.98 3 BCMA-83 241 0.99 4 BCMA-98 311 0.99 5 BCMA-71 284 0.99 6 BCMA-34 194 0.99 7 BCMA-74 185 0.99 8 BCMA-20 191 0.99

[0527] Expectedly, EC50-values were higher in cytotoxicity assays with unstimulated PBMC as effector cells than in cytotoxicity assays using enriched stimulated human CD8 T cells.

Example 13

[0528] Unstimulated Human PBMC Against the BCMA-Positive Human Multiple Myeloma Cell Line NCI-H929

[0529] The cytotoxic activity of BCMA/CD3 bispecific antibodies was analyzed in a FACS-based cytotoxicity assay using the BCMA-positive human multiple myeloma cell line NCI-H929 (ATCC CRL-9068) as source of target cells and unstimulated human PBMC as effector cells. The assay was carried out as described above (Example 8.3).

[0530] The results of this assay with another human multiple myeloma cell line (i.e. NCI-H929) expressing native BCMA on the cell surface confirm those obtained with human multiple myeloma cell line L363. Again, BCMA/CD3 bispecific antibodies of epitope cluster E1/E4—in contrast to their potent cytotoxic activity against CHO cell transfected with human BCMA—proved to be less potent in redirecting the cytotoxic activity of unstimulated PBMC against human multiple myeloma cells confirming the theory that the E1/E4 epitope of human BCMA may be less well accessible on natural BCMA expressers than on BCMA-transfected cells. Such an activity gap between BCMA-transfected target cells and natural expressers as seen for the E1/E4 binders was not found for the E3. BCMA/CD3 bispecific antibodies of the epitope cluster E3 presented with 2- to 3-digit pg/ml EC50-values and hence redirected unstimulated PBMC against NCI-H929 target cells with very good EC50-values (see FIG. 14 and Table 9).

TABLE-US-00009 TABLE 9 EC50 values [pg/ml] of BCMA/CD3 bispecific antibodies of epitope clusters E1/E4 (rows 1 and 2) and E3 (rows 3 to 8) as measured in a 48-hour FACS-based cytotoxicity assay with unstimulated human PBMC as effector cells and the human multiple myeloma cell line NCI-H929 as source of target cells. BCMA/CD3 bispecific antibody EC50 [pg/ml] R square value 1 BCMA-54 2604 0.99 2 BCMA-53 2474 0.99 3 BCMA-83 154 0.93 4 BCMA-98 67.6 0.87 5 BCMA-71 50.7 0.96 6 BCMA-34 227 0.99 7 BCMA-74 103 0.97 8 BCMA-20 123 0.97

[0531] As expected, EC50-values were lower with the human multiple myeloma cell line NCI-H929, which expresses higher levels of BCMA on the cell surface compared to L363.

Example 14

[0532] Macaque T Cells Against Macaque BCMA-Expressing Target Cells

[0533] Finally, the cytotoxic activity of BCMA/CD3 bispecific antibodies was analyzed in a FACS-based cytotoxicity assay using CHO cells transfected with macaque BCMA as target cells, and a macaque T cell line as source of effector cells.

[0534] The macaque T cell line 4119LnPx (Knappe et al. Blood 95:3256-61 (2000)) was used as source of effector cells. Target cell labeling of macaque BCMA-transfected CHO cells and flow cytometry based analysis of cytotoxic activity was performed as described above.

[0535] Macaque T cells from cell line 4119LnPx were induced to efficiently kill macaque BCMA-transfected CHO cells by BCMA/CD3 bispecific antibodies of the E3 epitope cluster. The antibodies presented very potently with 1-digit to low 2-digit pg/ml EC50-values in this assay, confirming that these antibodies are very active in the macaque system. On the other hand, BCMA/CD3 bispecific antibodies of the epitope cluster E1/E4 showed a significantly weaker potency with EC50-values in the 2-digit to 3-digit pg/ml range (see FIG. 15 and Table 10). The E3 specific antibodies are hence about 3 to almost 100 times more potent in the macaque system.

TABLE-US-00010 TABLE 10 EC50 values [pg/ml] of BCMA/CD3 bispecific antibodies of epitope clusters E1/E4 (rows 1 and 2) and E3 (rows 3 to 8) as measured in a 48-hour FACS-based cytotoxicity assay with macaque T cell line 4119LnPx as effector cells and CHO cells transfected with macaque BCMA as target cells. BCMA/CD3 bispecific antibody EC50 [pg/ml] R square value 1 BCMA-54 78.5 0.98 2 BCMA-53 183 0.96 3 BCMA-83 10.9 0.97 4 BCMA-98 2.5 0.89 5 BCMA-71 3.2 0.97 6 BCMA-34 2.1 0.95 7 BCMA-74 2.0 0.95 8 BCMA-20 26 0.98

Example 15

[0536] Potency Gap Between BCMA/CD3 Bispecific Antibody Monomer and Dimer

[0537] In order to determine the difference in cytotoxic activity between the monomeric and the dimeric isoform of individual BCMA/CD3 bispecific antibodies (referred to as potency gap), a 51-chromium release cytotoxicity assay as described hereinabove (Example 8.1) was carried out with purified BCMA/CD3 bispecific antibody monomer and dimer. The potency gap was calculated as ratio between EC50 values of the bispecific antibody's monomer and dimer. Potency gaps of the tested BCMA/CD3 bispecific antibodies of the epitope cluster E3 were between 0.03 and 1.2. There is hence no substantially more active dimer compared to its respective monomer.

Example 16

[0538] Monomer to Dimer Conversion after Three Freeze/Thaw Cycles

[0539] Bispecific BCMA/CD3 antibody monomer were subjected to three freeze/thaw cycles followed by high performance SEC to determine the percentage of initially monomeric antibody, which had been converted into antibody dimer.

[0540] 15 μg of monomeric antibody were adjusted to a concentration of 250 μg/ml with generic buffer and then frozen at −80° C. for 30 min followed by thawing for 30 min at room temperature. After three freeze/thaw cycles the dimer content was determined by HP-SEC. To this end, 15 μg aliquots of the monomeric isoforms of the antibodies were thawed and equalized to a concentration of 250 μg/ml in the original SEC buffer (10 mM citric acid—75 mM lysine HCl—4% trehalose—pH 7.2) followed by incubation at 37° C. for 7 days. A high resolution SEC Column TSK Gel G3000 SWXL (Tosoh, Tokyo-Japan) was connected to an Akta Purifier 10 FPLC (GE Lifesciences) equipped with an A905 Autosampler. Column equilibration and running buffer consisted of 100 mM KH2PO4-200 mM Na2SO4 adjusted to pH 6.6. After 7 days of incubation, the antibody solution (15 μg protein) was applied to the equilibrated column and elution was carried out at a flow rate of 0.75 ml/min at a maximum pressure of 7 MPa. The whole run was monitored at 280, 254 and 210 nm optical absorbance. Analysis was done by peak integration of the 210 nm signal recorded in the Akta Unicorn software run evaluation sheet. Dimer content was calculated by dividing the area of the dimer peak by the total area of monomer plus dimer peak.

[0541] The BCMA/CD3 bispecific antibodies of the epitope cluster E3 presented with dimer percentages of 0.7 to 1.1% after three freeze/thaw cycles, which is considered good. However, the dimer conversion rates of BCMA/CD3 bispecific antibodies of the epitope cluster E1/E4 reached unfavorably high values, exceeding the threshold to disadvantageous dimer values of ≥2.5% (4.7% and 3.8%, respectively), see Table 11.

TABLE-US-00011 TABLE 11 Percentage of monomeric versus dimeric BCMA/CD3 bispecific antibodies of epitope clusters E1/E4 (rows 1 and 2) and E3 (rows 3 to 8) after three freeze/thaw cycles as determined by High Performance Size Exclusion Chromatography (HP-SEC). BCMA/CD3 bispecific antibody Monomer [%] Dimer [%] 1 BCMA-54 95.3 4.7 2 BCMA-53 96.2 3.8 3 BCMA-83 99.1 0.9 4 BCMA-98 99.1 0.9 5 BCMA-71 99.1 0.9 6 BCMA-34 98.9 1.1 7 BCMA-74 99.3 0.7 8 BCMA-20 99.2 0.8

Example 17

[0542] Thermostability

[0543] Temperature melting curves were determined by Differential Scanning Calorimetry (DSC) to determine intrinsic biophysical protein stabilities of the BCMA/CD3 bispecific antibodies. These experiments were performed using a MicroCal LLC (Northampton, Mass., U.S.A.) VP-DSC device. The energy uptake of a sample containing BCMA/CD3 bispecific antibody was recorded from 20 to 90° C. compared to a sample which just contained the antibody's formulation buffer.

[0544] In detail, BCMA/CD3 bispecific antibodies were adjusted to a final concentration of 250 μg/ml in storage buffer. 300 μl of the prepared protein solutions were transferred into a deep well plate and placed into the cooled autosampler rack position of the DSC device. Additional wells were filled with the SEC running buffer as reference material for the measurement. For the measurement process the protein solution was transferred by the autosampler into a capillary. An additional capillary was filled with the SEC running buffer as reference. Heating and recording of required heating energy to heat up both capillaries at equal temperature ranging from 20 to 90° C. was done for all samples.

[0545] For recording of the respective melting curve, the overall sample temperature was increased stepwise. At each temperature T energy uptake of the sample and the formulation buffer reference was recorded. The difference in energy uptake Cp (kcal/mole/° C.) of the sample minus the reference was plotted against the respective temperature. The melting temperature is defined as the temperature at the first maximum of energy uptake.

[0546] All tested BCMA/CD3 bispecific antibodies of the epitope cluster E3 showed favorable thermostability with melting temperatures above 60° C., more precisely between 61.62° C. and 63.05° C.

Example 18

[0547] Exclusion of Plasma Interference by Flow Cytometry

[0548] To determine potential interaction of BCMA/CD3 bispecific antibodies with human plasma proteins, a plasma interference test was established. To this end, 10 μg/ml of the respective BCMA/CD3 bispecific antibodies were incubated for one hour at 37° C. in 90% human plasma. Subsequently, the binding to human BCMA expressing CHO cells was determined by flow cytometry.

[0549] For flow cytometry, 200,000 cells of the respective cell lines were incubated for 30 min on ice with 50 μl of purified antibody at a concentration of 5 μg/ml. The cells were washed twice in PBS/2% FCS and binding of the constructs was detected with a murine PentaHis antibody (Qiagen; diluted 1:20 in 50 μl PBS/2% FCS). After washing, bound PentaHis antibodies were detected with an Fc gamma-specific antibody (Dianova) conjugated to phycoerythrin, diluted 1:100 in PBS/2% FCS. Samples were measured by flow cytometry on a FACSCanto II instrument and analyzed by FACSDiva software (both from Becton Dickinson).

[0550] The obtained data were compared with a control assay using PBS instead of human plasma. Relative binding was calculated as follows:

[0551] (signal PBS sample/signal w/o detection agent)/(signal plasma sample/signal w/o detection agent).

[0552] In this experiment it became obvious that there was no significant reduction of target binding of the respective BCMA/CD3 bispecific antibodies of the epitope cluster E3 mediated by plasma proteins. The relative plasma interference value was below a value of 2 in all cases, more precisely between 1.29±0.25 and 1.70±0.26 (with a value of “2” being considered as lower threshold for interference signals).

Example 19

[0553] Therapeutic Efficacy of BCMA/CD3 Bispecific Antibodies in Human Tumor Xenograft Models

[0554] On day 1 of the study, 5×10.sup.6 cells of the human cancer cell line NCI-H929 were subcutaneously injected in the right dorsal flank of female NOD/SCID mice.

[0555] On day 9, when the mean tumor volume had reached about 100 mm.sup.3, in vitro expanded human CD3.sup.+ T cells were transplanted into the mice by injection of about 2×10.sup.7 cells into the peritoneal cavity of the animals. Mice of vehicle control group 1 (n=5) did not receive effector cells and were used as an untransplanted control for comparison with vehicle control group 2 (n=10, receiving effector cells) to monitor the impact of T cells alone on tumor growth.

[0556] The antibody treatment started on day 13, when the mean tumor volume had reached about 200 mm.sup.3. The mean tumor size of each treatment group on the day of treatment start was not statistically different from any other group (analysis of variance). Mice were treated with 0.5 mg/kg/day of the BCMA/CD3 bispecific antibodies BCMA-98 x CD3 (group 3, n=7) or BCMA-34 x CD3 (group 4, n=6) by intravenous bolus injection for 17 days.

[0557] Tumors were measured by caliper during the study and progress evaluated by intergroup comparison of tumor volumes (TV). The tumor growth inhibition T/C [%] was determined by calculating TV as T/C %=100×(median TV of analyzed group)/(median TV of control group 2). The results are shown in Table 12 and FIG. 16.

TABLE-US-00012 TABLE 12 Median tumor volume (TV) and tumor growth inhibition (T/C) at days 13 to 30. Dose group Data d13 d14 d15 d16 d18 d19 d21 d23 d26 d28 d30 1 Vehi. med. TV 238 288 395 425 543 632 863 1067 1116 1396 2023 control [mm.sup.3] w/o T/C [%] 120 123 127 118 104 114 122 113 87 85 110 T cells 2 med. TV 198 235 310 361 525 553 706 942 1290 1636 1839 Vehicle [mm.sup.3] control T/C [%] 100 100 100 100 100 100 100 100 100 100 100 3 med. TV 207 243 248 235 164 137 93.5 46.2 21.2 0.0 0.0 BCMA- [mm.sup.3] 98 T/C [%] 105 104 79.7 65.0 31.2 24.7 13.2 4.9 1.6 0.0 0.0 4 med. TV 206 233 212 189 154 119 56.5 17.4 0.0 0.0 0.0 BCMA- [mm.sup.3] 34 T/C [%] 104 99.2 68.2 52.3 29.4 21.5 8.0 1.8 0.0 0.0 0.0

Example 20

[0558] Exclusion of Lysis of Target Negative Cells

[0559] An in vitro lysis assay was carried out using the BCMA-positive human multiple myeloma cell line NCI-H929 and purified T cells at an effector to target cell ratio of 5:1 and with an incubation time of 24 hours. BCMA/CD3 bispecific antibodies of epitope cluster E3 (BCMA-34 and BCMA-98) showed high potency and efficacy in the lysis of NCI-H929. However, no lysis was detected in the BCMA negative cell lines HL60 (AML/myeloblast morphology), MES-SA (uterus sarcoma, fibroblast morphology), and SNU-16 (stomach carcinoma, epithelial morphology) for up to 500 nM of the respective antibody.

Example 21

[0560] Induction of T Cell Activation of Different PBMC Subsets

[0561] A FACS-based cytotoxicity assay (48 h; E:T=10:1) was carried out using human multiple myeloma cell lines NCI-H929, L-363 and OPM-2 as target cells and different subsets of human PBMC (CD4.sup.+/CD8.sup.+/CD25.sup.+/CD69.sup.+) as effector cells. The results (see Table 13) show that the degree of activation, as measured by the EC.sub.50 value, is essentially in the same range for the different analyzed PBMC subsets.

TABLE-US-00013 TABLE 13 EC50 values [ng/ml] of BCMA/CD3 bispecific antibodies of epitope cluster E3 as measured in a 48-hour FACS-based cytotoxicity assay with different subsets of human PBMC as effector cells and different human multiple myeloma cell lines as target cells. EC.sub.50 [ng/ml] Cell line PBMC BCMA-98 × CD3 BCMA-34 × CD3 NCI-H929 CD4.sup.+/CD25.sup.+ 1.46 1.20 CD8.sup.+/CD25.sup.+ 0.53 0.49 CD4.sup.+/CD69.sup.+ 0.59 0.47 CD8.sup.+/CD69.sup.+ 0.21 0.21 OPM-2 CD4.sup.+/CD25.sup.+ 2.52 4.88 CD8.sup.+/CD25.sup.+ 1.00 1.20 CD4.sup.+/CD69.sup.+ 1.65 2.27 CD8.sup.+/CD69.sup.+ 0.48 0.42 L-363 CD4.sup.+/CD25.sup.+ 0.54 0.62 CD8.sup.+/CD25.sup.+ 0.24 0.28 CD4.sup.+/CD69.sup.+ 0.35 0.34 CD8.sup.+/CD69.sup.+ 0.12 0.11

Example 22

[0562] Induction of Cytokine Release

[0563] A FACS-based cytotoxicity assay (48 h; E:T=10:1) was carried out using human multiple myeloma cell lines NCI-H929, L-363 and OPM-2 as target cells and human PBMC as effector cells. The levels of cytokine release [pg/mi] were determined at increasing concentrations of BCMA/CD3 bispecific antibodies of epitope cluster E3. The following cytokines were analyzed: II-2, IL-6, IL-10, TNF and IFN-gamma. The results are shown in Table 14 and FIGS. 17A-F.

TABLE-US-00014 TABLE 14 Release of IL-2, IL-6, IL-10, TNF and IFN-gamma [pg/ml] induced by 2.5 μg/ml of BCMA/CD3 bispecific antibodies of epitope cluster E3 (BCMA-98 and BCMA-34) in a 48-hour FACS-based cytotoxicity assay with human PBMC as effector cells and different human multiple myeloma cell lines as target cells (E:T = 10:1). Cytokine levels [pg/ml] IL-2 IL-6 IL-10 TNF IFN-gamma NCI-H929 BCMA-98 1357 699 2798 10828 73910 BCMA-34 1327 631 3439 6675 77042 OPM-2 BCMA-98 41 118 990 5793 33302 BCMA-34 28 109 801 4913 23214 L-363 BCMA-98 97 314 2433 5397 64981 BCMA-34 168 347 2080 5930 75681

TABLE-US-00015 SEQ ID NO Designation Designation Format/source Type Sequence 1 BCMA-1 BC 5G9 91- VH CDR1 aa NYDMA C7-610 2 BCMA-1 BC 5G9 91- VH CDR2 aa SIITSGDATYYRDSVKG C7-610 3 BCMA-1 BC 5G9 91- VH CDR3 aa HDYYDGSYGFAY C7-610 4 BCMA-1 BC 5G9 91- VL CDR1 aa KASQSVGINVD C7-610 5 BCMA-1 BC 5G9 91- VL CDR2 aa GASNRHT C7-610 6 BCMA-1 BC 5G9 91- VL CDR3 aa LQYGSIPFT C7-610 7 BCMA-1 BC 5G9 VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDATYYRDSVKGR 91-C7-610 FTISRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSS 8 BCMA-1 BC 5G9 91- VL aa EIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS C7-610 GREFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK 9 BCMA-1 BC 5G9 91- scFv aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDATYYRDSVKGR C7-610 FTISRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGREFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK 10 BCMA-1 HL × BC 5G9 91- bispecific aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDATYYRDSVKGR CD3 HL C7-B10 HL × molecule FTISRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGREFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 11 BCMA-2 BC 5G9 91- VH CDR1 aa NYDMA C7-D8 12 BCMA-2 BC 5G9 91- VH CDR2 aa SIITSGDMTYYRDSVKG C7-D8 13 BCMA-2 BC 5G9 91- VH CDR3 aa HDYYDGSYGFAY C7-D8 14 BCMA-2 BC 5G9 91- VL CDR1 aa KASQSVGINVD C7-D8 15 BCMA-2 BC 5G9 91- VL CDR2 aa GASNRHT C7-D8 16 BCMA-2 BC 5G9 91- VL CDR3 aa LQYGSIPFT C7-D8 17 BCMA-2 BC 5G9 91- VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR C7-D8 FTISRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSS 18 BCMA-2 BC 5G9 91- VL aa EIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS C7-D8 GREFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK 19 BCMA-2 BC 5G9 91- scFv aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR C7-D8 FTISRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGREFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK 20 BCMA-2 HL × BC 5G9 91- bispecific aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR CD3 HL C7-D8 HL × molecule FTISRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGREFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 21 BCMA-3 BC 5G9 91- VH CDR1 aa NYDMA E4-B10 22 BCMA-3 BC 5G9 91- VH CDR2 aa SIITSGDATYYRDSVKG E4-B10 23 BCMA-3 BC 5G9 91- VH CDR3 aa HDYYDGSYGFAY E4-B10 24 BCMA-3 BC 5G9 91- VL CDR1 aa KASQSVGINVD E4-B10 25 BCMA-3 BC 5G9 91- VL CDR2 aa GASNRHT E4-B10 26 BCMA-3 BC 5G9 91- VL CDR3 aa LQYGSIPFT E4-610 27 BCMA-3 BC 5G9 91- VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDATYYRDSVKGR E4-B10 FTISRDNSKNTLYLQMNSLRSEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSS 28 BCMA-3 BC 5G9 91- aa EIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS E4-B10 VL GTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK 29 BCMA-3 BC 5G9 91- scFv aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDATYYRDSVKGR E4-B10 FTISRDNSKNTLYLQMNSLRSEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK 30 BCMA-3 HL × BC 5G9 91- bispecific aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDATYYRDSVKGR CD3 HL E4-B10 HL × molecule FTISRDNSKNTLYLQMNSLRSEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 31 BCMA-4 BC 5G9 91- VH CDR1 aa NYDMA E4-D8 32 BCMA-4 BC 5G9 91- VH CDR2 aa SIITSGDMTYYRDSVKG E4-D8 33 BCMA-4 BC 5G9 91- VH CDR3 aa HDYYDGSYGFAY E4-D8 34 BCMA-4 BC 5G9 91- VL CDR1 aa KASQSVGINVD E4-D8 35 BCMA-4 BC 5G9 91- VL CDR2 aa GASNRHT E4-D8 36 BCMA-4 BC 5G9 91- VL CDR3 aa LQYGSIPFT E4-D8 37 BCMA-4 BC 5G9 91- VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR E4-D8 FTISRDNSKNTLYLQMNSLRSEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSS 38 BCMA-4 BC 5G9 91- VL aa EIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS E4-D8 GTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK 39 BCMA-4 BC 5G9 91- scFv aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR E4-D8 FTISRDNSKNTLYLQMNSLRSEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK 40 BCMA-4 HL × BC 5G9 91- bispecific aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR CD3 HL E4-D8 HL × molecule FTISRDNSKNTLYLQMNSLRSEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 41 BCMA-5 BC 5G9 91- VH CDR1 aa NYDMA D2-B10 42 BCMA-5 BC 5G9 91- VH CDR2 aa SIITSGDATYYRDSVKG D2-B10 43 BCMA-5 BC 5G9 91- VH CDR3 aa HDYYDGSYGFAY D2-B10 44 BCMA-5 BC 5G9 91- VL CDR1 aa KASQSVGINVD D2-B10 45 BCMA-5 BC 5G9 91- VL CDR2 aa GASNRHT D2-B10 46 BCMA-5 BC 5G9 91- VL CDR3 aa LQYGSIPFT D2-B10 47 BCMA-5 BC 5G9 91- VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDATYYRDSVKGR D2-B10 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSS 48 BCMA-5 BC 5G9 91- VL aa EIVMTQSPASMSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS D2-B10 GTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK 49 BCMA-5 BC 5G9 91- scFv aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDATYYRDSVKGR D2-B10 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPASMSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK 50 BCMA-5 HL × BC 5G9 91- bispecific aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDATYYRDSVKGR CD3 HL D2-B10 HL × molecule FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSEIVMTQSPASMSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 51 BCMA-6 BC 5G9 91- VH CDR1 aa NYDMA D2-D8 52 BCMA-6 BC 5G9 91- VH CDR2 aa SIITSGDMTYYRDSVKG D2-D8 53 BCMA-6 BC 5G9 91- VH CDR3 aa HDYYDGSYGFAY D2-D8 54 BCMA-6 BC 5G9 91- VL CDR1 aa KASQSVGINVD D2-D8 55 BCMA-6 BC 5G9 91- VL CDR2 aa GASNRHT D2-D8 56 BCMA-6 BC 5G9 91- VL CDR3 aa LQYGSIPFT D2-D8 57 BCMA-6 BC 5G9 91- VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR D2-D8 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSS 58 BCMA-6 BC 5G9 91- VL aa EIVMTQSPASMSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS D2-D8 GTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK 59 BCMA-6 BC 5G9 91- scFv aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR D2-D8 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPASMSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK 60 BCMA-6 HL × BC 5G9 91- bispecific aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR CD3 HL D2-D8 HL × molecule FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSEIVMTQSPASMSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 61 BCMA-7 BC 5G9 92- VH CDR1 aa NYDMA E10-B10 62 BCMA-7 BC 5G9 92- VH CDR2 aa SIITSGDATYYRDSVKG E10-B10 63 BCMA-7 BC 5G9 92- VH CDR3 aa HDYYDGSYGFAY E10-B10 64 BCMA-7 BC 5G9 92- VL CDR1 aa KASQSVGINVD E10-B105 65 BCMA-7 BC 5G9 92- VL CDR2 aa GASNRHT E10-B10 66 BCMA-7 BC 5G9 92- VL CDR3 aa LQYGSIPFT E10-B10 67 BCMA-7 BC 5G9 92- VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDATYYRDSVKGR E10-B10 FTVSRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSS 68 BCMA-7 BC 5G9 92- VL aa GTEIVMTQSPATLSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS E10-B10 GTEFTLTISSLQAEDFAVYYCLQYGSIPFTFGPGTKVDIK 69 BCMA-7 BC 5G9 92- scFv aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDATYYRDSVKGR E10-B10 FTVSRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQAEDFAVYYCLQYGSIPFTFGPGTKVDIK 70 BCMA-7 HL × BC 5G9 92- bispecific aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDATYYRDSVKGR CD3 HL E10B10 HL × molecule FTVSRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSEIVMTQSPATLSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQAEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 71 BCMA-8 BC 5G9 92- VH CDR1 aa NYDMA E10-D8 72 BCMA-8 BC 5G9 92- VH CDR2 aa SIITSGDMTYYRDSVKG E10-D8 73 BCMA-8 BC 5G9 92- VH CDR3 aa HDYYDGSYGFAY E10-D8 74 BCMA-8 BC 5G9 92- VL CDR1 aa KASQSVGINVD E10-D8 75 BCMA-8 BC 5G9 92- VL CDR2 aa GASNRHT E10-D8 76 BCMA-8 BC 5G9 92- VL CDR3 aa LQYGSIPFT E10-D8 77 BCMA-8 BC 5G9 92- VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR E10-D8 FTVSRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSS 78 BCMA-8 BC 5G9 92- VL aa EIVMTQSPATLSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS E10-D8 GTEFTLTISSLQAEDFAVYYCLQYGSIPFTFGPGTKVDIK 79 BCMA-8 BC 5G9 92- scFv aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR E10-D8 FTVSRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQAEDFAVYYCLQYGSIPFTFGPGTKVDIK 80 BCMA-8 HL × BC 5G9 92- bispecific aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR CD3 HL E10-D8 HL × molecule FTVSRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSEIVMTQSPATLSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQAEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 81 BCMA-9 BC H1 38- VH CDR1 aa NYWIH D2-A4 82 BCMA-9 BC H1 38- VH CDR2 aa AIYPGNSDTHYNQKFQG D2-A4 83 BCMA-9 BC H1 38- VH CDR3 aa SSYYYDGSLFAS D2-A4 84 BCMA-9 BC H1 38- VL CDR1 aa RSSQSIVHSNGNTYLY D2-A4 85 BCMA-9 BC H1 38- VL CDR2 aa RVSNRFS D2-A4 86 BCMA-9 BC H1 38- VL CDR3 aa FQGSTLPFT D2-A4 87 BCMA-9 BC H1 38- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK D2-A4 VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSS 88 BCMA-9 BC H1 38- VL aa DIVMTQTPLSLSVSPGQPASISCRSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPDRF D2-A4 SGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIK 89 BCMA-9 BC H1 38- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK D2-A4 VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG GSDIVMTQTPLSLSVSPGQPASISCRSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIK 90 BCMA-9 HL × BC H1 38- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK CD3 HL D2-A4 HL × molecule VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIVMTQTPLSLSVSPGQPASISCRSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQP GGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAAL TLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 91 BCMA-10 BC H1 38- VH CDR1 aa NYWIH D2-F12 92 BCMA-10 BC H1 238- VH CDR2 aa AIYPGNSDTHYNQKFQG D2-F12 93 BCMA-10 BC H1 238- VH CDR3 aa SSYYYDGSLFAS D2-F12 94 BCMA-10 BC H1 238- VL CDR1 aa RSSQSIVHSNGNTYLY D2-F12 95 BCMA-10 BC H1 38- VL CDR2 aa RVSNRFS D2-F12 96 BCMA-10 BC H1 38- VL CDR3 aa FQGSHLPFT D2-F12 97 BCMA-10 BC H1 38- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK D2-F12 VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSS 98 BCMA-10 BC H1 38- VL aa DIVMTQTPLSLSVSPGQPASISCRSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPDRF D2-F12 SGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIK 99 BCMA-10 BC H1 38- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK D2-F12 VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG GSDIVMTQTPLSLSVSPGQPASISCRSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIK 100 BCMA-10 HL × BC H1 38- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK CD3 HL D2-F12 HL × molecule VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIVMTQTPLSLSVSPGQPASISCRSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQP GGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAAL TLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 101 BCMA-11 BC H1 38- VH CDR1 aa NYWIH C1-A4 102 BCMA-11 BC H1 38- VH CDR2 aa AIYPGNSDTHYNQKFQG C1-A4 103 BCMA-11 BC H1 38- VH CDR3 aa SSYYYDGSLFAS C1-A4 104 BCMA-11 BC H1 38- VL CDR1 aa KSSQSIVHSNGNTYLY C1-A4 105 BCMA-11 BC H1 38- VL CDR2 aa RVSNRFS C1-A4 106 BCMA-11 BC H1 38- VL CDR3 aa FQGSTLPFT C1-A4 107 BCMA-11 BC H1 38- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK C1-A4 VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSS 108 BCMA-11 BC H1 38- VL aa DIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPDRF C1-A4 SGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIK 109 BCMA-11 BC H1 38- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK C1-A4 VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG GSDIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIK 110 BCMA-11 HL × BC H1 38- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK CD3 HL C1-A4 HL × molecule VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQP GGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAAL TLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 111 BCMA-12 BC H1 238- VH CDR1 aa NYWIH C1-F12 112 BCMA-12 BC H1 238- VH CDR2 aa AIYPGNSDTHYNQKFQG C1-F12 113 BCMA-12 BC H1 238- VH CDR3 aa SSYYYDGSLFAS C1-F12 114 BCMA-12 BC H1 238- VL CDR1 aa KSSQSIVHSNGNTYLY C1-F12 115 BCMA-12 BC H1 238- VL CDR2 aa RVSNRFS C1-F12 116 BCMA-12 BC H1 238- VL CDR3 aa FQGSHLPFT C1-F12 117 BCMA-12 BC H1 38- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK C1-F12 VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSS 118 BCMA-12 BC H1 38- VL aa DIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPDRF C1-F12 SGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIK 119 BCMA-12 BC H1 38- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK C1-F12 VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG GSDIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIK 120 BCMA-12 HL × BC H1 38- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK CD3 HL C1-F12 HL × molecule VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQP GGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAAL TLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 121 BCMA-13 BC H1 39- VH CDR1 aa NYWIH B2-A4 122 BCMA-13 BC H1 39- VH CDR2 aa AIYPGNSDTHYNQKFQG B2-A4 123 BCMA-13 BC H1 39- VH CDR3 aa SSYYYDGSLFAS B2-A4 124 BCMA-13 BC H1 39- VL CDR1 aa KSSQSIVHSNGNTYLY B2-A4 125 BCMA-13 BC H1 39- VL CDR2 aa RVSNRFS B2-A4 126 BCMA-13 BC H1 39- VL CDR3 aa FQGSTLPFT B2-A4 127 BCMA-13 BC H1 39- VH aa QVQLVQSGAVVAKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWMGAIYPGNSDTHYNQKFQGR B2-A4 VTLTTDTSASTAYMELSSLRNEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSS 128 BCMA-13 BC H1 39- VL aa DIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPDRF B2-A4 SGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIK 129 BCMA-13 BC H1 39- scFv aa QVQLVQSGAVVAKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWMGAIYPGNSDTHYNQKFQGR B2-A4 VTLTTDTSASTAYMELSSLRNEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG GSDIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIK 130 BCMA-13 HL × BC H1 39- bispecific aa QVQLVQSGAVVAKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWMGAIYPGNSDTHYNQKFQGR CD3 HL B2-A4 HL × molecule VTLTTDTSASTAYMELSSLRNEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQP GGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAAL TLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 131 BCMA-14 BC H1 39- VH CDR1 aa NYWIH B2-F12 132 BCMA-14 BC H1 39- VH CDR2 aa AIYPGNSDTHYNQKFQG B2-F12 133 BCMA-14 BC H1 39- VH CDR3 aa SSYYYDGSLFAS B2-F12 134 BCMA-14 BC H1 39- VL CDR1 aa KSSQSIVHSNGNTYLY B2-F12 135 BCMA-14 BC H1 39- VL CDR2 aa RVSNRFS B2-F12 136 BCMA-14 BC H1 39- VL CDR3 aa FQGSHLPFT B2-F12 137 BCMA-14 BC H1 39- VH aa QVQLVQSGAVVAKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWMGAIYPGNSDTHYNQKFQGR B2-F12 VTLTTDTSASTAYMELSSLRNEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSS 138 BCMA-14 BC H1 39- VL aa DIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPDRF B2-F12 SGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIK 139 BCMA-14 BC H1 39- scFv aa QVQLVQSGAVVAKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWMGAIYPGNSDTHYNQKFQGR B2-F12 VTLTTDTSASTAYMELSSLRNEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG GSDIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIK 140 BCMA-14 HL × BC H1 39- bispecific aa QVQLVQSGAVVAKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWMGAIYPGNSDTHYNQKFQGR CD3 HL B2-F12 HL × molecule VTLTTDTSASTAYMELSSLRNEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQP GGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAAL TLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 141 BCMA-15 BC H1 39- VH CDR1 aa SYWIH C9-A4 142 BCMA-15 BC H1 39- VH CDR2 aa AIYPGNSDTHYNQKFQG C9-A4 143 BCMA-15 BC H1 39- VH CDR3 aa SSYYYDGSLFAD C9-A4 144 BCMA-15 BC H1 39- VL CDR1 aa KSSQSIVHSNGNTYLY C9-A4 145 BCMA-15 BC H1 39- VL CDR2 aa RVSNRFS C9-A4 146 BCMA-15 BC H1 39- VL CDR3 aa FQGSTLPFT C9-A4 147 BCMA-15 BC H1 39- VH aa QVQLVQSGAEVKKPGTSVKVSCKASGYTFTSYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGR C9-A4 VTLTRDTSASTAYMELSSLRSEDSAVYYCTRSSYYYDGSLFADWGQGTLVTVSS 148 BCMA-15 BC H1 39- VL aa DIVMTQTPLSLSVTPGQPASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPDRF C9-A4 SGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIK 149 BCMA-15 BC H1 39- scFv aa QVQLVQSGAEVKKPGTSVKVSCKASGYTFTSYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGR C9-A4 VTLTRDTSASTAYMELSSLRSEDSAVYYCTRSSYYYDGSLFADWGQGTLVTVSSGGGGSGGGGSGGG GSDIVMTQTPLSLSVTPGQPASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIK QVQLVQSGAEVKKPGTSVKVSCKASGYTFTSYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGR VTLTRDTSASTAYMELSSLRSEDSAVYYCTRSSYYYDGSLFADWGQGTLVTVSSGGGGSGGGGSGGG GSDIVMTQTPLSLSVTPGQPASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD 150 BCMA-15 HL × BC H1 39- bispecific aa RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQP CD3 HL C9-A4 HL × molecule GGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTA CD3 HL YLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAAL TLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 151 BCMA-16 BC H1 39- VH CDR1 aa SYWIH C9-F12 152 BCMA-16 BC H1 39- VH CDR2 aa AIYPGNSDTHYNQKFQG C9-F12 153 BCMA-16 BC H1 39- VH CDR3 aa SSYYYDGSLFAD C9-F12 154 BCMA-16 BC H1 39- VL CDR1 aa KSSQSIVHSNGNTYLY C9-F12 155 BCMA-16 BC H1 39- VL CDR2 aa RVSNRFS C9-F12 156 BCMA-16 BC H1 39- VL CDR3 aa FQGSHLPFT C9-F12 157 BCMA-16 BC H1 39- VH aa QVQLVQSGAEVKKPGTSVKVSCKASGYTFTSYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGR C9-F12 VTLTRDTSASTAYMELSSLRSEDSAVYYCTRSSYYYDGSLFADWGQGTLVTVSS 158 BCMA-16 BC H1 39- VL aa DIVMTQTPLSLSVTPGQPASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPDRF C9-F12 SGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIK 159 BCMA-16 BC H1 39- scFv aa QVQLVQSGAEVKKPGTSVKVSCKASGYTFTSYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGR C9-F12 VTLTRDTSASTAYMELSSLRSEDSAVYYCTRSSYYYDGSLFADWGQGTLVTVSSGGGGSGGGGSGGG GSDIVMTQTPLSLSVTPGQPASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIK 160 BCMA-16 HL × BC H1 39- bispecific aa QVQLVQSGAEVKKPGTSVKVSCKASGYTFTSYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGR CD3 HL C9-F12 HL × molecule VTLTRDTSASTAYMELSSLRSEDSAVYYCTRSSYYYDGSLFADWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIVMTQTPLSLSVTPGQPASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQP GGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAAL TLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 161 BCMA-17 BC C3 33- VH CDR1 aa NFDMA D7-E6 162 BCMA-17 BC C3 33- VH CDR2 aa SITTGADHAIYADSVKG D7-E6 163 BCMA-17 BC C3 33- VH CDR3 aa HGYYDGYHLFDY D7-E6C3 164 BCMA-17 BC C3 33- VL CDR1 aa RASQGISNYLN D7-E6 165 BCMA-17 BC C3 33- VL CDR2 aa YTSNLQS D7-E6 166 BCMA-17 BC C3 33- VL CDR3 aa QQYDISSYT D7-E6 167 BCMA-17 BC C3 33- VH aa EVQLVE SGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR D7-E6 FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS 168 BCMA-17 BC C3 33- VL aa DIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS D7-E6 GTDYTLTISSLQPEDFATYYCQQYDISSYTFGQGTKLEIK 169 BCMA-17 BC C3 33- scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR D7-E6 FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQYDISSYTFGQGTKLEIK 170 BCMA-17 HL × BC C3 33- bispecific aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR CD3 HL D7-E6 HL molecule FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG ×CD3 HL GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQYDISSYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 171 BCMA-18 BC C3 33- VH CDR1 aa NFDMA D7-E6B1 172 BCMA-18 BC C3 33- VH CDR2 aa SITTGADHAIYADSVKG D7-E6B1 173 BCMA-18 BC C3 33- VH CDR3 aa HGYYDGYHLFDY D7-E6B1 174 BCMA-18 BC C3 33- VL CDR1 aa RASQGISNYLN D7-E6B1 175 BCMA-18 BC C3 33- VL CDR2 aa YTSNLQS D7-E6B1 176 BCMA-18 BC C3 33- VL CDR3 aa MGQTISSYT D7-E6B1 177 BCMA-18 BC C3 33- VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR D7-E6B1 FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS 178 BCMA-18 BC C3 33- VL aa DIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS D7-E6B1 GTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK 179 BCMA-18 BC C3 33- scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR D7-E6B1 FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK 180 BCMA-18 HL × BC C3 33- bispecific aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR CD3 HL D7-E6B1 molecule FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG HL × CD3 GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS HL GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 181 BCMA-19 BC C3 33- VH CDR1 aa NFDMA F8-E6 182 BCMA-19 BC C3 33- VH CDR2 aa SITTGADHAIYADSVKG F8-E6 183 BCMA-19 BC C3 33- VH CDR3 aa HGYYDGYHLFDY F8-E6 184 BCMA-19 BC C3 33- VL CDR1 aa RASQGISNYLN F8-E6 185 BCMA-19 BC C3 33- VL CDR2 aa YTSNLQS F8-E6 186 BCMA-19 BC C3 33- VL CDR3 aa QQYDISSYT F8-E6 187 BCMA-19 BC C3 33- VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR F8-E6 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS 188 BCMA-19 BC C3 33- VL aa DIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS F8-E6 GTDYTLTISSLQPEDFATYYCQQYDISSYTFGQGTKLEIK 189 BCMA-19 BC C3 33- scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR F8-E6 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQYDISSYTFGQGTKLEIK 190 BCMA-19 HL × BC C3 33- bispecific aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR CD3 HL F8-E6 HL × molecule FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQYDISSYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 191 BCMA-20 BC C3 33- VH CDR1 aa NFDMA F8-E6B1 192 BCMA-20 BC C3 33- VH CDR2 aa SITTGADHAIYADSVKG F8-E6B1 193 BCMA-20 BC C3 33- VH CDR3 aa HGYYDGYHLFDY F8-E6B1 194 BCMA-20 BC C3 33- VL CDR1 aa RASQGISNYLN F8-E6B1 195 BCMA-20 BC C3 33- VL CDR2 aa YTSNLQS F8-E6B1 196 BCMA-20 BC C3 33- VL CDR3 aa MGQTISSYT F8-E6B1 197 BCMA-20 BC C3 33- VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR F8-E6B1 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS 198 BCMA-20 BC C3 33- VL aa DIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS F8-E6B1 GTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK 199 BCMA-20 BC C3 33- scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR F8-E6B1 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK 200 BCMA-20 HL × BC C3 33- bispecific aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR CD3 HL F8-E6B1 molecule FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG HL HL × CD3 GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 201 BCMA-21 BC C3 33- VH CDR1 aa NFDMA F9-E6 202 BCMA-21 BC C3 33- VH CDR2 aa SITTGADHAIYADSVKG F9-E6 203 BCMA-21 BC C3 33- VH CDR3 aa HGYYDGYHLFDY F9-E6 204 BCMA-21 BC C3 33- VL CDR1 aa RASQGISNYLN F9-E6 205 BCMA-21 BC C3 33- VL CDR2 aa YTSNLQS F9-E6 206 BCMA-21 BC C3 33- VL CDR3 aa QQYDISSYT F9-E6 207 BCMA-21 BC C3 33- VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR F9-E6 FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS 208 BCMA-21 BC C3 33- VL aa DIQMTQSPSSLSASVGDRVTISCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS F9-E6 GTDYTLTISSLQPEDFATYYCQQYDISSYTFGQGTKLEIK 209 BCMA-21 BC C3 33- scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR F9-E6 FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQYDISSYTFGQGTKLEIK 210 BCMA-21 HL × BC C3 33- bispecific aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR CD3 HL F9-E6 HL × molecule FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASVGDRVTISCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQYDISSYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 211 BCMA-22 BC C3 33- VH CDR1 aa NFDMA F9-E6B1-E 212 BCMA-22 BC C3 33- VH CDR2 aa SITTGADHAIYAESVKG F9-E6B1-E 213 BCMA-22 BC C3 33- VH CDR3 aa HGYYDGYHLFDY F9-E6B1-E 214 BCMA-22 BC C3 33- VL CDR1 aa RASQGISNYLN F9-E6B1-E 215 BCMA-22 BC C3 33- VL CDR2 aa YTSNLQS F9-E6B1-E 216 BCMA-22 BC C3 33- VL CDR3 aa MGQTISSYT F9-E6B1-E 217 BCMA-22 BC C3 33- VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYAESVKGR F9-E6B1-E FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS 218 BCMA-22 BC C3 33- VL aa DIQMTQSPSSLSASVGDRVTISCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS F9-E6B1-E GTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK 219 BCMA-22 BC C3 33- scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYAESVKGR F9-E6B1-E FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK 220 BCMA-22 HL × BC C3 33- bispecific aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYAESVKGR CD3 HL F9-E6B1-E molecule FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG HL × CD3 GSDIQMTQSPSSLSASVGDRVTISCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS HL GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 221 BCMA-23 BC C3 33- VH CDR1 aa NFDMA F10-E6B1 222 BCMA-23 BC C3 33- VH CDR2 aa SITTGADHAIYADSVKG F10-E6B1 223 BCMA-23 BC C3 33- VH CDR3 aa HGYYDGYHLFDY F10-E6B1 224 BCMA-23 BC C3 33- VL CDR1 aa RASQGISNYLN F10-E6B1 225 BCMA-23 BC C3 33- VL CDR2 aa YTSNLQS F10-E6B1 226 BCMA-23 BC C3 33- VL CDR3 aa MGQTISSYT F10-E6B1 227 BCMA-23 BC C3 33- VH aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGADHAIYADSVKGR F10-E6B1 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS 228 BCMA-23 BC C3 33- VL aa DIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS F10-E6B1 GTDFTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK 229 BCMA-23 BC C3 33- scFv aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGADHAIYADSVKGR F10-E6B1 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK 230 BCMA-23 HL × BC C3 33- bispecific aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGADHAIYADSVKGR CD3 HL F10-E6B1 molecule FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG HL × CD3 GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS HL GSGTDFTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 231 BCMA-24 BC B6 64- VH CDR1 aa DYYIN H5-A4 232 BCMA-24 BC B6 64- VH CDR2 aa WIYFASGNSEYNQKFTG H5-A4 233 BCMA-24 BC B6 64- VH CDR3 aa LYDYDWYFDV H5-A4 234 BCMA-24 BC B6 64- VL CDR1 aa KSSQSLVHSNGNTYLH H5-A4 235 BCMA-24 BC B6 64- VL CDR2 aa KVSNRFS H5-A4 236 BCMA-24 BC B6 64- VL CDR3 aa AETSHVPWT H5-A4 237 BCMA-24 BC B6 64- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR H5-A4 VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS 238 BCMA-24 BC B6 64- VL aa DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF H5-A4 SGSGSGTDFTLKINRVEAEDVGVYYCAETSHVPWTFGQGTKLEIK 239 BCMA-24 BC B6 64- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR H5-A4 VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKINRVEAEDVGVYYCAETSHVPWTFGQGTKLEIK 240 BCMA-24 HL × BC B6 64- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL H5-A4 HL × molecule VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS CD3 HL DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKINRVEAEDVGVYYCAETSHVPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 241 BCMA-25 BC B6 64- VH CDR1 aa DYYIN H5-H9 242 BCMA-25 BC B6 64- VH CDR2 aa WIYFASGNSEYNQKFTG H5-H9 243 BCMA-25 BC B6 64- VH CDR3 aa LYDYDWYFDV H5-H9 244 BCMA-25 BC B6 64- VL CDR1 aa KSSQSLVHSNGNTYLH H5-H9 245 BCMA-25 BC B6 64- VL CDR2 aa KVSNRFS H5-H9 246 BCMA-25 BC B6 64- VL CDR3 aa LTTSHVPWT H5-H9 247 BCMA-25 BC B6 64- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR H5-H9 VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS 248 BCMA-25 BC B6 64- VL aa DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF H5-H9 SGSGSGTDFTLKINRVEAEDVGVYYCLITSHVPWTFGQGTKLEIK 249 BCMA-25 BC B6 64- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR H5-H9 VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKINRVEAEDVGVYYCLTTSHVPWTFGQGTKLEIK 250 BCMA-25 HL × BC B6 64- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL H5-H9 HL × molecule VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS CD3 HL DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKINRVEAEDVGVYYCLTTSHVPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 251 BCMA-26 BC B6 65- VH CDR1 aa DYYIN B5-A4 252 BCMA-26 BC B6 65- VH CDR2 aa WIYFASGNSEYNQKFTG B5-A4 253 BCMA-26 BC B6 65- VH CDR3 aa LYDYDWYFDV B5-A4 254 BCMA-26 BC B6 65- VL CDR1 aa KSSQSLVHSNGNTYLH B5-A4 255 BCMA-26 BC B6 65- VL CDR2 aa KVSNRFS B5-A4 256 BCMA-26 BC B6 65- VL CDR3 aa AETSHVPWT B5-A4 257 BCMA-26 BC B6 65- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR B5-A4 VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS 258 BCMA-26 BC B6 65- VL aa DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF B5-A4 SGSGSGTDFTLKISRVEAEDVGVYYCAETSHVPWTFGQGTKLEIK 259 BCMA-26 BC B6 65- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR B5-A4 VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCAETSHVPWTFGQGTKLEIK 260 BCMA-26 HL × BC B6 65- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL B5-A4 HL × molecule VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS CD3 HL DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCAETSHVPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 261 BCMA-27 BC B6 65- VH CDR1 aa DYYIN B5-H9 262 BCMA-27 BC B6 65- VH CDR2 aa WIYFASGNSEYNQKFTG B5-H9 263 BCMA-27 BC B6 65- VH CDR3 aa LYDYDWYFDV B5-H9 264 BCMA-27 BC B6 65- VL CDR1 aa KSSQSLVHSNGNTYLH B5-H9 265 BCMA-27 BC B6 65- VL CDR2 aa KVSNRFS B5-H9 266 BCMA-27 BC B6 65- VL CDR3 aa LTTSHVPWT B5-H9 267 BCMA-27 BC B6 65- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR B5-H9 VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS 268 BCMA-27 BC B6 65- VL aa DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF B5-H9 SGSGSGTDFTLKISRVEAEDVGVYYCLTTSHVPWTFGQGTKLEIK 269 BCMA-27 BC B6 65- scFv aaz QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR B5-H9 VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCLTTSHVPWTFGQGTKLEIK 270 BCMA-27 HL × BC B6 65- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL B5-H9 HL × molecule VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS CD3 HL DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCLTTSHVPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 271 BCMA-28 BC B6 65- VH CDR1 aa DYYIN H7-A4 272 BCMA-28 BC B6 65- VH CDR2 aa WIYFASGNSEYNQKFTG 273 BCMA-28 BC B6 65- VH CDR3 aa LYDYDWYFDV H7-A4 274 BCMA-28 BC B6 65- VL CDR1 aa KSSQSLVHSNGNTYLH H7-A4 275 BCMA-28 BC B6 65- VL CDR2 aa KVSNRFS H7-A4 276 BCMA-28 BC B6 65- VL CDR3 aa AETSHVPWT H7-A4 277 BCMA-28 BC B6 65- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR H7-A4 VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS 278 BCMA-28 BC B6 65- VL aa DIVMTQTPLSLSVSPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF H7-A4 SGSGSGTDFTLKISRVEAEDVGVYYCAETSHVPWTFGQGTKLEIK 279 BCMA-28 BC B6 65- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR H7-A4 VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVSPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCAETSHVPWTFGQGTKLEIK 280 BCMA-28 HL × BC B6 65- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL H7-A4 HL × molecule VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS CD3 HL DIVMTQTPLSLSVSPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCAETSHVPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 281 BCMA-29 BC B6 65- VH CDR1 aa DYYIN H7-H9 282 BCMA-29 BC B6 65- VH CDR2 aa WIYFASGNSEYNQKFTG H7-H9 283 BCMA-29 BC B6 65- VH CDR3 aa LYDYDWYFDV H7-H9 284 BCMA-29 BC B6 65- VL CDR1 aa KSSQSLVHSNGNTYLH H7-H9 285 BCMA-29 BC B6 65- VL CDR2 aa KVSNRFS H7-H9 286 BCMA-29 BC B6 65- VL CDR3 aa LTTSHVPWT H7-H9 287 BCMA-29 BC B6 65- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR H7-H9 VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS 288 BCMA-29 BC B6 65- VL aa DIVMTQTPLSLSVSPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF H7-H9 SGSGSGTDFTLKISRVEAEDVGVYYCLTTSHVPWTFGQGTKLEIK 289 BCMA-29 BC B6 65- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR H7-H9 VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVSPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCLTTSHVPWTFGQGTKLEIK 290 BCMA-29 HL × BC B6 65- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL H7-H9 HL × molecule VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS CD3 HL DIVMTQTPLSLSVSPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCLTTSHVPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 291 BCMA-30 BC B6 65- VH CDR1 aa DYYIN H8-A4 292 BCMA-30 BC B6 65- VH CDR2 aa WIYFASGNSEYNQKFTG H8-A4 293 BCMA-30 BC B6 65- VH CDR3 aa LYDYDWYFDV H8-A4 294 BCMA-30 BC B6 65- VL CDR1 aa KSSQSLVHSNGNTYLH H8-A4 295 BCMA-30 BC B6 65- VL CDR2 aa KVSNRFS H8-A4 296 BCMA-30 BC B6 65- VL CDR3 aa AETSHVPWT H8-A4 297 BCMA-30 BC B6 65- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR H8-A4 VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS 298 BCMA-30 BC B6 65- VL aa DIVMTQTPLSLSVTPGEPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF H8-A4 SGSGSGADFTLKISRVEAEDVGVYYCAETSHVPWTFGQGTKLEIK 299 BCMA-30 BC B6 65- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR H8-A4 VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGEPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGADFTLKISRVEAEDVGVYYCAETSHVPWTFGQGTKLEIK 300 BCMA-30 HL × BC B6 65- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL H8-A4 HL × molecule VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS CD3 HL DIVMTQTPLSLSVTPGEPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGADFTLKISRVEAEDVGVYYCAETSHVPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 301 BCMA-31 BC B6 65- VH CDR1 aa DYYIN H8-H9 302 BCMA-31 BC B6 65- VH CDR2 aa WIYFASGNSEYNQKFTG H8-H9 303 BCMA-31 BC B6 65- VH CDR3 aa LYDYDWYFDV H8-H9 304 BCMA-31 BC B6 65- VL CDR1 aa KSSQSLVHSNGNTYLH H8-H9 305 BCMA-31 BC B6 65- VL CDR2 aa KVSNRFS H8-H9 306 BCMA-31 BC B6 65- VL CDR3 aa LTTSHVPWT H8-H9 307 BCMA-31 BC B6 65- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR H8-H9 VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS 308 BCMA-31 BC B6 65- VL aa DIVMTQTPLSLSVTPGEPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF H8-H9 SGSGSGADFTLKISRVEAEDVGVYYCLTTSHVPWTFGQGTKLEIK 309 BCMA-31 BC B6 65- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR H8-H9 VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGEPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGADFTLKISRVEAEDVGVYYCLTTSHVPWTFGQGTKLEIK 310 BCMA-31 HL × BC B6 65- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL H8-H9 HL × molecule VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS CD3 HL DIVMTQTPLSLSVTPGEPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGADFTLKISRVEAEDVGVYYCLTTSHVPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYMANWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 311 BCMA-32 BC A7 27- VH CDR1 aa NHIIH A6-G7 312 BCMA-32 BC A7 27- VH CDR2 aa YINPYPGYHAYNEKFQG A6-G7 313 BCMA-32 BC A7 27- VH CDR3 aa DGYYRDTDVLDY A6-G7 314 BCMA-32 BC A7 27- VL CDR1 aa QASQDISNYLN A6-G7 315 BCMA-32 BC A7 27- VL CDR2 aa YTSRLHT A6-G7 316 BCMA-32 BC A7 27- VL CDR3 aa QQGNTLPWT A6-G7 317 BCMA-32 BC A7 27- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYPGYHAYNEKFQGR A6-G7 ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSS 318 BCMA-32 BC A7 27- VL aa DIQMTQSPSSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGS A6-G7 GTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIK 319 BCMA-32 BC A7 27- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYPGYHAYNEKFQGR A6-G7 ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIK 320 BCMA-32 HL × BC A7 27- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYPGYHAYNEKFQGR CD3 HL A6-G7 HL × molecule ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 321 BCMA-33 BC A7 27- VH CDR1 aa NHIIH A6-H11 322 BCMA-33 BC A7 27- VH CDR2 aa YINPYDGWGDYNEKFQG A6-H11 323 BCMA-33 BC A7 27- VH CDR3 aa DGYYRDADVLDY A6-H11 324 BCMA-33 BC A7 27- VL CDR1 aa QASQDISNYLN A6-H11 325 BCMA-33 BC A7 27- VL CDR2 aa YTSRLHT A6-H11 326 BCMA-33 BC A7 27- VL CDR3 aa QQGNTLPWT A6-H11 327 BCMA-33 BC A7 27- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYDGWGDYNEKFQGR A6-H11 ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSS 328 BCMA-33 BC A7 27- VL aa DIQMTQSPSSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGS A6-H11 GTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIK 329 BCMA-33 BC A7 27- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYDGWGDYNEKFQGR A6-H11 ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIK 330 BCMA-33 HL × BC A7 27- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYDGWGDYNEKFQGR CD3 HL A6-H11 HL × molecule ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 331 BCMA-34 BC A7 27- VH CDR1 aa NHIIH C4-G7 332 BCMA-34 BC A7 27- VH CDR2 aa YINPYPGYHAYNEKFQG C4-G7 333 BCMA-34 BC A7 27- VH CDR3 aa DGYYRDTDVLDY C4-G7 334 BCMA-34 BC A7 27- VL CDR1 aa QASQDISNYLN C4-G7 335 BCMA-34 BC A7 27- VL CDR2 aa YTSRLHT C4-G7 336 BCMA-34 BC A7 27- VL CDR3 aa QQGNTLPWT C4-G7 337 BCMA-34 BC A7 27- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYPGYHAYNEKFQGR C4-G7 ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSS 338 BCMA-34 BC A7 27- VL aa DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGS C4-G7 GTDFTFTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIK 339 BCMA-34 BC A7 27- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYPGYHAYNEKFQGR C4-G7 ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIK 340 BCMA-34 HL × BC A7 27- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYPGYHAYNEKFQGR CD3 HL C4-G7 HL × molecule ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 341 BCMA-35 BC A7 27- VH CDR1 aa NHIIH C4-H11 342 BCMA-35 BC A7 27- VH CDR2 aa YINPYDGWGDYNEKFQG C4-H11 343 BCMA-35 BC A7 27- VH CDR3 aa DGYYRDADVLDY C4-H11 344 BCMA-35 BC A7 27- VL CDR1 aa QASQDISNYLN C4-H11 345 BCMA-35 BC A7 27- VL CDR2 aa YTSRLHT C4-H11 346 BCMA-35 BC A7 27- VL CDR3 aa QQGNTLPWT C4-H11 347 BCMA-35 BC A7 27- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYDGWGDYNEKFQGR C4-H11 ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSS 348 BCMA-35 BC A7 27- VL aa DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGS C4-H11 GTDFTFTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIK 349 BCMA-35 BC A7 27- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYDGWGDYNEKFQGR C4-H11 ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIK 350 BCMA-35 HL × BC A7 27- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYDGWGDYNEKFQGR CD3 HL C4-H11 HL × molecule ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 351 BCMA-36 BC A7 15- VH CDR1 aa NHIIH H2-G7 352 BCMA-36 BC A7 15- VH CDR2 aa YINPYPGYHAYNQKFQG H2-G7 353 BCMA-36 BC A7 15- VH CDR3 aa DGYYRDTDVLDY H2-G7 354 BCMA-36 BC A7 15- VL CDR1 aa QASQDISNYLN H2-G7 355 BCMA-36 BC A7 15- VL CDR2 aa YTSRLHT H2-G7 356 BCMA-36 BC A7 15- VL CDR3 aa QQGNTLPWT H2-G7 357 BCMA-36 BC A7 15- VH aa QVQLVQSGAKVIKPGASVKVSCKASGYTTFTNIIHWVRQKPGQGLEWMGYINPYPGYHAYNQKFQGR H2-G7 VTMTRDKSTSTVYMELSSLTSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSS 358 BCMA-36 BC A7 15- VL aa DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGRAPKLLIYYTSRLHTGVPSRFSGSGS H2-G7 GTDYSFTISSLQPEDIATYYCQQGNTLPWTFGQGTKVEIK 359 BCMA-36 BC A7 15- scFv aa QVQLVQSGAKVIKPGASVKVSCKASGYTFTNHIIHWVRQKPGQGLEWMGYINPYPGYHAYNQKFQGR H2-G7 VTMTRDKSTSTVYMELSSLTSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGRAPKLLIYYTSRLHTGVPSRFSGS GSGTDYSFTISSLQPEDIATYYCQQGNTLPWTFGQGTKVEIK 360 BCMA-36 HL × BC A7 15- bispecific aa QVQLVQSGAKVIKPGASVKVSCKASGYTFTNHIIHWVRQKPGQGLEWMGYINPYPGYHAYNQKFQGR CD3 HL H2-G7 HL × molecule VTMTRDKSTSTVYMELSSLTSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGRAPKLLIYYTSRLHTGVPSRFSGS GSGTDYSFTISSLQPEDIATYYCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 361 BCMA-37 BC A7 15- VH CDR1 aa NHIIH H2-H11 362 BCMA-37 BC A7 15- VH CDR2 aa YINPYDGWGDYNQKFQG H2-H11 363 BCMA-37 BC A7 15- VH CDR3 aa DGYYRDADVLDY H2-H11 364 BCMA-37 BC A7 15- VL CDR1 aa QASQDISNYLN H2-H11 365 BCMA-37 BC A7 15- VL CDR2 aa YTSRLHT H2-H11 366 BCMA-37 BC A7 15- VL CDR3 aa QQGNTLPWT H2-H11 367 BCMA-37 BC A7 15- VH aa QVQLVQSGAKVIKPGASVKVSCKASGYTFTNHIIHWVRQKPGQGLEWMGYINPYDGWGDYNQKFQGR H2-H11 VTMTRDKSTSTVYMELSSLTSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSS 368 BCMA-37 BC A7 15- VL aa DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGRAPKLLIYYTSRLHTGVPSRFSGSGS H2-H11 GTDYSFTISSLQPEDIATYYCQQGNTLPWTFGQGTKVEIK 369 BCMA-37 BC A7 15- scFv aa QVQLVQSGAKVIKPGASVKVSCKASGYTFTNHIIHWVRQKPGQGLEWMGYINPYDGWGDYNQKFQGR H2-H11 VTMTRDKSTSTVYMELSSLTSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGRAPKLLIYYTSRLHTGVPSRFSGS GSGTDYSFTISSLQPEDIATYYCQQGNTLPWTFGQGTKVEIK 370 BCMA-37 HL × BC A7 15- bispecific aa QVQLVQSGAKVIKPGASVKVSCKASGYTFTNHIIHWVRQKPGQGLEWMGYINPYDGWGDYNQKFQGR CD3 HL H2-H11 HL × molecule VTMTRDKSTSTVYMELSSLTSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGRAPKLLIYYTSRLHTGVPSRFSGS GSGTDYSFTISSLQPEDIATYYCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 371 BCMA-38 BC A7 15- VH CDR1 aa NHIIH H8-G7 372 BCMA-38 BC A7 15- VH CDR2 aa YINPYPGYHAYNQKFQG H8-G7 373 BCMA-38 BC A7 15- VH CDR3 aa DGYYRDTDVLDY H8-G7 374 BCMA-38 BC A7 15- VL CDR1 aa QASQDISNYLN H8-G7 375 BCMA-38 BC A7 15- VL CDR2 aa YTSRLHT H8-G7 376 BCMA-38 BC A7 15- VL CDR3 aa QQGNTLPWT H8-G7 377 BCMA-38 BC A7 15- VH aa QVQLVQSGAEVIKPGASVKVSCKASGYTFTNHIIHWVRQKPGQGLEWIGYINPYPGYHAYNQKFQGK H8-G7 VTMTRDTSTSTVYMELSSLTSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSS 378 BCMA-38 BC A7 15- VL aa DIQMTQ SP SSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGS H8-G7 GTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIK 379 BCMA-38 BC A7 15- scFv aa QVQLVQSGAEVIKPGASVKVSCKASGYTFTNHIIHWVRQKPGQGLEWIGYINPYPGYHAYNQKFQGK H8-G7 VTMTRDTSTSTVYMELSSLTSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIK 380 BCMA-38 HL × BC A7 15- bispecific aa QVQLVQSGAEVIKPGASVKVSCKASGYTFTNHIIHWVRQKPGQGLEWIGYINPYPGYHAYNQKFQGK CD3 HL H8-G7 HL × molecule VTMTRDTSTSTVYMELSSLTSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGIVTLICGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 381 BCMA-39 BC A7 15- VH CDR1 aa NHIIH H8-H11 382 BCMA-39 BC A7 15- VH CDR2 aa YINPYDGWGDYNQKFQG H8-H11 383 BCMA-39 BC A7 15- VH CDR3 aa DGYYRDADVLDY H8-H11 384 BCMA-39 BC A7 15- VL CDR1 aa QASQDISNYLN H8-H11 385 BCMA-39 BC A7 15- VL CDR2 aa YTSRLHT H8-H11 386 BCMA-39 BC A7 15- VL CDR3 aa QQGNTLPWT H8-H11 387 BCMA-39 BC A7 15- VH aa QVQLVQSGAEVIKPGASVKVSCKASGYTFTNHIIHWVRQKPGQGLEWIGYINPYDGWGDYNQKFQGK H8-H11 VTMTRDTSTSTVYMELSSLTSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSS 388 BCMA-39 BC A7 15- VL aa DIQMTQSPSSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGS H8-H11 GTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIK 389 BCMA-39 BC A7 15- scFv aa QVQLVQSGAEVIKPGASVKVSCKASGYTFTNHIIHWVRQKPGQGLEWIGYINPYDGWGDYNQKFQGK H8-H11 VTMTRDTSTSTVYMELSSLTSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIK 390 BCMA-39 HL × BC A7 15- bispecific aa QVQLVQSGAEVIKPGASVKVSCKASGYTFTNHIIHWVRQKPGQGLEWIGYINPYDGWGDYNQKFQGK CD3 HL H8-H11 HL × molecule VTMTRDTSTSTVYMELSSLTSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 391 BCMA-40 BC 7A4 96- VH CDR1 aa DYYIN D4-A12 392 BCMA-40 BC 7A4 96- VH CDR2 aa WIYFASGNSEYNQKFTG D4-A12 393 BCMA-40 BC 7A4 96- VH CDR3 aa LYDYDWYFDV D4-A12 394 BCMA-40 BC 7A4 96- VL CDR1 aa KSSQSLVHSNGNTYLH D4-A12 395 BCMA-40 BC 7A4 96- VL CDR2 aa KVSNRFS D4-A12 396 BCMA-40 BC 7A4 96- aa SQSSTAPWT D4-A12 VL CDR3 397 BCMA-40 BC 7A4 96- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR D4-A12 VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS 398 BCMA-40 BC 7A4 96- VL aa DIVMTQTPLSLPVTLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF D4-A12 SGSGSGTDFTLKISRVEAEDVGVYYCSQSSTAPWTFGQGTKLEIK 399 BCMA-40 BC 7A4 96- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR D4-A12 VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLPVTLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSTAPWTFGQGTKLEIK 400 BCMA-40 HL × BC 7A4 96- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL D4-A12 HL × molecule VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS CD3 HL DIVMTQTPLSLPVTLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSTAPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 401 BCMA-41 BC 7A4 96- VH CDR1 aa DYYIN D4-D7 402 BCMA-41 BC 7A4 96- VH CDR2 aa WIYFASGNSEYNQKFTG D4-D7 403 BCMA-41 BC 7A4 96- VH CDR3 aa LYDYDWYFDV D4-D7 404 BCMA-41 BC 7A4 96- VL CDR1 aa KSSQSLVHSNGNTYLH D4-D7 405 BCMA-41 BC 7A4 96- VL CDR2 aa KVSNRFS D4-D7 406 BCMA-41 BC 7A4 96- VL CDR3 aa SQSSIYPWT D4-D7 407 BCMA-41 BC 7A4 96- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR D4-D7 VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS 408 BCMA-41 BC 7A4 96- VL aa DIVMTQTPLSLPVTLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF D4-D7 SGSGSGTDFTLKISRVEAEDVGVYYCSQSSIYPWTFGQGTKLEIK 409 BCMA-41 BC 7A4 96- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR D4-D7 VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLPVTLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSIYPWTFGQGTKLEIK 410 BCMA-41 HL × BC 7A4 96- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL D4-D7 HL × molecule VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS CD3 HL DIVMTQTPLSLPVTLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSIYPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 411 BCMA-42 BC 7A4 96- VH CDR1 aa DYYIN D4-E7 412 BCMA-42 BC 7A4 96- VH CDR2 aa WIYFASGNSEYNQKFTG D4-E7 413 BCMA-42 BC 7A4 96- VH CDR3 aa LYDYDWYFDV D4-E7 414 BCMA-42 BC 7A4 96- VL CDR1 aa D4-E7 KSSQSLVHSNGNTYLH 415 BCMA-42 BC 7A4 96- VL CDR2 aa KVSNRFS D4-E7 416 BCMA-42 BC 7A4 96- VL CDR3 aa SQSTYPEFT D4-E7 417 BCMA-42 BC 7A4 96- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR D4-E7 VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS 418 BCMA-42 BC 7A4 96- VL aa DIVMTQTPLSLPVTLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF D4-E7 SGSGSGTDFTLKISRVEAEDVGVYYCSQSTYPEFTFGQGTKLEIK 419 BCMA-42 BC 7A4 96- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR D4-E7 VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLPVTLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSTYPEFTFGQGTKLEIK 420 BCMA-42 HL × BC 7A496- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL D4-E7 HL × molecule VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS CD3 HL DIVMTQTPLSLPVTLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSTYPEFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 421 BCMA-43 BC 7A4 96- VH CDR1 aa DYYIN F4-A12 422 BCMA-43 BC 7A4 96- VH CDR2 aa WIYFASGNSEYNQKFTG F4-A12 423 BCMA-43 BC 7A4 96- VH CDR3 aa LYDYDWYFDV F4-A12 424 BCMA-43 BC 7A4 96- VL CDR1 aa KSSQSLVHSNGNTYLH F4-A12 425 BCMA-43 BC 7A4 96- VL CDR2 aa KVSNRFS F4-A12 426 BCMA-43 BC 7A4 96- VL CDR3 aa SQSSTAPWT F4-A12 427 BCMA-43 BC 7A4 96- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR F4-A12 VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS 428 BCMA-43 BC 7A4 96- VL aa DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF F4-A12 SGSGSGTDFTLKISRVEAEDVGVYYCSQSSTAPWTFGQGTKLEIK 429 BCMA-43 BC 7A4 96- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR F4-A12 VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSTAPWTFGQGTKLEIK 430 BCMA-43 HL × BC 7A4 96- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL F4-A12 HL × molecule VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS CD3 HL DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSTAPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 431 BCMA-44 BC 7A4 96- VH CDR1 aa DYYIN F4-D7 432 BCMA-44 BC 7A4 96- VH CDR2 aa WIYFASGNSEYNQKFTG F4-D7 433 BCMA-44 BC 7A4 96- VH CDR3 aa LYDYDWYFDV F4-D7 434 BCMA-44 BC 7A4 96- VL CDR1 aa KSSQSLVHSNGNTYLH F4-D7 435 BCMA-44 BC 7A4 96- VL CDR2 aa KVSNRFS F4-D7 436 BCMA-44 BC 7A4 96- VL CDR3 aa SQSSIYPWT F4-D7 437 BCMA-44 BC 7A4 96- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR F4-D7 VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS 438 BCMA-44 BC 7A4 96- VL aa DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF F4-D7 SGSGSGTDFTLKISRVEAEDVGVYYCSQSSIYPWTFGQGTKLEIK 439 BCMA-44 BC 7A4 96- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR F4-D7 VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSIYPWTFGQGTKLEIK 440 BCMA-44 HL × BC 7A4 96- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL F4-D7 HL × molecule VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS CD3 HL DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSIYPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYMANWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 441 BCMA-45 BC 7A4 96- VH CDR1 aa DYYIN F4-E7 442 BCMA-45 BC 7A4 96- VH CDR2 aa WIYFASGNSEYNQKFTG F4-E7 443 BCMA-45 BC 7A4 96- VH CDR3 aa LYDYDWYFDV F4-E7 444 BCMA-45 BC 7A4 96- VL CDR1 aa KSSQSLVHSNGNTYLH F4-E7 445 BCMA-45 BC 7A4 96- VL CDR2 aa KVSNRFS F4-E7 446 BCMA-45 BC 7A4 96- VL CDR3 aa SQSTYPEFT F4-E7 447 BCMA-45 BC 7A4 96- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR F4-E7 VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS 448 BCMA-45 BC 7A4 96- VL aa DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF F4-E7 SGSGSGTDFTLKISRVEAEDVGVYYCSQSTYPEFTFGQGTKLEIK 449 BCMA-45 BC 7A4 96- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR F4-E7 VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSTYPEFTFGQGTKLEIK 450 BCMA-45 HL × BC 7A4 96- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL F4-E7 HL × molecule VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS CD3 HL DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSTYPEFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 451 BCMA-46 BC 7A4 96- VH CDR1 aa DYYIN G2-A12 452 BCMA-46 BC 7A4 96- VH CDR2 aa WIYFASGNSEYNEKFTG G2-A12 453 BCMA-46 BC 7A4 96- VH CDR3 aa LYDYDWYFDV G2-A12 454 BCMA-46 BC 7A4 96- VL CDR1 aa KSSQSLVHSNGNTYLH G2-A12 455 BCMA-46 BC 7A4 96- VL CDR2 aa KVSNRFS G2-A12 456 BCMA-46 BC 7A4 96- VL CDR3 aa SQSSTAPWT G2-A12 457 BCMA-46 BC 7A4 96- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNEKFTGR G2-A12 VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS 458 BCMA-46 BC 7A4 96- VL aa DIVMTQTPLSLSVSLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF G2-A12 SGSGSGTDFTLKISRVEAEDVGVYYCSQSSTAPWTFGQGTKLEIK 459 BCMA-46 BC 7A4 96- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNEKFTGR G2-A12 VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVSLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSTAPWTFGQGTKLEIK 460 BCMA-46 HL × BC 7A4 96- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNEKFTGR CD3 HL G2-A12 HL × molecule VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS CD3 HL DIVMTQTPLSLSVSLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSTAPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 461 BCMA-47 BC 7A4 96- VH CDR1 aa DYYIN G2-D7 462 BCMA-47 BC 7A4 96- VH CDR2 aa WIYFASGNSEYNEKFTG G2-D7 463 BCMA-47 BC 7A4 96- VH CDR3 aa LYDYDWYFDV G2-D7 464 BCMA-47 BC 7A4 96- VL CDR1 aa KSSQSLVHSNGNTYLH G2-D7 465 BCMA-47 BC 7A4 96- VL CDR2 aa KVSNRFS G2-D7 466 BCMA-47 BC 7A4 96- VL CDR3 aa SQSSIYPWT G2-D7 467 BCMA-47 BC 7A4 96- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNEKFTGR G2-D7 VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS 468 BCMA-47 BC 7A4 96- VL aa DIVMTQTPLSLSVSLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF G2-D7 SGSGSGTDFTLKISRVEAEDVGVYYCSQSSIYPWTFGQGTKLEIK 469 BCMA-47 BC 7A4 96- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNEKFTGR G2-D7 VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVSLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSIYPWTFGQGTKLEIK 470 BCMA-47 HL × BC 7A4 96- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNEKFTGR CD3 HL G2-D7 HL × molecule VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS CD3 HL DIVMTQTPLSLSVSLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSIYPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 471 BCMA-48 BC 7A4 96- VH CDR1 aa DYYIN G2-E7 472 BCMA-48 BC 7A4 96- VH CDR2 aa WIYFASGNSEYNEKFTG G2-E7 473 BCMA-48 BC 7A4 96- VH CDR3 aa LYDYDWYFDV G2-E7 474 BCMA-48 BC 7A4 96- VL CDR1 aa KSSQSLVHSNGNTYLH G2-E7 475 BCMA-48 BC 7A4 96- VL CDR2 aa KVSNRFS G2-E7 476 BCMA-48 BC 7A4 96- VL CDR3 aa SQSTYPEFT G2-E7 477 BCMA-48 BC 7A4 96- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNEKFTGR G2-E7 VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS 478 BCMA-48 BC 7A4 96- VL aa DIVMTQTPLSLSVSLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF G2-E7 SGSGSGTDFTLKISRVEAEDVGVYYCSQSTYPEFTFGQGTKLEIK 479 BCMA-48 BC 7A4 96- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNEKFTGR G2-E7 VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVSLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSTYPEFTFGQGTKLEIK 480 BCMA-48 HL × BC 7A4 96- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNEKFTGR CD3 HL G2-E7 HL × molecule VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS CD3 HL DIVMTQTPLSLSVSLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSTYPEFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 481 BCMA-49 BC 7A4 97- VH CDR1 aa DYYIN A3-A12 482 BCMA-49 BC 7A4 97- VH CDR2 aa WIYFASGNSEYNQKFTG A3-A12 483 BCMA-49 BC 7A4 97- VH CDR3 aa LYDYDWYFDV A3-A12 484 BCMA-49 BC 7A4 97- VL CDR1 aa KSSQSLVHSNGNTYLH A3-A12 485 BCMA-49 BC 7A4 97- VL CDR2 aa KVSNRFS A3-A12 486 BCMA-49 BC 7A4 97- VL CDR3 aa SQSSTAPWT A3-A12 487 BCMA-49 BC 7A4 97- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR A3-A12 VTMTRDTSINTAYMELSSLTSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS 488 BCMA-49 BC 7A4 97- VL aa DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF A3-A12 SGSGSGTDFTLKISRVEAEDVGIYYCSQSSTAPWTFGQGTKLEIK 489 BCMA-49 BC 7A4 97- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR A3-A12 VTMTRDTSINTAYMELSSLTSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGIYYCSQSSTAPWTFGQGTKLEIK 490 BCMA-49 HL × BC 7A4 97- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL A3-A12 HL × molecule VTMTRDTSINTAYMELSSLTSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS CD3 HL DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGIYYCSQSSTAPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 491 BCMA-50 BC 7A4 97- VH CDR1 aa DYYIN A3-D7 492 BCMA-50 BC 7A4 97- VH CDR2 aa WIYFASGNSEYNQKFTG A3-D7 493 BCMA-50 BC 7A4 97- VH CDR3 aa LYDYDWYFDV A3-D7 494 BCMA-50 BC 7A4 97- VL CDR1 aa KSSQSLVHSNGNTYLH A3-D7 495 BCMA-50 BC 7A4 97- VL CDR2 aa KVSNRFS A3-D7 496 BCMA-50 BC 7A4 97- VL CDR3 aa SQSSIYPWT A3-D7 497 BCMA-50 BC 7A4 97- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR A3-D7 VTMTRDTSINTAYMELSSLTSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS 498 BCMA-50 BC 7A4 97- VL aa DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF A3-D7 SGSGSGTDFTLKISRVEAEDVGIYYCSQSSIYPWTFGQGTKLEIK 499 BCMA-50 BC 7A4 97- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR A3-D7 VTMTRDTSINTAYMELSSLTSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGIYYCSQSSIYPWTFGQGTKLEIK 500 BCMA-50 HL × BC 7A4 97- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL A3-D7 HL × molecule VTMTRDTSINTAYMELSSLTSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS CD3 HL DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGIYYCSQSSIYPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYMANWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 501 BCMA-51 BC 7A4 97- VH CDR1 aa DYYIN A3-E7 502 BCMA-51 BC 7A4 97- VH CDR2 aa WIYFASGNSEYNQKFTG A3-E7 503 BCMA-51 BC 7A4 97- VH CDR3 aa LYDYDWYFDV A3-E7 504 BCMA-51 BC 7A4 97- VL CDR1 aa KSSQSLVHSNGNTYLH A3-E7 505 BCMA-51 BC 7A4 97- VL CDR2 aa KVSNRFS A3-E7 506 BCMA-51 BC 7A4 97- VL CDR3 aa SQSTYPEFT A3-E7 507 BCMA-51 BC 7A4 97- VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR A3-E7 VTMTRDTSINTAYMELSSLTSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS 508 BCMA-51 BC 7A4 97- VL aa DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF A3-E7 SGSGSGTDFTLKISRVEAEDVGIYYCSQSTYPEFTFGQGTKLEIK 509 BCMA-51 BC 7A4 97- scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR A3-E7 VTMTRDTSINTAYMELSSLTSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGIYYCSQSTYPEFTFGQGTKLEIK 510 BCMA-51 HL × BC 7A4 97- bispecific aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL A3-E7 HL × molecule VTMTRDTSINTAYMELSSLTSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS CD3 HL DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGIYYCSQSTYPEFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGIVTLICGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 511 BCMA-52 BC E11 19- VH CDR1 aa NAWMD F11-F8 512 BCMA-52 BC E11 19- VH CDR2 aa QITAKSNNYATYYAEPVKG F11-F8 513 BCMA-52 BC E11 19- VH CDR3 aa DGYH F11-F8 514 BCMA-52 BC E11 19- VL CDR1 aa RASEDIRNGLA F11-F8 515 BCMA-52 BC E11 19- VL CDR2 aa NANSLHT F11-F8 516 BCMA-52 BC E11 19- VL CDR3 aa EDTSKYPYT F11-F8 517 BCMA-52 BC E11 19- VH aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWVAQITAKSNNYATYYAEPVK F11-F8 GRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTDDGYHWGQGTLVTVSS 518 BCMA-52 BC E11 19- VL aa AIQMTQSPSSLSASVGETVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGS F11-F8 GTEFTLKISSLQPEDEATYYCEDTSKYPYTFGQGTKLEIK 519 BCMA-52 BC E11 19- scFv aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWVAQITAKSNNYATYYAEPVK F11-F8 GRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM TQSPSSLSASVGETVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGSGTEF TLKISSLQPEDEATYYCEDTSKYPYTFGQGTKLEIK 520 BCMA-52 HL × BC E11 19- bispecific aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWVAQITAKSNNYATYYAEPVK CD3 HL F11-F8 HL ×  molecule GRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM CD3 HL TQSPSSLSASVGETVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGSGTEF TLKISSLQPEDEATYYCEDTSKYPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAAS GFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTED TAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVT LTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCVLWYSNRWVFGGGTKLTVL 521 BCMA-53 BC E11 19- VH CDR1 aa NAWMD G3-F8 522 BCMA-53 BC E11 19- VH CDR2 aa QITAKSNNYATYYAAPVKG G3-F8 523 BCMA-53 BC E11 19- VH CDR3 aa DGYH G3-F8 524 BCMA-53 BC E11 19- VL CDR1 aa RASEDIRNGLA G3-F8 525 BCMA-53 BC E11 19- VL CDR2 aa NANSLHS G3-F8 526 BCMA-53 BC E11 19- VL CDR3 aa EDTSKYPYT G3-F8 527 BCMA-53 BC E11 19- VH aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQITAKSNNYATYYAAPVK G3-F8 GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSS 528 BCMA-53 BC E11 19- VL aa AIQMTQSPSSLSASVGDRVTIKCRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHSGVPSRFSGSGS G3-F8 GTDFTLTISSMQPEDEGTYYCEDTSKYPYTFGQGTKLEIK 529 BCMA-53 BC E11 19- scFv aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQITAKSNNYATYYAAPVK G3-F8 GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM TQSPSSLSASVGDRVTIKCRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHSGVPSRFSGSGSGTDF TLTISSMQPEDEGTYYCEDTSKYPYTFGQGTKLEIK 530 BCMA-53 HL × BC E11 19- bispecific aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQITAKSNNYATYYAAPVK CD3 HL G3-F8 HL × molecule GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM CD3 HL TQSPSSLSASVGDRVTIKCRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHSGVPSRFSGSGSGTDF TLTISSMQPEDEGTYYCEDTSKYPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAAS GFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTED TAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVT LTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCVLWYSNRWVFGGGTKLTVL 531 BCMA-54 BC E11 19- VH CDR1 aa NAWMD B2-F8 532 BCMA-54 BC E11 19- VH CDR2 aa QITAKSNNYATYYAAPVKG B2-F8 533 BCMA-54 BC El1 19- VH CDR3 aa DGYH B2-F8 534 BCMA-54 BC E11 19- VL CDR1 aa RASEDIRNGLA B2-F8 535 BCMA-54 BC E11 19- VL CDR2 aa NANSLHT B2-F8 536 BCMA-54 BC E11 19- VL CDR3 aa EDTSKYPYT B2-F8 537 BCMA-54 BC E11 19- VH aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQITAKSNNYATYYAAPVK B2-F8 GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSS 538 BCMA-54 BC E11 19- VL aa AIQMTQSPSSLSASVGDRVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGS B2-F8 GTDFTLTISSLQPEDEAIYYCEDTSKYPYTFGQGTKLEIK 539 BCMA-54 BC E11 19- scFv aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQITAKSNNYATYYAAPVK B2-F8 GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM TQSPSSLSASVGDRVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGSGTDF TLTISSLQPEDEAIYYCEDTSKYPYTFGQGTKLEIK 540 BCMA-54 HL × BC E11 19- bispecific aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQITAKSNNYATYYAAPVK CD3 HL B2-F8 HL × molecule GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM CD3 HL TQSPSSLSASVGDRVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGSGTDF TLTISSLQPEDEAIYYCEDTSKYPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAAS GFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTED TAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVT LTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCVLWYSNRWVFGGGTKLTVL 541 BCMA-55 BC E11-20- VH CDR1 aa NAWMD H9-E9 542 BCMA-55 BC E11-20- VH CDR2 aa QITAKSNNYATYYAAPVKG H9-E9 543 BCMA-55 BC E11-20- VH CDR3 aa DGYH H9-E9 544 BCMA-55 BC E11-20- VL CDR1 aa RASEDIRNGLA H9-E9 545 BCMA-55 BC E11-20- VL CDR2 aa NANSLHT H9-E9 546 BCMA-55 BC E11-20- VL CDR3 aa EETLKYPYT H9-E9 547 BCMA-55 BC E11-20- VH aa EVQLVESGGSLVKPGGSLRLSCAASGFTFSNAWMDWVRQAPGKRLEWVAQITAKSNNYATYYAAPVK H9-E9 GRFTISRDDSKNTLYLQMNSLKEEDTAVYYCTDDGYHWGQGTLVTVSS 548 BCMA-55 BC E11-20- VL aa AIQMTQSPSSLSASVGDRVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGS H9-E9 GTDFTLTISNLQPEDEATYYCEETLKYPYTFGQGTKLEIK 549 BCMA-55 BC E11-20- scFv aa EVQLVESGGSLVKPGGSLRLSCAASGFTFSNAWMDWVRQAPGKRLEWVAQITAKSNNYATYYAAPVK H9-E9 GRFTISRDDSKNTLYLQMNSLKEEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM TQSPSSLSASVGDRVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGSGTDF TLTISNLQPEDEATYYCEETLKYPYTFGQGTKLEIK 550 BCMA-55 HL × BC E11-20- bispecific aa EVQLVESGGSLVKPGGSLRLSCAASGFTFSNAWMDWVRQAPGKRLEWVAQITAKSNNYATYYAAPVK CD3 HL H9-E9 HL × molecule GRFTISRDDSKNTLYLQMNSLKEEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM CD3 HL TQSPSSLSASVGDRVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGSGTDF TLTISNLQPEDEATYYCEETLKYPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAAS GFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTED TAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVT LTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCVLWYSNRWVFGGGTKLTVL 551 BCMA-56 BC E11-19- VH CDR1 aa NAWMD F11-E9 552 BCMA-56 BC E11-19- VH CDR2 aa QITAKSNNYATYYAEPVKG F11-E9 553 BCMA-56 BC E11-19- VH CDR3 aa DGYH F11-E9 554 BCMA-56 BC E11-19- VL CDR1 aa RASEDIRNGLA F11-E9 555 BCMA-56 BC E11-19- VL CDR2 aa NANSLHT F11-E9 556 BCMA-56 BC E11-19- VL CDR3 aa EETLKYPYT F11-E9 557 BCMA-56 BC E11-19- VH aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWVAQITAKSNNYATYYAEPVK F11-E9 GRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTDDGYHWGQGTLVTVSS 558 BCMA-56 BC E11-19- VL aa AIQMTQSPSSLSASVGETVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGS F11-E9 GTEFTLKISSLQPEDEATYYCEETLKYPYTFGQGTKLEIK 559 BCMA-56 BC E11-19- scFv aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWVAQITAKSNNYATYYAEPVK F11-E9 GRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM TQSPSSLSASVGETVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGSGTEF TLKISSLQPEDEATYYCEETLKYPYTFGQGTKLEIK 560 BCMA-56 HL × BC E11-19- bispecific aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWVAQITAKSNNYATYYAEPVK CD3 HL F11-E9 HL × molecule GRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM CD3 HL TQSPSSLSASVGETVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGSGTEF TLKISSLQPEDEATYYCEETLKYPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAAS GFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTED TAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVT LTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCVLWYSNRWVFGGGTKLTVL 561 BCMA-57 BC E11-19- VH CDR1 aa NAWMD B2-E9 562 BCMA-57 BC E11-19- VH CDR2 aa QITAKSNNYATYYAAPVKG B2-E9 563 BCMA-57 BC E11-19- VH CDR3 aa DGYH B2-E9 564 BCMA-57 BC E11-19- VL CDR1 aa RASEDIRNGLA B2-E9 565 BCMA-57 BC E11-19- VL CDR2 aa NANSLHT B2-E9 566 BCMA-57 BC E11-19- VL CDR3 aa EETLKYPYT B2-E9 567 BCMA-57 BC E11-19- VH aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQITAKSNNYATYYAAPVK B2-E9 GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSS 568 BCMA-57 BC E11-19- VL aa AIQMTQSPSSLSASVGDRVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGS B2-E9 GTDFTLTISSLQPEDEAIYYCEETLKYPYTFGQGTKLEIK 569 BCMA-57 BC E11-19- scFv aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQITAKSNNYATYYAAPVK B2-E9 GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM TQSPSSLSASVGDRVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGSGTDF TLTISSLQPEDEAIYYCEETLKYPYTFGQGTKLEIK 570 BCMA-57 HL × BC E11-19- bispecific aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQITAKSNNYATYYAAPVK CD3 HL B2-E9 HL × molecule GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM CD3 HL TQSPSSLSASVGDRVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGSGTDF TLTISSLQPEDEAIYYCEETLKYPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAAS GFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTED TAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVT TLCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCVLWYSNRWVFGGGTKLTVL 571 BCMA-58 BC E11-19- VH CDR1 aa NAWMD G3-E9 572 BCMA-58 BC E11-19- VH CDR2 aa QITAKSNNYATYYAAPVKG G3-E9 573 BCMA-58 BC E11-19- VH CDR3 aa DGYH G3-E9 574 BCMA-58 BC E11-19- VL CDR1 aa RASEDIRNGLA G3-E9 575 BCMA-58 BC E11-19- VL CDR2 aa NANSLHS G3-E9 576 BCMA-58 BC E11-19- VL CDR3 aa EETLKYPYT G3-E9 577 BCMA-58 BC E11-19- VH aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQITAKSNNYATYYAAPVK G3-E9 GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSS 578 BCMA-58 BC E11-19- VL aa AIQMTQSPSSLSASVGDRVTIKCRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHSGVPSRFSGSGS G3-E9 GTDFTLTISSMQPEDEGTYYCEETLKYPYTFGQGTKLEIK 579 BCMA-58 BC E11-19- scFv aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQ ITAKSNNYATYYAAPVK G3-E9 GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM TQSPSSLSASVGDRVTIKCRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHSGVPSRFSGSGSGTDF TLTISSMQPEDEGTYYCEETLKYPYTFGQGTKLEIK 580 BCMA-58 HL × BC E11-19- bispecific aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQITAKSNNYATYYAAPVK CD3 HL G3-E9 HL × molecule GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM CD3 HL TQSPSSLSASVGDRVTIKCRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHSGVPSRFSGSGSGTDF TLTISSMQPEDEGTYYCEETLKYPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAAS GFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTED TAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVT LTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCVLWYSNRWVFGGGTKLTVL 581 BCMA-59 BC 5G9- VH CDR1 aa NYDMA 91-D2 582 BCMA-59 BC 5G9- VH CDR2 aa SIITSGGDNYYRDSVKG 91-D2 583 BCMA-59 BC 5G9- VH CDR3 aa HDYYDGSYGFAY 91-D2 584 BCMA-59 BC 5G9- VL CDR1 aa KASQSVGINVD 91-D2 585 BCMA-59 BC 5G9- VL CDR2 aa GASNRHT 91-D2 586 BCMA-59 BC 5G9- VL CDR3 aa LQYGSIPFT 91-D2 587 BCMA-59 BC 5G9- VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR 91-D2 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSS 588 BCMA-59 BC 5G9- VL aa EIVMTQSPASMSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS 91-D2 GTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK 589 BCMA-59 BC 5G9- scFv aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR 91-D2 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPASMSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK 590 BCMA-59 HL × BC 5G9- bispecific aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR CD3 HL 91-D2 HL × molecule FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSEIVMTQSPASMSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 591 BCMA-60 BC 5G9- VH CDR1 aa NYDMA 91-C7 592 BCMA-60 BC 5G9- VH CDR2 aa SIITSGGDNYYRDSVKG 91-C7 593 BCMA-60 BC 5G9- VH CDR3 aa HDYYDGSYGFAY 91-C7 594 BCMA-60 BC 5G9- VL CDR1 aa KASQSVGINVD 91-C7 595 BCMA-60 BC 5G9- VL CDR2 aa GASNRHT 91-C7 596 BCMA-60 BC 5G9- VL CDR3 aa LQYGSIPFT 91-C7 597 BCMA-60 BC 5G9- VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR 91-C7 FTISRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSS 598 BCMA-60 BC 5G9- VL aa EIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS 91-C7 GREFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK 599 BCMA-60 BC 5G9- scFv aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR 91-C7 FTISRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGREFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK 600 BCMA-60 HL × BC 5G9- bispecific aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR CD3 HL 91-C7 HL × molecule FTISRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGREFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 601 BCMA-61 BC 5G9- VH CDR1 aa NYDMA 91-E4 602 BCMA-61 BC 5G9- VH CDR2 aa SIITSGGDNYYRDSVKG 91-E4 603 BCMA-61 BC 5G9- VH CDR3 aa HDYYDGSYGFAY 91-E4 604 BCMA-61 BC 5G9- VL CDR1 aa KASQSVGINVD 91-E4 605 BCMA-61 BC 5G9- VL CDR2 aa GASNRHT 91-E4 606 BCMA-61 BC 5G9- VL CDR3 aa LQYGSIPFT 91-E4 607 BCMA-61 BC 5G9- VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR 91-E4 FTISRDNSKNTLYLQMNSLRSEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSS 608 BCMA-61 BC 5G9- VL aa EIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS 91-E4 GTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK 609 BCMA-61 BC 5G9- scFv aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR 91-E4 FTISRDNSKNTLYLQMNSLRSEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK 610 BCMA-61 HL × BC 5G9- bispecific aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR CD3 HL 91-E4 HL × molecule FTISRDNSKNTLYLQMNSLRSEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 611 BCMA-62 BC 5G9- VH CDR1 aa NYDMA 92-E10 612 BCMA-62 BC 5G9- VH CDR2 aa SIITSGGDNYYRDSVKG 92-E10 613 BCMA-62 BC 5G9- VH CDR3 aa HDYYDGSYGFAY 92-E10 614 BCMA-62 BC 5G9- VL CDR1 aa KASQSVGINVD 92-E10 615 BCMA-62 BC 5G9- VL CDR2 aa GASNRHT 92-E10 616 BCMA-62 BC 5G9- VL CDR3 aa LQYGSIPFT 92-E10 617 BCMA-62 BC 5G9- VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR 92-E10 FTVSRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSS 618 BCMA-62 BC 5G9- VL aa EIVMTQSPATLSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS 92-E10 GTEFTLTISSLQAEDFAVYYCLQYGSIPFTFGPGTKVDIK 619 BCMA-62 BC 5G9- scFv aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR 92-E10 FTVSRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQAEDFAVYYCLQYGSIPFTFGPGTKVDIK 620 BCMA-62 HL × BC 5G9- bispecific aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR CD3 HL 92-E10 HL × molecule FTVSRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSEIVMTQSPATLSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQAEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 621 BCMA-63 BC 3A4-37- VH CDR1 aa NYDMA C8 622 BCMA-63 BC 3A4-37- VH CDR2 aa SISTRGDITSYRDSVKG C8 623 BCMA-63 BC 3A4-37- VH CDR3 aa QDYYTDYMGFAY C8 624 BCMA-63 BC 3A4-37- VL CDR1 aa RASEDIYNGLA C8 625 BCMA-63 BC 3A4-37- VL CDR2 aa GASSLQD C8 626 BCMA-63 BC 3A4-37- VL CDR3 aa QQSYKYPLT C8 627 BCMA-63 BC 3A4-37- VH aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR C8 FTISRDNAKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSS 628 BCMA-63 BC 3A4-37- VL aa AIQMTQSPSSLSASVGDTVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGSGS C8 GTDYTLTISSLQPEDEATYYCQQSYKYPLTFGGGTKVEIK 629 BCMA-63 BC 3A4-37- scFv aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR C8 FTISRDNAKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDTVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDYTLTISSLQPEDEATYYCQQSYKYPLTFGGGTKVEIK 630 BCMA-63 HL × BC 3A4-37- bispecific aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR CD3 HL C8 HL × molecule FTISRDNAKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSAIQMTQSPSSLSASVGDTVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDYTLTISSLQPEDEATYYCQQSYKYPLTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 631 BCMA-64 BC 3A4-37- VH CDR1 aa NYDMA C9 632 BCMA-64 BC 3A4-37- VH CDR2 aa SISTRGDITSYRDSVKG C9 633 BCMA-64 BC 3A4-37- VH CDR3 aa QDYYTDYMGFAY C9 634 BCMA-64 BC 3A4-37- VL CDR1 aa RASEDIYNGLA C9 635 BCMA-64 BC 3A4-37- VL CDR2 aa GASSLQD C9 636 BCMA-64 BC 3A4-37- VL CDR3 aa QQSYKYPLT C9 637 BCMA-64 BC 3A4-37- VH aa EVQLLESGGGLVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR C9 FTISRDNSKNTLYLQMNSLRAE DTAVYYCARQDYYTDYMGFAYWGQGTLVTVSS 638 BCMA-64 BC 3A4-37- VL aa AIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGSGS C9 GTDFTLTISSMQPEDEATYYCQQSYKYPLTFGGGTKVEIK 639 BCMA-64 BC 3A4-37- scFv aa EVQLLESGGGLVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR C9 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDFTLTISSMQPEDEATYYCQQSYKYPLTFGGGTKVEIK 640 BCMA-64 HL × BC 3A4-37- bispecific aa EVQLLESGGGLVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR CD3 HL C9 HL × molecule FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDFTLTISSMQPEDEATYYCQQSYKYPLTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 641 BCMA-65 BC 3A4-37- VH CDR1 aa NYDMA E11 642 BCMA-65 BC 3A4-37- VH CDR2 aa SISTRGDITSYRDSVKG E11 643 BCMA-65 BC 3A4-37- VH CDR3 aa QDYYTDYMGFAY E11 644 BCMA-65 BC 3A4-37- VL CDR1 aa RASEDIYNGLA E11 645 BCMA-65 BC 3A4-37- VL CDR2 aa GASSLQD E11 646 BCMA-65 BC 3A4-37- VL CDR3 aa QQSYKYPLT E11 647 BCMA-65 BC 3A4-37- VH aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR E11 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSS 648 BCMA-65 BC 3A4-37- VL aa AIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGSGS E11 GTHYTLTISSLQPEDEATYYCQQSYKYPLTFGGGTKVEIK 649 BCMA-65 BC 3A4-37- scFv aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR E11 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTHYTLTISSLQPEDEATYYCQQSYKYPLTFGGGTKVEIK 650 BCMA-65 HL × BC 3A4-37- bispecific aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR CD3 HL E11 HL × molecule FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTHYTLTISSLQPEDEATYYCQQSYKYPLTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 651 BCMA-66 BC 3A4-37- VH CDR1 aa NYDMA C8-G1 652 BCMA-66 BC 3A4-37- VH CDR2 aa SISTRGDITSYRDSVKG C8-G1 653 BCMA-66 BC 3A4-37- VH CDR3 aa QDYYTDYMGFAY C8-G1 654 BCMA-66 BC 3A4-37- VL CDR1 aa RASEDIYNGLA C8-G1 655 BCMA-66 BC 3A4-37- VL CDR2 aa GASSLQD C8-G1 656 BCMA-66 BC 3A4-37- VL CDR3 aa AGPHKYPLT C8-G1 657 BCMA-66 BC 3A4-37- VH aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR C8-G1 FTISRDNAKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSS 658 BCMA-66 BC 3A4-37- VL aa AIQMTQSPSSLSASVGDTVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGSGS C8-G1 GTDYTLTISSLQPEDEATYYCAGPHKYPLTFGGGTKVEIK 659 BCMA-66 BC 3A4-37- scFv aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR C8-G1 FTISRDNAKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDTVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDYTLTISSLQPEDEATYYCAGPHKYPLTFGGGTKVEIK 660 BCMA-66 HL × BC 3A4-37- bispecific aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR CD3 HL C8-G1 HL × molecule FTISRDNAKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSAIQMTQSPSSLSASVGDTVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDYTLTISSLQPEDEATYYCAGPHKYPLTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 661 BCMA-67 BC 3A4-37- VH CDR1 aa NYDMA E11-G1 662 BCMA-67 BC 3A4-37- VH CDR2 aa SISTRGDITSYRDSVKG E11-G1 663 BCMA-67 BC 3A4-37- VH CDR3 aa QDYYTDYMGFAY E11-G1 664 BCMA-67 BC 3A4-37- VL CDR1 aa RASEDIYNGLA E11-G1 665 BCMA-67 BC 3A4-37- VL CDR2 aa GASSLQD E11-G1 666 BCMA-67 BC 3A4-37- VL CDR3 aa AGPHKYPLT E11-G1 667 BCMA-67 BC 3A4-37- VH aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR E11-G1 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSS 668 BCMA-67 BC 3A4-37- VL aa AIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGSGS E11-G1 GTHYTLTISSLQPEDEATYYCAGPHKYPLTFGGGTKVEIK 669 BCMA-67 BC 3A4-37-  scFv aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR E11-G1 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTHYTLTISSLQPEDEATYYCAGPHKYPLTFGGGTKVEIK 670 BCMA-67 HL × BC 3A4-37- bispecific aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR CD3 HL E11-G1 HL × molecule FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTHYTLTISSLQPEDEATYYCAGPHKYPLTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 671 BCMA-68 BC 3A4-37- VH CDR1 aa NYDMA C8-G8 672 BCMA-68 BC 3A4-37- VH CDR2 aa SISTRGDITSYRDSVKG C8-G8 673 BCMA-68 BC 3A4-37- VH CDR3 aa QDYYTDYMGFAY C8-G8 674 BCMA-68 BC 3A4-37- VL CDR1 aa RASEDIYNGLA C8-G8 675 BCMA-68 BC 3A4-37- VL CDR2 aa GASSLQD C8-G8 676 BCMA-68 BC 3A4-37- VL CDR3 aa QQSRNYQQT C8-G8 677 BCMA-68 BC 3A4-37- VH aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR C8-G8 FTISRDNAKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSS 678 BCMA-68- BC 3A4-37- VL aa AIQMTQSPSSLSASVGDTVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGSGS C8-G8 GTDYTLTISSLQPEDEATYYCQQSRNYQQTFGGGTKVEIK 679 BCMA-68 BC 3A4-37- scFv aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR C8-G8 FTISRDNAKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDTVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDYTLTISSLQPEDEATYYCQQSRNYQQTFGGGTKVEIK 680 BCMA-68 HL × BC 3A4-37- bispecific aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR CD3 HL C8-G8 HL × molecule FTISRDNAKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSAIQMTQSPSSLSASVGDTVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDYTLTISSLQPEDEATYYCQQSRNYQQTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 681 BCMA-69 BC 3A4-37- VH CDR1 aa NYDMA E11-G8 682 BCMA-69 BC 3A4-37- VH CDR2 aa SISTRGDITSYRDSVKG E11-G8 683 BCMA-69 BC 3A4-37- VH CDR3 aa QDYYTDYMGFAY E11-G8 684 BCMA-69 BC 3A4-37- VL CDR1 aa RASEDIYNGLA E11-G8 685 BCMA-69 BC 3A4-37- VL CDR2 aa GASSLQD E11-G8 686 BCMA-69 BC 3A4-37- VL CDR3 aa QQSRNYQQT E11-G8 687 BCMA-69 BC 3A4-37- VH aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR E11-G8 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSS 688 BCMA-69 BC 3A4-37- VL aa AIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGSGS E11-G8 GTHYTLTISSLQPEDEATYYCQQSRNYQQTFGGGTKVEIK 689 BCMA-69 BC 3A4-37- scFv aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR E11-G8 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTHYTLTISSLQPEDEATYYCQQSRNYQQTFGGGTKVEIK 690 BCMA-69 HL × BC 3A4-37- bispecific aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR CD3 HL E11-G8 HL × molecule FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTHYTLTISSLQPEDEATYYCQQSRNYQQTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 691 BCMA-70 BC 3A4-37- VH CDR1 aa NYDMA A11-G8 692 BCMA-70 BC 3A4-37- VH CDR2 aa SISTRGDITSYRDSVKG A11-G8 693 BCMA-70 BC 3A4-37- VH CDR3 aa QDYYTDYMGFAY A11-G8 694 BCMA-70 BC 3A4-37- VL CDR1 aa RASEDIYNGLA A11-G8 695 BCMA-70 BC 3A4-37- VL CDR2 aa GASSLQD A11-G8 696 BCMA-70 BC 3A4-37- VL CDR3 aa QQSRNYQQT A11-G8 697 BCMA-70 BC 3A4-37- VH aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR A11-G8 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSS 698 BCMA-70 BC 3A4-37- VL aa AIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGSGS A11-G8 GTEFTLTISSLQPEDEATYYCQQSRNYQQTFGGGTKVEIK 699 BCMA-70 BC 3A4-37- scFv aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR A11-G8 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTEFTLTISSLQPEDEATYYCQQSRNYQQTFGGGTKVEIK 700 BCMA-70 HL × BC 3A4-37- bispecific aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR CD3 HL A11-G8 HL × molecule FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTEFTLTISSLQPEDEATYYCQQSRNYQQTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 701 BCMA-71 BC 3A4-37- VH CDR1 aa NYDMA A11-G1 702 BCMA-71 BC 3A4-37- VH CDR2 aa SISTRGDITSYRDSVKG A11-G1 703 BCMA-71 BC 3A4-37- VH CDR3 aa QDYYTDYMGFAY A11-G1 704 BCMA-71 BC 3A4-37- VL CDR1 aa RASEDIYNGLA A11-G1 705 BCMA-71 BC 3A4-37- VL CDR2 aa GASSLQD A11-G1 706 BCMA-71 BC 3A4-37- VL CDR3 aa AGPHKYPLT A11-G1 707 BCMA-71 BC 3A4-37- VH aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR A11-G1 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSS 708 BCMA-71 BC 3A4-37- VL aa AIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGSGS A11-G1 GTEFTLTISSLQPEDEATYYCAGPHKYPLTFGGGTKVEIK 709 BCMA-71 BC 3A4-37- scFv aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR A11-G1 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTEFTLTISSLQPEDEATYYCAGPHKYPLTFGGGTKVEIK 710 BCMA-71 HL × BC 3A4-37- bispecific aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR CD3 HL A11-G1 HL × molecule FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTEFTLTISSLQPEDEATYYCAGPHKYPLTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 711 BCMA-72 BC 3A4-37- VH CDR1 aa NYDMA C9-G1 712 BCMA-72 BC 3A4-37- VH CDR2 aa SISTRGDITSYRDSVKG C9-G1 713 BCMA-72 BC 3A4-37- VH CDR3 aa QDYYTDYMGFAY C9-G1 714 BCMA-72 BC 3A4-37- VL CDR1 aa RASEDIYNGLA C9-G1 715 BCMA-72 BC 3A4-37- VL CDR2 aa GASSLQD C9-G1 716 BCMA-72 BC 3A4-37- VL CDR3 aa AGPHKYPLT C9-G1 717 BCMA-72 BC 3A4-37- VH aa EVQLLESGGGLVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR C9-G1 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSS 718 BCMA-72 BC 3A4-37- VL aa AIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGSGS C9-G1 GTDFTLTISSMQPEDEATYYCAGPHKYPLTFGGGTKVEIK 719 BCMA-72 BC 3A4-37- scFv aa EVQLLESGGGLVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR C9-G1 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDFTLTISSMQPEDEATYYCAGPHKYPLTFGGGTKVEIK 720 BCMA-72 HL × BC 3A4-37- bispecific aa EVQLLESGGGLVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR CD3 HL C9-G1 HL × molecule FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDFTLTISSMQPEDEATYYCAGPHKYPLTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 721 BCMA-73 BC 3A4-37- VH CDR1 aa NYDMA C9-G8 722 BCMA-73 BC 3A4-37- VH CDR2 aa SISTRGDITSYRDSVKG C9-G8 723 BCMA-73 BC 3A4-37- VH CDR3 aa QDYYTDYMGFAY C9-G8 724 BCMA-73 BC 3A4-37- VL CDR1 aa RASEDIYNGLA C9-G8 725 BCMA-73 BC 3A4-37- VL CDR2 aa GASSLQD C9-G8 726 BCMA-73 BC 3A4-37- VL CDR3 aa QQSRNYQQT C9-G8 727 BCMA-73 BC 3A4-37- VH aa EVQLLESGGGLVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR C9-G8 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSS 728 BCMA-73 BC 3A4-37- VL aa AIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGSGS C9-G8 GTDFTLTISSMQPEDEATYYCQQSRNYQQTFGGGTKVEIK 729 BCMA-73 BC 3A4-37- scFv aa EVQLLESGGGLVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR C9-G8 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDFTLTISSMQPEDEATYYCQQSRNYQQTFGGGTKVEIK 730 BCMA-73 HL × BC 3A4-37- bispecific aa EVQLLESGGGLVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR CD3 HL C9-G8 HL × molecule FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDFTLTISSMQPEDEATYYCQQSRNYQQTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 731 BCMA-74 BC C3-33- VH CDR1 aa NFDMA D7-B1 732 BCMA-74 BC C3-33- VH CDR2 aa SITTGGGDTYYADSVKG D7-B1 733 BCMA-74 BC C3-33- VH CDR3 aa HGYYDGYHLFDY D7-B1 734 BCMA-74 BC C3-33- VL CDR1 aa RASQGISNYLN D7-B1 735 BCMA-74 BC C3-33- VL CDR2 aa YTSNLQS D7-B1 736 BCMA-74 BC C3-33- VL CDR3 aa MGQTISSYT D7-B1 737 BCMA-74 BC C3-33- VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR D7-B1 FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS 738 BCMA-74 BC C3-33- VL aa DIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS D7-B1 GTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK 739 BCMA-74 BC C3-33- scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR D7-B1 FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK 740 BCMA-74 HL × BC C3-33- bispecific aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR CD3 HL D7-B1 HL × molecule FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 741 BCMA-75 BC C3-33- VH CDR1 aa NFDMA F8-B1 742 BCMA-75 BC C3-33- VH CDR2 aa SITTGGGDTYYADSVKG F8-B1 743 BCMA-75 BC C3-33- VH CDR3 aa HGYYDGYHLFDY F8-B1 744 BCMA-75 BC C3-33- VL CDR1 aa RASQGISNYLN F8-B1 745 BCMA-75 BC C3-33- VL CDR2 aa YTSNLQS F8-B1 746 BCMA-75 BC C3-33- VL CDR3 aa MGQTISSYT F8-B1 747 BCMA-75 BC C3-33- VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR F8-B1 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS 748 BCMA-75 BC C3-33- VL aa DIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS F8-B1 GTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK 749 BCMA-75 BC C3-33- scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR F8-B1 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK 750 BCMA-75 HL × BC C3-33- bispecific aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR CD3 HL F8-B1 HL × molecule FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 751 BCMA-76 BC C3-33- VH CDR1 aa NFDMA F9-B1 752 BCMA-76 BC C3-33- VH CDR2 aa SITTGGGDTYYADSVKG F9-B1 753 BCMA-76 BC C3-33- VH CDR3 aa HGYYDGYHLFDY F9-B1 754 BCMA-76 BC C3-33- VL CDR1 aa RASQGISNYLN F9-B1 755 BCMA-76 BC C3-33- VL CDR2 aa YTSNLQS F9-B1 756 BCMA-76 BC C3-33- VL CDR3 aa MGQTISSYT F9-B1 757 BCMA-76 BC C3-33- VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR F9-B1 FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS 758 BCMA-76 BC C3-33- VL aa DIQMTQSPSSLSASVGDRVTISCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS F9-B1 GTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK 759 BCMA-76 BC C3-33- scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR F9-B1 FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK 760 BCMA-76 HL × BC C3-33- bispecific aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR CD3 HL F9-B1 HL × molecule FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASVGDRVTISCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 761 BCMA-77 BC C3-33- VH CDR1 aa NFDMA F10B1 762 BCMA-77 BC C3-33- VH CDR2 aa SITTGGGDTYYADSVKG F10B1 763 BCMA-77 BC C3-33- VH CDR3 aa HGYYDGYHLFDY F10B1 764 BCMA-77 BC C3-33- VL CDR1 aa RASQGISNYLN F10B1 765 BCMA-77 BC C3-33- VL CDR2 aa YTSNLQS F10B1 766 BCMA-77 BC C3-33- VL CDR3 aa MGQTISSYT F10B1 767 BCMA-77 BC C3-33- VH aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGGGDTYYADSVKGR F10B1 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS 768 BCMA-77 BC C3-33- VL aa DIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS F10B1 GTDFTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK 769 BCMA-77 BC C3-33- scFv aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGGGDTYYADSVKGR F10B1 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK 770 BCMA-77 HL × BC C3-33- bispecific aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGGGDTYYADSVKGR CD3 HL F10B1 HL × molecule FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQE PSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 771 BCMA-78 BC E5-33- VH CDR1 aa NFDMA A11-A10 772 BCMA-78 BC E5-33- VH CDR2 aa SITTGGGDTYYADSVKG A11-A10 773 BCMA-78 BC E5-33- VH CDR3 aa HGYYDGYHLFDY A11-A10 774 BCMA-78 BC E5-33- VL CDR1 aa RASQGISNHLN A11-A10 775 BCMA-78 BC E5-33- VL CDR2 aa YTSNLQS A11-A10 776 BCMA-78 BC E5-33- VL CDR3 aa QQYFDRPYT A11-A10 777 BCMA-78 BC E5-33- VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR A11-A10 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS 778 BCMA-78 BC E5-33- VL aa DIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWFQQKPGRAPKPLIYYTSNLQSGVPSRFSGSGS A11-A10 GTDFTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIK 779 BCMA-78 BC E5-33- scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR A11-A10 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWFQQKPGRAPKPLIYYTSNLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIK 780 BCMA-78 HL × BC E5-33- bispecific aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR CD3 HL A11-A10 molecule FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG HL × CD3 GSDIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWFQQKPGRAPKPLIYYTSNLQSGVPSRFSGS HL GSGTDFTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 781 BCMA-79 BC E5-33- VH CDR1 aa NFDMA B11-A10 782 BCMA-79 BC E5-33- VH CDR2 aa SITTGGGDTYYADSVKG B11-A10 783 BCMA-79 BC E5-33- VH CDR3 aa HGYYDGYHLFDY B11-A10 784 BCMA-79 BC E5-33- VL CDR1 aa RASQGISNHLN B11-A10 785 BCMA-79 BC E5-33- VL CDR2 aa YTSNLQS B11-A10 786 BCMA-79 BC E5-33- VL CDR3 aa QQYFDRPYT B11-A10 787 BCMA-79 BC E5-33- VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR B11-A10 FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS 788 BCMA-79 BC E5-33- VL aa DIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS B11-A10 GTDYTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIK 789 BCMA-79 BC E5-33- scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR B11-A10 FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIK 790 BCMA-79 HL × BC E5-33- bispecific aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR CD3 HL B11-A10 molecule FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG HL × CD3 GSDIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS HL GSGTDYTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 791 BCMA-80 BC E5-33- VH CDR1 aa NFDMA G11-A10 792 BCMA-80 BC E5-33- VH CDR2 aa SITTGGGDTYYADSVKG G11-A10 793 BCMA-80 BC E5-33- VH CDR3 aa HGYYDGYHLFDY G11-A10 794 BCMA-80 BC E5-33- VL CDR1 aa RASQGISNHLN G11-A10 795 BCMA-80 BC E5-33- VL CDR2 aa YTSNLQS G11-A10 796 BCMA-80 BC E5-33- VL CDR3 aa QQYFDRPYT G11-A10 797 BCMA-80 BC E5-33- VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR G11-A10 FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS 798 BCMA-80 BC E5-33- VL aa DIQMTQSPSSLSASVGDRVTITCRASQGISNHLNWFQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS G11-A10 GTDFTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIK 799 BCMA-80 BC E5-33- scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR G11-A10 FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNHLNWFQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIK 800 BCMA-80 HL × BC E5-33- bispecific aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR CD3 HL G11-A10 molecule FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG HL × CD3 GSDIQMTQSPSSLSASVGDRVTITCRASQGISNHLNWFQQKPGKAPKPLIYYTSNLQSGVPSRFSGS HL GSGTDFTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 801 BCMA-81 BC E5-33- VH CDR1 aa NFDMA G12-A10 802 BCMA-81 BC E5-33- VH CDR2 aa SITTGGGDTYYADSVKG G12-A10 803 BCMA-81 BC E5-33- VH CDR3 aa HGYYDGYHLFDY G12-A10 804 BCMA-81 BC E5-33- VL CDR1 aa RASQGISNHLN G12-A10 805 BCMA-81 BC E5-33- VL CDR2 aa YTSNLQS G12-A10 806 BCMA-81 BC E5-33- VL CDR3 aa QQYFDRPYT G12-A10 807 BCMA-81 BC E5-33- VH aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGGGDTYYADSVKGR G12-A10 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS 808 BCMA-81 BC E5-33- VL aa DIQMTQSPSSLSASVGERVTITCRASQGISNHLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGSGS G12-A10 GTDFTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIK 809 BCMA-81 BC E5-33- scFv aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGGGDTYYADSVKGR G12-A10 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGERVTITCRASQGISNHLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIK 810 BCMA-81 HL × BC E5-33- bispecific aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGGGDTYYADSVKGR CD3 HL G12-A10 molecule FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG HL × CD3 GSDIQMTQSPSSLSASVGERVTITCRASQGISNHLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGS HL GSGTDFTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 811 BCMA-82 BC E5-33- VH CDR1 aa NFDMA A11-B8 812 BCMA-82 BC E5-33- VH CDR2 aa SITTGGGDTYYADSVKG A11-B8 813 BCMA-82 BC E5-33- VH CDR3 aa HGYYDGYHLFDY A11-B8 814 BCMA-82 BC E5-33- VL CDR1 aa RASQGISNHLN A11-B8 815 BCMA-82 BC E5-33- VL CDR2 aa YTSNLQS A11-B8 816 BCMA-82 BC E5-33- VL CDR3 aa QQYSNLPYT A11-B8 817 BCMA-82 BC E5-33- VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR A11-B8 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS 818 BCMA-82 BC E5-33- VL aa DIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWFQQKPGRAPKPLIYYTSNLQSGVPSRFSGSGS A11-B8 GTDFTLTISSLQPEDFATYYCQQYSNLPYTFGGGTKVEIK 819 BCMA-82 BC E5-33- scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR A11-B8 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWFQQKPGRAPKPLIYYTSNLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQYSNLPYTFGGGTKVEIK 820 BCMA-82 HL × BC E5-33- bispecific aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR CD3 HL A11-B8 HL × molecule FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWFQQKPGRAPKPLIYYTSNLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQYSNLPYTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 821 BCMA-83 BC E5-33- VH CDR1 aa NFDMA B11-B8 822 BCMA-83 BC E5-33- VH CDR2 aa SITTGGGDTYYADSVKG B11-B8 823 BCMA-83 BC E5-33- VH CDR3 aa HGYYDGYHLFDY B11-B8 824 BCMA-83 BC E5-33- VL CDR1 aa RASQGISNHLN B11-B8 825 BCMA-83 BC E5-33- VL CDR2 aa YTSNLQS B11-B8 826 BCMA-83 BC E5-33- VL CDR3 aa QQYSNLPYT B11-B8 827 BCMA-83 BC E5-33-  VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR B11-B8 FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS 828 BCMA-83 BC E5-33- VL aa DIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS B11-B8 GTDYTLTISSLQPEDFATYYCQQYSNLPYTFGGGTKVEIK 829 BCMA-83 BC E5-33- scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR B11-B8 FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQYSNLPYTFGGGTKVEIK 830 BCMA-83 HL × BC E5-33- bispecific aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR CD3 HL B11-B8 HL molecule FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG × CD3 HL GSDIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQYSNLPYTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 831 BCMA-84 BC E5-33- VH CDR1 aa NFDMA G12-B8 832 BCMA-84 BC E5-33- VH CDR2 aa SITTGGGDTYYADSVKG G12-B8 833 BCMA-84 BC E5-33- VH CDR3 aa HGYYDGYHLFDY G12-B8 834 BCMA-84 BC E5-33- VL CDR1 aa RASQGISNHLN G12-B8 835 BCMA-84 BC E5-33- VL CDR2 aa YTSNLQS G12-B8 836 BCMA-84 BC E5-33- VL CDR3 aa QQYSNLPYT G12-B8 837 BCMA-84 BC E5-33- VH aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGGGDTYYADSVKGR G12-B8 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS 838 BCMA-84 BC E5-33- VL aa DIQMTQSPSSLSASVGERVTITCRASQGISNHLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGSGS G12-B8 GTDFTLTISSLQPEDFATYYCQQYSNLPYTFGGGTKVEIK 839 BCMA-84 BC E5-33- scFv aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGGGDTYYADSVKGR G12-B8 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGERVTITCRASQGISNHLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQYSNLPYTFGGGTKVEIK 840 BCMA-84 HL × BC E5-33- bispecific aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGGGDTYYADSVKGR CD3 HL G12-B8 HL × molecule FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASVGERVTITCRASQGISNHLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQYSNLPYTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 841 BCMA-85 BC C6-97- VH CDR1 aa NFGMN G5 842 BCMA-85 BC C6-97- VH CDR2 aa WINTYTGESIYADDFKG G5 843 BCMA-85 BC C6-97- VH CDR3 aa GGVYGGYDAMDY G5 844 BCMA-85 BC C6-97- VL CDR1 aa RASQDISNYLN G5 845 BCMA-85 BC C6-97- VL CDR2 aa YTSRLHS G5 846 BCMA-85 BC C6-97- VL CDR3 aa QQGNTLPWT G5 847 BCMA-85 BC C6-97- VH aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR G5 FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSS 848 BCMA-85 BC C6-97- VL aa DIQMTQSPSSLSASLGDRVTITCRASQDISNYLNWYQQKPDKAPKLLIYYTSRLHSGVPSRFSGSGS G5 GTDYTLTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIK 849 BCMA-85 BC C6-97- scFv aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR G5 FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASLGDRVTITCRASQDISNYLNWYQQKPDKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIK 850 BCMA-85 HL × BC C6-97- bispecific aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR CD3 HL G5 HL × molecule FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASLGDRVTITCRASQDISNYLNWYQQKPDKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 851 BCMA-86 BC C6-98- VH CDR1 aa NFGMN C8 852 BCMA-86 BC C6-98- VH CDR2 aa WINTYTGESIYADDFKG C8 853 BCMA-86 BC C6-98- VH CDR3 aa GGVYGGYDAMDY C8 854 BCMA-86 BC C6-98- VL CDR1 aa RASQDISNYLN C8 855 BCMA-86 BC C6-98- VL CDR2 aa YTSRLHS C8 856 BCMA-86 BC C6-98- VL CDR3 aa QQGNTLPWT C8 857 BCMA-86 BC C6-98- VH aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR C8 FVFSSDTSVSTAYLQINSLKAEDTAVYFCARGGVYGGYDAMDYWGQGTLVTVSS 858 BCMA-86 BC C6-98- VL aa DIQMTQTPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKALKLLIYYTSRLHSGVPSRFSGSGS C8 GTDYSLTISNLQPEDIATYYCQQGNTLPWTFGQGTKVEIK 859 BCMA-86 BC C6-98- scFv aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR C8 FVFSSDTSVSTAYLQINSLKAEDTAVYFCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQTPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKALKLLIYYTSRLHSGVPSRFSGS GSGTDYSLTISNLQPEDIATYYCQQGNTLPWTFGQGTKVEIK 860 BCMA-86 HL × BC C6-98- bispecific aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR CD3 HL C8 HL molecule FVFSSDTSVSTAYLQINSLKAEDTAVYFCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG × CD3 HL GSDIQMTQTPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKALKLLIYYTSRLHSGVPSRFSGS GSGTDYSLTISNLQPEDIATYYCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 861 BCMA-87 BC C6-97- VH CDR1 aa NFGMN A6 862 BCMA-87 BC C6-97- VH CDR2 aa WINTYTGESIYADDFKG A6 863 BCMA-87 BC C6-97- VH CDR3 aa GGVYGGYDAMDY A6 864 BCMA-87 BC C6-97- VL CDR1 aa RASQDISNYLN A6 865 BCMA-87 BC C6-97- VL CDR2 aa YTSRLHS A6 866 BCMA-87 BC C6-97- VL CDR3 aa QQGNTLPWT A6 867 BCMA-87 BC C6-97- VH aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR A6 FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSS 868 BCMA-87 BC C6-97- VL aa DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGS A6 GTDYTLTISSLEQEDIATYFCQQGNTLPWTFGQGTKVEIK 869 BCMA-87 BC C6-97- scFv aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR A6 FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEQEDIATYFCQQGNTLPWTFGQGTKVEIK 870 BCMA-87 HL × BC C6-97- bispecific aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR CD3 HL A6 HL × molecule FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEQEDIATYFCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 871 BCMA-88 BC C6-98- VH CDR1 aa NFGMN C8-E3 872 BCMA-88 BC C6-98- VH CDR2 aa WINTYTGESIYADDFKG C8-E3 873 BCMA-88 BC C6-98- VH CDR3 aa GGVYGGYDAMDY C8-E3 874 BCMA-88 BC C6-98- VL CDR1 aa RASQDISNYLN C8-E3 875 BCMA-88 BC C6-98- VL CDR2 aa YTSRLHS C8-E3 876 BCMA-88 BC C6-98- VL CDR3 aa QSFATLPWT C8-E3 877 BCMA-88 BC C6-98- VH aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR C8-E3 FVFSSDTSVSTAYLQINSLKAEDTAVYFCARGGVYGGYDAMDYWGQGTLVTVSS 878 BCMA-88 BC C6-98- VL aa DIQMTQTPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKALKLLIYYTSRLHSGVPSRFSGSGS C8-E3 GTDYSLTISNLQPEDIATYYCQSFATLPWTFGQGTKVEIK 879 BCMA-88 BC C6-98- scFv aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR C8-E3 FVFSSDTSVSTAYLQINSLKAEDTAVYFCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQTPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKALKLLIYYTSRLHSGVPSRFSGS GSGTDYSLTISNLQPEDIATYYCQSFATLPWTFGQGTKVEIK 880 BCMA-88 HL × BC C6-98- bispecific aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR CD3 HL C8-E3 HL × molecule FVFSSDTSVSTAYLQINSLKAEDTAVYFCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQTPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKALKLLIYYTSRLHSGVPSRFSGS GSGTDYSLTISNLQPEDIATYYCQSFATLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 881 BCMA-89 BC C6-98- VH CDR1 aa NFGMN A1-E3 882 BCMA-89 BC C6-98- VH CDR2 aa WINTYTGESIYADDFKG A1-E3 883 BCMA-89 BC C6-98- VH CDR3 aa GGVYGGYDAMDY A1-E3 884 BCMA-89 BC C6-98- VL CDR1 aa RASQDISNYLN A1-E3 885 BCMA-89 BC C6-98- VL CDR2 aa YTSRLHS A1-E3 886 BCMA-89 BC C6-98- VL CDR3 aa QSFATLPWT A1-E3 887 BCMA-89 BC C6-98- VH aa QVQLVQSGSELKKPGASVKISCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR A1-E3 FVFSSDTSVSTAYLQINNLKAEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSS 888 BCMA-89 BC C6-98- VL aa DIQMTQSPSSLSASVGDRVTISCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGS A1-E3 GTDYTFTISNLQPEDIATYYCQSFATLPWTFGQGTKVEIK 889 BCMA-89 BC C6-98- scFv aa QVQLVQSGSELKKPGASVKISCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR A1-E3 FVFSSDTSVSTAYLQINNLKAEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTFTISNLQPEDIATYYCQSFATLPWTFGQGTKVEIK 890 BCMA-89 HL × BC C6-98- bispecific aa QVQLVQSGSELKKPGASVKISCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR CD3 HL A1-E3 HL × molecule FVFSSDTSVSTAYLQINNLKAEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASVGDRVTISCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTFTISNLQPEDIATYYCQSFATLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 891 BCMA-90 BC C6-97- VH CDR1 aa NFGMN G5-E3 892 BCMA-90 BC C6-97- VH CDR2 aa WINTYTGESIYADDFKG G5-E3 893 BCMA-90 BC C6-97- VH CDR3 aa GGVYGGYDAMDY G5-E3 894 BCMA-90 BC C6-97- VL CDR1 aa RASQDISNYLN G5-E3 895 BCMA-90 BC C6-97- VL CDR2 aa YTSRLHS G5-E3 896 BCMA-90 BC C6-97- VL CDR3 aa QSFATLPWT G5-E3 897 BCMA-90 BC C6-97- VH aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR G5-E3 FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSS 898 BCMA-90 BC C6-97- VL aa DIQMTQSPSSLSASLGDRVTITCRASQDISNYLNWYQQKPDKAPKLLIYYTSRLHSGVPSRFSGSGS G5-E3 GTDYTLTISSLEPEDIATYYCQSFATLPWTFGQGTKVEIK 899 BCMA-90 BC C6-97- scFv aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR G5-E3 FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASLGDRVTITCRASQDISNYLNWYQQKPDKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEPEDIATYYCQSFATLPWTFGQGTKVEIK 900 BCMA-90 HL × BC C6-97- bispecific aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR CD3 HL G5-E3 HL × molecule FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASLGDRVTITCRASQDISNYLNWYQQKPDKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEPEDIATYYCQSFATLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 901 BCMA-91 BC C6-97- VH CDR1 aa NFGMN A6-E3 902 BCMA-91 BC C6-97- VH CDR2 aa WINTYTGESIYADDFKG A6-E3 903 BCMA-91 BC C6-97- VH CDR3 aa GGVYGGYDAMDY A6-E3 904 BCMA-91 BC C6-97- VL CDR1 aa RASQDISNYLN A6-E3 905 BCMA-91 BC C6-97- VL CDR2 aa YTSRLHS A6-E3 906 BCMA-91 BC C6-97- VL CDR3 aa QSFATLPWT A6-E3 907 BCMA-91 BC C6-97- VH aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR A6-E3 FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSS 908 BCMA-91 BC C6-97- VL aa DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGS A6-E3 GTDYTLTISSLEQEDIATYFCQSFATLPWTFGQGTKVEIK 909 BCMA-91 BC C6-97- scFv aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR A6-E3 FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEQEDIATYFCQSFATLPWTFGQGTKVEIK 910 BCMA-91 HL × BC C6-97- bispecific aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR CD3 HL A6-E3 HL × molecule FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEQEDIATYFCQSFATLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 911 BCMA-92 BC C6-97- VH CDR1 aa NFGMN G5-G9 912 BCMA-92 BC C6-97- VH CDR2 aa WINTYTGESIYADDFKG G5-G9 913 BCMA-92 BC C6-97- VH CDR3 aa GGVYGGYDAMDY G5-G9 914 BCMA-92 BC C6-97- VL CDR1 aa RASQDISNYLN G5-G9 915 BCMA-92 BC C6-97- VL CDR2 aa YTSRLHS G5-G9 916 BCMA-92 BC C6-97- VL CDR3 aa QHFRTLPWT G5-G9 917 BCMA-92 BC C6-97- VH aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR G5-G9 FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSS 918 BCMA-92 BC C6-97- VL aa DIQMTQSPSSLSASLGDRVTITCRASQDISNYLNWYQQKPDKAPKLLIYYTSRLHSGVPSRFSGSGS G5-G9 GTDYTLTISSLEPEDIATYYCQHFRTLPWTFGQGTKVEIK 919 BCMA-92 BC C6-97- scFv aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR G5-G9 FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASLGDRVTITCRASQDISNYLNWYQQKPDKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEPEDIATYYCQHFRTLPWTFGQGTKVEIK 920 BCMA-92 HL × BC C697- bispecific aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR CD3 HL G5-G9 HL × molecule FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASLGDRVTITCRASQDISNYLNWYQQKPDKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEPEDIATYYCQHFRTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 921 BCMA-93 BC C6-98- VH CDR1 aa NFGMN C8-G9 922 BCMA-93 BC C6-98- VH CDR2 aa WINTYTGESIYADDFKG C8-G9 923 BCMA-93 BC C6-98- VH CDR3 aa GGVYGGYDAMDY C8-G9 924 BCMA-93 BC C6-98- VL CDR1 aa RASQDISNYLN C8-G9 925 BCMA-93 BC C6-98- VL CDR2 aa YTSRLHS C8-G9 926 BCMA-93 BC C6-98- VL CDR3 aa QHFRTLPWT C8-G9 927 BCMA-93 BC C6-98- VH aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR C8-G9 FVFSSDTSVSTAYLQINSLKAEDTAVYFCARGGVYGGYDAMDYWGQGTLVTVSS 928 BCMA-93 BC C6-98- VL aa DIQMTQTPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKALKLLIYYTSRLHSGVPSRFSGSGS C8-G9 GTDYSLTISNLQPEDIATYYCQHFRTLPWTFGQGTKVEIK 929 BCMA-93 BC C6-98- scFv aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR C8-G9 FVFSSDTSVSTAYLQINSLKAEDTAVYFCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQTPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKALKLLIYYTSRLHSGVPSRFSGS GSGTDYSLTISNLQPEDIATYYCQHFRTLPWTFGQGTKVEIK 930 BCMA-93 HL × BC C6-98- bispecific aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR CD3 HL C8-G9 HL × molecule FVFSSDTSVSTAYLQINSLKAEDTAVYFCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQTPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKALKLLIYYTSRLHSGVPSRFSGS GSGTDYSLTISNLQPEDIATYYCQHFRTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 931 BCMA-94 BC C6-97- VH CDR1 aa NFGMN A6-G9 932 BCMA-94 BC C6-97- VH CDR2 aa WINTYTGESIYADDFKG A6-G9 933 BCMA-94 BC C6-97- VH CDR3 aa GGVYGGYDAMDY A6-G9 934 BCMA-94 BC C6-97- VL CDR1 aa RASQDISNYLN A6-G9 935 BCMA-94 BC C6-97- VL CDR2 aa YTSRLHS A6-G9 936 BCMA-94 BC C6-97- VL CDR3 aa QHFRTLPWT A6-G9 937 BCMA-94 BC C6-97- VH aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR A6-G9 FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSS 938 BCMA-94 BC C6-97- VL aa DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGS A6-G9 GTDYTLTISSLEQEDIATYFCQHFRTLPWTFGQGTKVEIK 939 BCMA-94 BC C6-97- scFv aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR A6-G9 FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEQEDIATYFCQHFRTLPWTFGQGTKVEIK 940 BCMA-94 HL × BC C6-97- bispecific aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR CD3 HL A6-G9 HL × molecule FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEQEDIATYFCQHFRTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 941 BCMA-95 BC C6-98- VH CDR1 aa NFGMN A1-G9 942 BCMA-95 BC C6-98- VH CDR2 aa WINTYTGESIYADDFKG A1-G9 943 BCMA-95 BC C6-98- VH CDR3 aa GGVYGGYDAMDY A1-G9 944 BCMA-95 BC C6-98- VL CDR1 aa RASQDISNYLN A1-G9 945 BCMA-95 BC C6-98- VL CDR2 aa YTSRLHS A1-G9 946 BCMA-95 BC C6-98- VL CDR3 aa QHFRTLPWT A1-G9 947 BCMA-95 BC C6-98- VH aa QVQLVQSGSELKKPGASVKISCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR A1-G9 FVFSSDTSVSTAYLQINNLKAEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSS 948 BCMA-95 BC C6-98- VL aa DIQMTQSPSSLSASVGDRVTISCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGS A1-G9 GTDYTFTISNLQPEDIATYFCQHFRTLPWTFGQGTKVEIK 949 BCMA-95 BC C6-98- scFv aa QVQLVQSGSELKKPGASVKISCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR A1-G9 FVFSSDTSVSTAYLQINNLKAEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTFTISNLQPEDIATYFCQHFRTLPWTFGQGTKVEIK 950 BCMA-95 HL × BC C6-98- bispecific aa QVQLVQSGSELKKPGASVKISCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR CD3 HL A1-G9 HL × molecule FVFSSDTSVSTAYLQINNLKAEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASVGDRVTISCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTFTISNLQPEDIATYFCQHFRTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 951 BCMA-96 BC C6 98- VH CDR1 aa NFGMN A1 952 BCMA-96 BC C6 98- VH CDR2 aa WINTYTGESIYADDFKG A1 953 BCMA-96 BC C6 98- VH CDR3 aa GGVYGGYDAMDY A1 954 BCMA-96 BC C6 98- VL CDR1 aa RASQDISNYLN A1 955 BCMA-96 BC C6 98- VL CDR2 aa YTSRLHS A1 956 BCMA-96 BC C6 98- VL CDR3 aa QQGNTLPWT A1 957 BCMA-96 BC C6 98- VH aa QVQLVQSGSELKKPGASVKISCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR A1 FVFSSDTSVSTAYLQINNLKAEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSS 958 BCMA-96 BC C6 98- VL aa DIQMTQSPSSLSASVGDRVTISCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGS A1 GTDYTFTISNLQPEDIATYYCQQGNTLPWTFGQGTKVEIK 959 BCMA-96 BC C6 98- scFv aa QVQLVQSGSELKKPGASVKISCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR A1 FVFSSDTSVSTAYLQINNLKAEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTFTISNLQPEDIATYYCQQGNTLPWTFGQGTKVEIK 960 BCMA-96 HL × BC C6 98- bispecific aa QVQLVQSGSELKKPGASVKISCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR CD3 HL A1 HL × molecule FVFSSDTSVSTAYLQINNLKAEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASVGDRVTISCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTFTISNLQPEDIATYYCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 961 BCMA-97 BC B12-33- VH CDR1 aa NFDMA G2-B2 962 BCMA-97 BC B12-33- VH CDR2 aa SITTGGGDTYYADSVKG G2-B2 963 BCMA-97 BC B12-33- VH CDR3 aa HGYYDGYHLFDY G2-B2 964 BCMA-97 BC B12-33- VL CDR1 aa RASQGISNNLN G2-B2 965 BCMA-97 BC B12-33- VL CDR2 aa YTSNLQS G2-B2 966 BCMA-97 BC B12-33- VL CDR3 aa QQFTSLPYT G2-B2 967 BCMA-97 BC B12-33- VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR G2-B2 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS 968 BCMA-97 BC B12-33- VL aa DIQMTQSPSSMSASVGDRVTITCRASQGISNNLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGSGS G2-B2 GTDYTLTISSLQPEDFATYYCQQFTSLPYTFGQGTKLEIK 969 BCMA-97 BC B12-33- scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR G2-B2 FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSMSASVGDRVTITCRASQGISNNLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQFTSLPYTFGQGTKLEIK 970 BCMA-97 HL × BC B12-33- bispecific aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR CD3 HL G2-B2 HL × molecule FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSMSASVGDRVTITCRASQGISNNLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQFTSLPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 971 BCMA-98 BC B12-33- VH CDR1 aa NFDMA A4-B2 972 BCMA-98 BC B12-33- VH CDR2 aa SITTGGGDTYYADSVKG A4-B2 973 BCMA-98 BC B12-33- VH CDR3 aa HGYYDGYHLFDY A4-B2 974 BCMA-98 BC B12-33- VL CDR1 aa RANQGISNNLN A4-B2 975 BCMA-98 BC B12-33- VL CDR2 aa YTSNLQS A4-B2 976 BCMA-98 BC B12-33- VL CDR3 aa QQFTSLPYT A4-B2 977 BCMA-98 BC B12-33- VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR A4-B2 FTISRDNAKSTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS 978 BCMA-98 BC B12-33- VL aa DIQMTQSPSSLSASVGDRVTITCRANQGISNNLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS A4-B2 GTDYTLTISSLQPEDFATYYCQQFTSLPYTFGQGTKLEIK 979 BCMA-98 BC B12-33- scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR A4-B2 FTISRDNAKSTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRANQGISNNLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQFTSLPYTFGQGTKLEIK 980 BCMA-98 HL × BC B12-33- bispecific aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR CD3 HL A4-B2 HL × molecule FTISRDNAKSTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSLSASVGDRVTITCRANQGISNNLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQFTSLPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 981 BCMA-99 BC B12-33- VH CDR1 aa NFDMA A5-B2 982 BCMA-99 BC B12-33- VH CDR2 aa SITTGGGDTYYADSVKG A5-B2 983 BCMA-99 BC B12-33- VH CDR3 aa HGYYDGYHLFDY A5-B2 984 BCMA-99 BC B12-33- VL CDR1 aa RASQGISNNLN A5-B2 985 BCMA-99 BC B12-33- VL CDR2 aa YTSNLQS A5-B2 986 BCMA-99 BC B12-33- VL CDR3 aa QQFTSLPYT A5-B2 987 BCMA-99 BC B12-33- VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR A5-B2 FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS 988 BCMA-99 BC B12-33- VL aa DIQMTQSPSSMSASVGDRVTITCRASQGISNNLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGSGS A5-B2 GTDYTLTISSLQPEDFATYYCQQFTSLPYTFGQGTKLEIK 989 BCMA-99 BC B12-33- scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR A5-B2 FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSMSASVGDRVTITCRASQGISNNLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQFTSLPYTFGQGTKLEIK 990 BCMA-99 HL × BC B12-33- bispecific aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR CD3 HL A5-B2 HL × molecule FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSMSASVGDRVTITCRASQGISNNLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQFTSLPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 991 BCMA-100 BC B12-33- VH CDR1 aa NFDMA A5-C10 992 BCMA-100 BC B12-33- VH CDR2 aa SITTGGGDTYYADSVKG A5-C10 993 BCMA-100 BC B12-33- VH CDR3 aa HGYYDGYHLFDY A5-C10 994 BCMA-100 BC B12-33- VL CDR1 aa RASQGISNNLN A5-C10 995 BCMA-100 BC B12-33- VL CDR2 aa YTSNLQS A5-C10 996 BCMA-100 BC B12-33- VL CDR3 aa QQFAHLPYT A5-C10 997 BCMA-100 BC B12-33- VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR A5-C10 FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS 998 BCMA-100 BC B12-33- VL aa DIQMTQSPSSMSASVGDRVTITCRASQGISNNLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGSGS A5-C10 GTDYTLTISSLQPEDFATYYCQQFAHLPYTFGQGTKLEIK 999 BCMA-100 BC B12-33- scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR A5-C10 FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSMSASVGDRVTITCRASQGISNNLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQFAHLPYTFGQGTKLEIK 1000 BCMA-100 HL × BC B12-33- bispecific aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR CD3 HL A5-C10 HL × molecule FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG CD3 HL GSDIQMTQSPSSMSASVGDRVTITCRASQGISNNLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQFAHLPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1001 human BCMA human na atgttgcagatggctgggcagtgctcccaaaatgaatattttgacagtttgttgcatgcttgcatac cttgtcaacttcgatgttcttctaatactcctcctctaacatgtcagcgttattgtaatgcaagtgt gaccaattcagtgaaaggaacgaatgcgattctctggacctgtttgggactgagcttaataatttct ttggcagttttcgtgctaatgtttttgctaaggaagataaactctgaaccattaaaggacgagttta aaaacacaggatcaggtctcctgggcatggctaacattgacctggaaaagagcaggactggtgatga aattattcttccgagaggcctcgagtacacggtggaagaatgcacctgtgaagactgcatcaagagc aaaccgaaggtcgactctgaccattgctttccactcccagctatggaggaaggcgcaaccattcttg tcaccacgaaaacgaatgactattgcaagagcctgccagctgctttgagtgctacggagatagagaa atcaatttctgctaggtaa 1002 human BCMA human aa MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSVKGTNAILWTCLGLSLIIS LAVFVLMFLLRKINSEPLKDEFKNTGSGLLGMANIDLEKSRTGDEIILPRGLEYTVEECTCEDCIKS KPKVDSDHCFPLPAMEEGATILVTTKTNDYCKSLPAALSATEIEKSISAR 1003 mouse BCMA murine na atggcgcaacagtgtttccacagtgaatattttgacagtctgctgcatgcttgcaaaccgtgtcact tgcgatgttccaaccctcctgcaacctgtcagccttactgtgatccaagcgtgaccagttcagtgaa agggacgtacacggtgctctggatcttcttggggctgaccttggtcctctctttggcacttttcaca atctcattcttgctgaggaagatgaaccccgaggccctgaaggacgagcctcaaagcccaggtcagc ttgacggatcggctcagctggacaaggccgacaccgagctgactaggatcagggctggtgacgacag gatctttccccgaagcctggagtatacagtggaagagtgcacctgtgaggactgtgtcaagagcaaa cccaagggggattctgaccatttcttcccgcttccagccatggaggagggggcaaccattcttgtca ccacaaaaacgggtgactacggcaagtcaagtgtgccaactgctttgcaaagtgtcatggggatgga gaagccaactcacactagataa 1004 mouse BCMA murine aa MAQQCFHSEYFDSLLHACKPCHLRCSNPPATCQPYCDPSVTSSVKGTYTVLWIFLGLTLVLSLALFT ISFLLRKMNPEALKDEPQSPGQLDGSAQLDKADTELTRIRAGDDRIFPRSLEYTVEECTCEDCVKSK PKGDSDHFFPLPAMEEGATILVTTKTGDYGKSSVPTALQSVMGMEKPTHIR 1005 macaque BCMA rhesus na atgttgcagatggctcggcagtgctcccaaaatgaatattttgacagtttgttgcatgattgcaaac cttgtcaacttcgatgttctagtactcctcctctaacatgtcagcgttattgcaatgcaagtatgac caattcagtgaaaggaatgaatgcgattctctggacctgtttgggactgagcttgataatttctttg gcagttttcgtgctaacgtttttgctaaggaagatgagctctgaaccattaaaggatgagtttaaaa acacaggatcaggtctcctgggcatggctaacattgacctggaaaagggcaggactggtgatgaaat tgttcttccaagaggcctggagtacacggtggaagaatgcacctgtgaagactgcatcaagaataaa ccaaaggttgattctgaccattgctttccactcccagccatggaggaaggcgcaaccattctcgtca ccacgaaaacgaatgactattgcaatagcctgtcagctgctttgagtgttacggagatagagaaatc aatttctgctaggtaa 1006 macaque BCMA rhesus aa MLQMARQCSQNEYFDSLLHDCKPCQLRCSSTPPLTCQRYCNASMINSVKGMNAILWTCLGLSLIISL AVFVLTFLLRKMSSEPLKDEFKNTGSGLLGMANIDLEKGRTGDEIVLPRGLEYTVEECTCEDCIKNK PKVDSDHCFPLPAMEEGATILVTTKTNDYCNSLSAALSVTEIEKSISAR 1007 hu BCMA-ECD = positions human aa MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNIPPLTCQRYCNASVINSVKGTNA 1-54 of SEQ ID NO: 1002 1008 mu BCMA-ECD = positions murine aa MAQQCFHSEYFDSLLHACKPCHLRCSNPPATCQPYCDPSVTSSVKGTYT 1-49 of SEQ ID NO: 1004 1009 hu BCMA-ECD/E1 murine chimeric aa MAQQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSVKGTNA hu/mu 1010 hu BCMA-ECD/E2 murine chimeric aa MLQMAGQCFHSEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSVKGTNA hu/mu 1011 hu BCMA-ECD/E3 murine chimeric aa MLQMAGQCSQNEYFDSLLHACIPCHLRCSNPPATCQPYCNASVTNSVKGTNA hu/mu 1012 hu BCMA-ECD/E4 murine chimeric aa MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCDPSVTSSVKGTYT hu/mu 1013 hu BCMA-ECD/E5 murine chimeric aa MLQMAGQCSQNEYFDSLLHACKPCQLRCSSNTPPLTCQRYCNASVTNSVKGTNA hu/mu 1014 hu BCMA-ECD/E6 murine chimeric aa MLQMAGQCSQNEYFDSLLHACIPCHLRCSSNTPPLTCQRYCNASVTNSVKGTNA hu/mu 1015 hu BCMA-ECD/E7 murine chimeric aa MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQPYCNASVTNSVKGTNA hu/mu 1016 hu BCMA-epitope cluster 3 human aa CQLRCSSNTPPLTCQRYC 1017 mac BCMA-epitope cluster 3 macaque aa CQLRCSSTPPLTCQRYC 1018 hu BCMA-epitope cluster 1 human aa MLQMAGQ 1019 hu BCMA-epitope cluster 4 human aa NASVTNSVKGTNA 1020 mac BCMA-epitope cluster 1 macaque aa MLQMARQ 1021 mac BCMA-epitope cluster 4 macaque aa NASMTNSVKGMNA 1022 BCMA-101 BC 5G9 VH CDR1 aa GFTFSNYDMA 1023 BCMA-101 BC 5G9 VH CDR2 aa SIITSGGDNYYRDSVKG 1024 BCMA-101 BC 5G9 VH CDR3 aa HDYYDGSYGFAY 1025 BCMA-101 BC 5G9 VL CDR1 aa KASQSVGINVD 1026 BCMA-101 BC 5G9 VL CDR2 aa GASNRHT 1027 BCMA-101 BC 5G9 VL CDR3 aa LQYGSIPFT 1028 BCMA-101 BC 5G9 VH aa EVQLVESGGGLVQPGRSLKLSCAASGFTFSNYDMAWVRQAPTKGLEWVASIITSGGDNYYRDSVKGR FTVSRDNAKSTLYLQMDSLRSEDTATYYCVRHDYYDGSYGFAYWGQGTLVTVSS 1029 BCMA-101 BC 5G9 VL aa ETVMTQSPTSMSTSIGERVTLNCKASQSVGINVDWYQQTPGQSPKLLIYGASNRHTGVPDRFTGSGF GRDFTLTISNVEAEDLAVYYCLQYGSIPFTFGSGTKLELK 1030 BCMA-101 BC 5G9 scFv aa EVQLVESGGGLVQPGRSLKLSCAASGFTFSNYDMAWVRQAPTKGLEWVASIITSGGDNYYRDSVKGR FTVSRDNAKSTLYLQMDSLRSEDTATYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGGSGG GGSETVMTQSPTSMSTSIGERVTLNCKASQSVGINVDWYQQTPGQSPKLLIYGASNRHTGVPDRFTG SGFGRDFTLTISNVEAEDLAVYYCLQYGSIPFTFGSGTKLELK 1031 BCMA-102 BC 244-A7 VH CDR1 aa GYTFTNHIIH 1032 BCMA-102 BC 244-A7 VH CDR2 aa YINPYNDDTEYNEKFKG 1033 BCMA-102 BC 244-A7 VH CDR3 aa DGYYRDMDVMDY 1034 BCMA-102 BC 244-A7 VL CDR1 aa RASQDISNYLN 1035 BCMA-102 BC 244-A7 VL CDR2 aa YTSRLHS 1036 BCMA-102 BC 244-A7 VL CDR3 aa QQGNTLPWT 1037 BCMA-102 BC 244-A7 VH aa EVQLVEQSGPELVKPGASVKMSCKASGYTFTNHIIHWVKQKPGQGLEWIGYINPYNDDTEYNEKFKG KATLTSDKSSTTAYMELSSLTSEDSAVYYCARDGYYRDMDVMDYWGQGTTVTVSS 1038 BCMA-102 BC 244-A7 VL aa ELVMTQTPSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGS GTDYSLTISNLEQEDIATYFCQQGNTLPWTFGGGTKLEIK 1039 BCMA-102 BC 244-A7 scFv aa EVQLVEQSGPELVKPGASVKMSCKASGYTFTNHIIHWVKQKPGQGLEWIGYINPYNDDTEYNEKFKG KATLTSDKSSTTAYMELSSLTSEDSAVYYCARDGYYRDMDVMDYWGQGTTVTVSSGGGGSGGGGSGG GGSELVMTQTPSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSG SGSGTDYSLTISNLEQEDIATYFCQQGNTLPWTFGGGTKLEIK 1040 BCMA-103 BC 263-A4 VH CDR1 aa GFTFSNYDMA 1041 BCMA-103 BC 263-A4 VH CDR2 aa SISTRGDITSYRDSVKG 1042 BCMA-103 BC 263-A4 VH CDR3 aa QDYYTDYMGFAY 1043 BCMA-103 BC 263-A4 VL CDR1 aa RASEDIYNGLA 1044 BCMA-103 BC 263-A4 VL CDR2 aa GASSLQD 1045 BCMA-103 BC 263-A4 VL CDR3 aa QQSYKYPLT 1046 BCMA-103 BC 263-A4 VH aa EVQLVEESGGGLLQPGRSLKLSCAASGFTFSNYDMAWVRQAPTKGLEWVASISTRGDITSYRDSVKG RFTISRDNAKSTLYLQMDSLRSEDTATYYCARQDYYTDYMGFAYWGQGTLVTVSS 1047 BCMA-103 BC 263-A4 VL aa ELVMTQSPASLSASLGETVTIECRASEDIYNGLAWYQQKPGKSPQLLIYGASSLQDGVPSRFSGSGS GTQYSLKISGMQPEDEANYFCQQSYKYPLTFGSGTKLELK 1048 BCMA-103 BC 263-A4 scFv aa EVQLVEESGGGLLQPGRSLKLSCAASGFTFSNYDMAWVRQAPTKGLEWVASISTRGDITSYRDSVKG RFTISRDNAKSTLYLQMDSLRSEDTATYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGG GELVMTQSPASLSASLGETVTIECRASEDIYNGLAWYQQKPGKSPQLLIYGASSLQDGVPSRFSGSG SGTQYSLKISGMQPEDEANYFCQQSYKYPLTFGSGTKLELKGS 1049 BCMA-104 BC 271-C3 VH CDR1 aa GFTFSNFDMA 1050 BCMA-104 BC 271-C3 VH CDR2 aa SITTGGGDTYYRDSVKG 1051 BCMA-104 BC 271-C3 VH CDR3 aa HGYYDGYHLFDY 1052 BCMA-104 BC 271-C3 VL CDR1 aa RASQGISNYL 1053 BCMA-104 BC 271-C3 VL CDR2 aa YTSNLQS 1054 BCMA-104 BC 271-C3 VL CDR3 aa QQYDISSYT 1055 BCMA-104 BC 271-C3 VH aa EVQLVEESGGGLVQPGRSLKLSCAASGFTFSNFDMAWVRQAPTRGLEWVASITTGGGDTYYRDSVKG RFTISRDNAKSTLYLQMDSLRSEDTATYYCVRHGYYDGYHLFDYWGQGASVTVSS 1056 BCMA-104 BC 271-C3 VL aa ELVMTQTPSSMPASLGERVTISCRASQGISNYLNWYQQKPDGTIKPLIYYTSNLQSGVPSRFSGSGS GTDYSLTINSLEPEDFAVYYCQQYDISSYTFGAGTKLEIK 1057 BCMA-104 BC 271-C3 scFv aa EVQLVEESGGGLVQPGRSLKLSCAASGFTFSNFDMAWVRQAPTRGLEWVASITTGGGDTYYRDSVKG RFTISRDNAKSTLYLQMDSLRSEDTATYYCVRHGYYDGYHLFDYWGQGASVTVSSGGGGSGGGGSGG GGSELVMTQTPSSMPASLGERVTISCRASQGISNYLNWYQQKPDGTIKPLIYYTSNLQSGVPSRFSG SGSGTDYSLTINSLEPEDFAVYYCQQYDISSYTFGAGTKLEIK 1058 BCMA-105 BC 265-E5 VH CDR1 aa GFTFSNFDMA 1059 BCMA-105 BC 265-E5 VH CDR2 aa SITTGGGDTYYRDSVKG 1060 BCMA-105 BC 265-E5 VH CDR3 aa HGYYDGYHLFDY 1061 BCMA-105 BC 265-E5 VL CDR1 aa RASQGISNHLN 1062 BCMA-105 BC 265-E5 VL CDR2 aa YTSNLQS 1063 BCMA-105 BC 265-E5 VL CDR3 aa QQYDSFPLT 1064 BCMA-105 BC 265-E5 VH aa EVQLVEESGGGLVQPGRSLKLSCAASGFTFSNFDMAWVRQAPTRGLEWVASITTGGGDTYYRDSVKG RFTISRDNAKSTLYLQMDSLRSEDTATYYCVRHGYYDGYHLFDYWGQGTLVTVSS 1065 BCMA-105 BC 265-E5 VL aa ELVMTQTPSSMPASLGERVTISCRASQGISNHLNWYQQKPDGTIKPLIYYTSNLQSGVPSRFSGSGS GTDYSLTISSLEPEDFAMYYCQQYDSFPLTFGSGTKLEIK 1066 BCMA-105 BC 265-E5 scFv aa EVQLVEESGGGLVQPGRSLKLSCAASGFTFSNFDMAWVRQAPTRGLEWVASITTGGGDTYYRDSVKG RFTISRDNAKSTLYLQMDSLRSEDTATYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGG GGSELVMTQTPSSMPASLGERVTISCRASQGISNHLNWYQQKPDGTIKPLIYYTSNLQSGVPSRFSG SGSGTDYSLTISSLEPEDFAMYYCQQYDSFPLTFGSGTKLEIK 1067 BCMA-106 BC271-B12 VH CDR1 aa GFTFSNFDMA 1068 BCMA-106 BC271-B12 VH CDR2 aa SITTGGGDTYYRDSVKG 1069 BCMA-106 BC271-B12 VH CDR3 aa HGYYDGYHLFDY 1070 BCMA-106 BC271-B12 VL CDR1 aa RASQGISNNLN 1071 BCMA-106 BC271-B12 VL CDR2 aa YTSNLQS 1072 BCMA-106 BC271-B12 VL CDR3 aa QQFDTSPYT 1073 BCMA-106 BC271-B12 VH aa EVQLVEESGGGLVQPGRSLKLSCAASGFTFSNFDMAWVRQAPTRGLEWVASITTGGGDTYYRDSVKG RFTISRDNAKSTLYLQMDSLRSEDTATYYCVRHGYYDGYHLFDYWGQGVMVIVSS 1074 BCMA-106 BC271-B12 VL aa ELVMTQTPSSMPASLGERVTISCRASQGISNNLNWYQQKPDGTIKPLIYYTSNLQSGVPSRFSGSGS GTDYSLTISSLEPEDFAMYYCQQFDTSPYTFGAGTKLEIK 1075 BCMA-106 BC271-B12 scFv aa EVQLVEESGGGLVQPGRSLKLSCAASGFTFSNFDMAWVRQAPTRGLEWVASITTGGGDTYYRDSVKG RFTISRDNAKSTLYLQMDSLRSEDTATYYCVRHGYYDGYHLFDYWGQGVMVTVSSGGGGSGGGGSGG GGSELVMTQTPSSMPASLGERVTISCRASQGISNNLNWYQQKPDGTIKPLIYYTSNLQSGVPSRFSG SGSGTDYSLTISSLEPEDFAMYYCQQFDTSPYTFGAGTKLEIK 1076 BCMA-107 BC 247-A4 VH CDR1 aa GYSFPDYYIN 1077 BCMA-107 BC 247-A4 VH CDR2 aa WIYFASGNSEYNE 1078 BCMA-107 BC 247-A4 VH CDR3 aa LYDYDWYFDV 1079 BCMA-107 BC 247-A4 VL CDR1 aa RSSQSLVHSNGNTYLH 1080 BCMA-107 BC 247-A4 VL CDR2 aa KVSNRFS 1081 BCMA-107 BC 247-A4 VL CDR3 aa SQSTHVPYT 1082 BCMA-107 BC 247-A4 VH aa EVQLVEQSGPELVKPGASVKISCKVSGYSFPDYYINWVKQRPGQGLEWIGWIYFASGNSEYNERFTG KATLTVDTSSNTAYMQLSSLTSEDTAVYFCASLYDYDWYFDVWGQGTTVTVSS 1083 BCMA-107 BC 247-A4 VL aa ELVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRF SGSGSGADFTLKISRVEAEDLGVYFCSQSTHVPYTFGGGTKLEIK 1084 BCMA-107 BC 247-A4 scFv aa EVQLVEQSGPELVKPGASVKISCKVSGYSFPDYYINWVKQRPGQGLEWIGWIYFASGNSEYNERFTG KATLTVDTSSNTAYMQLSSLTSEDTAVYFCASLYDYDWYFDVWGQGTTVTVSSGGGGSGGGGSGGGG SELVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDR FSGSGSGADFTLKISRVEAEDLGVYFCSQSTHVPYTFGGGTKLEIK 1085 BCMA-108 BC 246-B6 VH CDR1 aa GYSFPDYYIN 1086 BCMA-108 BC 246-B6 VH CDR2 aa WIYFASGNSEYNE 1087 BCMA-108 BC 246-B6 VH CDR3 aa LYDYDWYFDV 1088 BCMA-108 BC 246-B6 VL CDR1 aa RSSQSLVHSNGNTYLH 1089 BCMA-108 BC 246-B6 VL CDR2 aa KVSNRFS 1090 BCMA-108 BC 246-B6 VL CDR3 aa FQGSHVPWT 1091 BCMA-108 BC 246-B6 VH aa EVQLVEQSGPQLVKPGASVKISCKVSGYSFPDYYINWVKQRPGQGLEWIGWIYFASGNSEYNERFTG KATLTVDTSSNTAYMQLSSLTSEDTAVYFCASLYDYDWYFDVWGQGTTVTVSS 1092 BCMA-108 BC 246-B6 VL aa ELVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPGRF SGSGSGTDFTLKINRVEAEDLGVYYCFQGSHVPWTFGGGTKLEIK 1093 BCMA-108 BC 246-B6 scFv aa EVQLVEQSGPQLVKPGASVKISCKVSGYSFPDYYINWVKQRPGQGLEWIGWIYFASGNSEYNERFTG KATLTVDTSSNTAYMQLSSLTSEDTAVYFCASLYDYDWYFDVWGQGTTVTVSSGGGGSGGGGSGGGG SELVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPGR FSGSGSGTDFTLKINRVEAEDLGVYYCFQGSHVPWTFGGGTKLEIK